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Abstract 
 
Mammalian development involves the process by which a single fertilized egg 
develops into an adult with over 200 specialized cell types, each with a distinct gene 
expression pattern controlling its cellular state. As cells differentiate into specialized 
cell types, changes in the gene expression program occur with associated changes in 
chromatin. An understanding of the roles for chromatin regulators in the control of 
gene expression programs during differentiation is fundamental to understanding 
development.  Although it is not yet feasible to elucidate the functions of all chromatin 
regulators in all vertebrate cells, recent work in embryonic stem (ES) cells has 
demonstrated that regulatory features of differentiation can be elucidated by focusing 
on the chromatin regulators involved in the changes in the pluripotent gene expression 
program as ES cells differentiate.  New insights reveal that chromatin regulators of 
opposing functions share a common set of active genes in ES cells, suggesting a 
dynamic balance in the control of embryonic stem cell state and differentiation. I 
describe here the molecular mechanisms by which chromatin regulators contribute to 
the control of the ES cell state and differentiation, where these regulators play critical 
roles both in activating new gene expression programs and in silencing old programs.  
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Preamble 
 
In the first chapter of this thesis I discuss new themes that have been uncovered based 
on recent studies of the roles of chromatin regulators in the control of the embryonic 
stem (ES) cell state, and in the differentiation of embryonic stem cells.  I first 
introduce chromatin regulators and discuss their roles in regulating the gene 
expression program that is necessary to maintain ES cells in a pluripotent state.  I then 
highlight the mechanisms involved in ES cell differentiation, where chromatin 
regulators play critical roles both in activating new gene expression programs and in 
silencing old programs. I discuss new insights uncovered from my, and others’ work, 
underscoring their potential implications. Based on my thesis work, I describe a 
model, wherein chromatin regulators with opposing activities co-occupy the same 
genes in ES cells, where a dynamic balance between these regulators governs the 
changes in chromatin and associated gene expression during ES cell differentiation. In 
Chapter 2, I describe how LSD1 and the NuRD complex function during 
differentiation of ES cells, which I propose works in a dynamic fashion to 
decommission enhancers that are active in ES cells; this work was published in 2012 
in Nature. In the final chapter, I offer future challenges and possible approaches to test 
this model in other cell types. I have also appended 3 published papers, on which I 
participated as coauthor, that focus on other aspects of gene regulation and 
differentiation. 
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Chapter 1 
 
Roles For Chromatin Regulators In  
Transcriptional Control Of Embyronic Stem Cells 
  
	   15	  
Introduction 
 
During development, cells of the inner cell mass (ICM) of the developing 
blastocyst differentiate to generate an adult organism consisting of specialized cell 
types (Fig 1). Deciphering the molecular mechanisms controlling cellular 
differentiation is key to understanding development. Many diseases are the result 
of defects in development, and may lead to new therapies for diseases associated 
with developmental defects. 
As cells differentiate, changes in the gene expression program occur that involve 
silencing of some genes and activation of others. The coordinated actions of 
transcription factors, chromatin regulators, signaling factors, and small RNAs that 
control gene expression programs have been the subject of much study in 
embryonic stem (ES) cells (reviewed in ref. 1). Only recently have investigators 
begun to understand how chromatin regulators contribute to the dynamic changes 
in gene expression programs as cells differentiate. I briefly describe the broad 
array of histone-modifying enzymes (reviewed in ref. 2), ATP-dependent 
nucleosome-remodeling complexes (reviewed in ref. 3), and DNA 
methyltransferases (reviewed in ref. 4) that are involved in the establishment and 
maintenance of ES cell state (Fig 2a), and discuss how they contribute to the 
control of this state. I then discuss new insights into how these regulators 
participate in the changes in the gene expression program as ES cells differentiate  
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_____________________________________________________________________ 
Figure 1: High level view of mammalian development  
During mammalian embryonic development, a single fertilized egg develops and 
forms the blastocyst, which harbors the inner cell mass (ICM). Once derived from 
the ICM, embryonic stem (ES) cells can be derived in culture in a pluripotent state 
almost indefinitely (Box 1). After blastocyst formation, signaling cues trigger cells 
within the ICM to differentiate and generate an adult organism, consisting of over 
200 specialized cell types, each with a distinct gene expression program 
controlling its cellular identity. 
_____________________________________________________________________ 
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Figure 2 
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_____________________________________________________________________ 
Figure 2: Models for chromatin regulators at transcriptionally active, poised 
and silent genes 
 
a) Chromatin regulators generally fall into three different classes. 
Left panel – Histone-modifying proteins consist of enzymes that either catalyze the 
addition of a modification (termed writers) or the removal of a modification 
(termed erasers). Histone-modifying proteins also include proteins that recognize 
and occupy sites containing specific histone modifications (termed readers). 
Middle panel – ATP-dependent nucleosome remodeling proteins alter chromatin 
structure by sliding nucleosomes along DNA in cis or displacing histone proteins 
in trans. These proteins exist as multi-subunit complexes and generally belong to 
four different families: SWI/SNF, CHD, INO80 and ISWI. 
Right panel – DNA methyltransferases catalyze the methylation of CpG 
dinucleotides on DNA strands. 
b) Chromatin regulators contribute to the regulation of active, poised and silent 
genes in ES cells. 
Upper panel – At active genes, enhancers are typically bound by multiple 
transcription factors, which recruit cofactors that can interact with RNA 
polymerase II (RNA Pol2) at the core promoter. Chromatin regulators, which 
include nucleosome-remodeling complexes such as SWI/SNF and histone-
modifying proteins such as TrxG, are recruited by transcription factors or the 
transcription apparatus and mobilize or modify nucleosomes. The modifications 
catalyzed by these regulators localize in a stereotypic pattern and can serve as 
docking sites for factors that facilitate further transcription. 
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Middle panel – At poised genes, transcription initiation and recruitment of TrxG 
complexes can occur, but elongation and recruitment of Set2 and Dot1L do not 
occur. The PcG and SetDB1 chromatin regulators can contribute to this repression, 
and these can be recruited by some transcription factors and by noncoding RNAs. 
RNA Pol2 levels are lower at poised genes compared to the levels detected at 
active genes. 
Lower panel – Silent genes show little or no evidence of transcription initiation or 
elongation. These genes are often occupied by DNA methyltransferases and and 
other chromatin regulators that methylate histone H3K9. 
_____________________________________________________________________ 
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to establish new cell states. From these insights, an intriguing model is emerging 
involving a dynamic competition between regulators of opposing functions that 
control gene expression and cellular differentiation. Knowledge of the chromatin 
regulators involved in the control of gene expression programs as cells transition to 
new cell states can guide efforts to reprogram cells back to a pluripotent state and 
holds great promise for both disease therapeutics and regenerative medicine. 
 
Control of the Pluripotent State 
Once derived from the ICM, ES cells can be maintained in culture in a pluripotent 
state almost indefinitely (Fig 1). Control of the pluripotent state includes the 
regulation of the ES cell gene expression program by specific transcription factors 
and chromatin regulators, among other factors1 (Box 1). Transcription factors 
recognize and bind specific DNA sequences to either activate or prevent 
transcription5. In ES cells, the gene expression program is largely governed by the 
core transcription factors Oct4, Sox2, and Nanog6-8. The core transcription factors 
function together to positively regulate their own promoters, forming an 
interconnected autoregulatory loop. This keeps ES cells in a state that is 
maintained by a positive-feedback-controlled gene expression program when the 
transcription factors are expressed at normal levels. This state is no longer 
maintained and differentiates when one of the core transcription factors is no 
longer functioning.  
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The core transcription factors activate a large fraction of the actively transcribed 
protein-coding and miRNA genes in ES cells9,10. Oct4, Sox2 and Nanog also 
occupy repressed genes encoding lineage-specific transcription factors, and the 
repression of these genes is essential for ES cells to maintain a stable pluripotent 
state10-17. The loss of these core transcription factors leads to activation of these 
developmental genes, indicating that these genes are poised for activation.  In 
addition to Oct4, Sox2 and Nanog, other transcription factors have been shown to 
play important roles in control of ES cell state18-28. Thus, the functions of the core 
transcription factors are augmented by the functions of many transcription factors 
implicated in control of ES cell state at actively transcribed genes.  
 
Transcription factors can bind to chromatin regulators that alter chromatin 
structure and influence gene expression29-32. Chromatin regulators generally fall 
into three classes: histone-modifying proteins, ATP-dependent nucleosome 
remodeling protein complexes, and DNA methyltransferases. These regulators 
play roles in ES cells, where they alter chromatin to influence gene expression. I 
briefly describe models for the functions of chromatin regulators in the control of 
the ES cell gene expression program, including gene activation, establishment of a 
poised state for gene activation, and gene silencing (Fig 2). These models provide 
the foundation for our understanding on the roles of chromatin regulators in 
control of the pluripotent state (Table 1). 
 
Gene activation 
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The master ES cell transcription factors Oct4, Sox2 and Nanog bind to enhancer 
elements and recruit chromatin regulators and associated cofactors to facilitate 
transcription. These regulators participate in at least three aspects of gene 
activation (Fig 2b, upper panel): (1) Chromatin regulators are recruited to 
enhancer elements and core promoters, where they open chromatin to create 
accessible binding sites. (2) Chromatin regulators alter chromatin architecture to 
link enhancer elements to core promoters. (3) Chromatin regulators facilitate 
transcription initiation and (4) transcription elongation. 
Gene activation – Creation of accessible binding sites 
During gene activation, chromatin regulators are recruited and open chromatin to 
create accessible binding sites. These regulators include cofactors, which are 
protein complexes that contribute to activation (coactivators) and repression 
(corepressors) but do not have DNA-binding properties of their own. In ES cells, 
Oct4, Sox2 and Nanog bind active enhancers and bind coactivators such as the 
histone acetyltransferase p300. Histone acetyltransferases (HATs) are histone-
modifying enzymes (Fig 2a) that utilize acetyl CoA as a cofactor to catalyze the 
transfer of an acetyl group to the ε-amino group of lysine side chains, and are 
generally divided into three main families (reviewed in ref. 33): Gcn5-related N-
acetyltransferases (GNAT), MOZ, Ybf22/Sas3, Sas2, and Tip60 (MYST), and 
CREB-binding protein (CBP)/p300. The p300 cofactor occupies most active 
enhancers and promoters in ES cells34, where they catalyze acetylation of histones. 
Histone acetylation is thought to regulate chromatin accessibility by affecting the 
nucleosome net charge and by reducing electrostatic interactions between histones 
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and DNA or between histones of neighboring nucleosomes35-38. In ES cells, p300 
regulates Nanog levels by acetylation of the Nanog distal enhancer39. Nucleosomes 
containing acetylated histones also serve as docking sites for bromodomain 
effector proteins. For example, human TAF1, a subunit of TFIID of RNA 
Polymerase II (RNA Pol2), contains double bromodomains that bind multiply 
acetylated histone H4, and participates in the assembly of the transcription 
machinery40. 
Components of nucleosome-remodeling complexes have also been implicated in 
the regulation of chromatin accesibility3,11,41-45. ATP-dependent nucleosome-
remodeling complexes can be recruited to gene promoters, where they utilize ATP 
to slide nucleosomes in cis along the DNA, or displace histones in trans (Fig 2a), 
resulting in positive or negative effects on gene activity (reviewed in ref. 46). 
These remodelers generally fall into four families: switch/sucrose nonfermentable 
(SWI/SNF; reviewed in ref. 3), chromodomain helicase DNA-binding (CHD; 
reviewed in ref. 47), inositol-requiring 80 (INO80; reviewed in ref. 48), and 
imitation switch (ISWI; reviewed in ref. 49). In ES cells, the CHD subunit Chd1 is 
associated with the enhancers and promoters of active genes, where it interacts 
with Oct4/Sox2/Nanog master transcription factors and RNA Pol2 and prevents 
heterochromatin formation41.  It is unclear how Chd1 acts to maintain an open 
chromatin structure. An intriguing possibility is that Chd1 may mediate 
incorporation of the histone variant H3.3, which is generally associated with active 
genes and is less prone to nucleosome compaction and heterochromatin 
formation50,51. Thus, histone-modifying enzymes and nucleosome remodeling 
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complexes are present at key active ES cell genes, where they contribute to 
opening chromatin to create accessible binding sites. 
Gene activation – Linking enhancer elements to core promoters 
In addition to increasing chromatin accessibility for binding, chromatin regulators 
participate in the linking of enhancer elements to core promoters. The mediator 
coactivator physically links Oct4/Sox2/Nanog-bound enhancers to the promoters 
of active genes in ES cells52. At Oct4/Sox2/Nanog-regulated promoters, mediator 
associates with cohesin, and this complex forms a DNA loop between enhancers 
and master promoters that is necessary for normal gene activity. Mediator also 
plays an important role in the transcriptional response to signaling cues. CDK8, the 
kinase subunit of mediator, can influence the activity of signaling transcription 
factors53-55. For example, CDK8-meditated phosphorylation of the linker region 
within Smad1/5 or Smad2/3 complexes can activate these transcription factor 
complexes, but it also targets them for proteasomal degradation. A dynamic cycle 
of transcription factor activation and destruction ensures maintained gene 
activation and may facilitate rapid changes in cell state when signaling is altered. 
Hence, the association of mediator with cohesin and its contribution to both DNA 
looping and gene activity in ES cells makes it both an essential cofactor and a key 
chromatin regulator52. 
 
Gene activation – Transcripton initiation 
Once enhancer elements are brought in to close proximity with core promoters, 
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chromatin regulators can facilitate the initiation of transcription and production of 
full-length messenger RNA transcripts. In ES cells, Oct4/Sox2/Nanog-regulated 
promoters are occupied by Trithorax group (TrxG) proteins56,57. These proteins 
were discovered in D. melanogaster as activators of Hox genes (reviewed in ref. 
58). The SET-domain containing Mll proteins are TrxG proteins that catalyze 
trimethylation of histone H3 lysine 4 (H3K4me3) and facilitate maintenance of 
active gene states during development, in part by antagonizing the functions of 
Polycomb group (PcG) proteins. Mll proteins are recruited to promoters by various 
mechanisms58, including the transcription apparatus59, and short RNAs60. Recent 
evidence suggests RNA Pol2 transcribes short RNA transcripts, which then tether 
to TrxG proteins to either target or stabilize these proteins at Pol2-occupied 
promoters60. The TrxG protein Wdr5 has recently been implicated in control of ES 
cell state by regulating H3K4me3 levels and contributing to gene activity57. The 
molecular mechanisms by which this occurs is unclear, but likely involves 
H3K4me3 serving as a docking site for nucleosome remodeling complexes and 
HATs that facilitate chromatin remodeling and transcription41,45,61,62. For example, 
the nucleosome remodeling subunit Bptf has a PHD domain that recognizes 
methylation of histone H3K4.  This interaction recruits the ISWI nucleosome 
remodeling complex NuRF to disrupt chromatin at the promoter and enhance RNA 
Pol2 clearance61. In ES cells, the Tip60-p400 complex, an INO80 nucleosome 
remodeling complex containing histone acetyltransferase activity, has been shown 
to be recruited directly by H3K4me3 to enhancers and promoters45. Histone 
acetylation at gene enhancers and promoters serves as a docking site for the 
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binding of the bromodomain-containing protein Brd4 and mediates recruitment of 
positive transcription elongation factor b (pTEF-b), which is necessary for the 
release of the promoter-proximal paused RNA Pol2 (ref. 62). Thus, the link of 
H3K4 methylation to histone acetylation and chromatin remodeling may regulate 
chromatin accessibility and increased escape of RNA Pol2 from active core 
promoters in ES cells.  
 
Gene activation – Transcription elongation 
After RNA Pol2 release, the mechanisms by which chromatin regulators facilitate 
transcription elongation at a subset of genes in ES cells are not fully understood. 
Based on studies in yeast, transcription elongation involves targeting of TrxG 
complexes via interactions with the polymerase-associated factor 1 (Paf1) 
elongating complex, resulting in di- and trimethylation of histone H3K4 (ref. 63). 
Paf1 also regulates the histone-modifying enzyme Dot1L, which is recruited to 
elongating RNA Pol2 through its association with various elongating factors. 
Dot1L catalyzes dimethylation of histone H3 lysine 79 (H3K79me2), likely to 
maintain active transcription and/or serve as a transcription memory63. The 
histone-modifying enzyme Set2, which catalyzes trimethylation of histone H3 
lysine 36 (H3K36me3), is also linked to transcription elongation, presumably to 
maintain chromatin structure via the recruitment of a histone deacetylase complex 
to prevent cryptic initiation of transcription63-66. In ES cells, the Paf1 complex may 
play similar roles, as reduction in Paf1 proteins leads to reduced levels of histone 
H3K4me3 at actively transcribed genes67. 
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In summary, chromatin regulators are recruited by transcription factors, the 
transcription apparatus or short RNAs to create accessible binding sites, alter 
chromatin architecture and facilitate transcription by mobilizing or modifying local 
nucleosomes. These modifications localize in a stereotypic pattern, and serve as 
docking sites for recruitment of regulators that further facilitate gene activation 
(Fig 2b, upper panel). 
 
Poised state for gene activation 
Oct4, Sox2, and Nanog also bind repressed genes encoding lineage-specific 
transcription factors, and the repression of these genes is essential to maintain a 
stable pluripotent ES cell state10-14,17,68,69 (Fig 2b, middle panel). Loss of these 
master transcription factors leads to rapid induction of a wide spectrum of genes 
encoding lineage-specific regulators, indicating that these genes are poised for 
activation. The chromatin regulators known to have a profound impact on ES cell 
state are histone-modifying enzymes that repress genes encoding lineage-specific 
transcription factors. These include SetDB1 and the PcG protein complexes. 
 
Multiple histone-modifying enzymes that methylate histone H3 lysine 9 (H3K9) 
have been implicated in control of ES cell state11,70,71. Oct4 can bind sumoylated 
SetDB1, a histone-modifying enzyme that trimethylates H3K9 (H3K9me3), at a 
subset of the repressed genes that encode lineage-specific developmental 
regulators, including those involved in generating the extraembryonic trophoblast 
lineage11,70,71. At the promoters of these genes, SetDB1 is responsible for catalyzing 
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H3K9 methylation11,70,71. Histone H3K9me3 serves as a docking site for the 
recruitment of the effector protein heterochromatin protein 1 (HP1), which 
recognizes and binds methylated histone H3K911,70,71. Once HP1 occupies sites 
containing H3K9me3, the effector protein oligomerizes to bridge nearby 
nucleosomes to compact chromatin72-74. At SetDB1-occupied lineage-specific 
genes in ES cells, H3K9me3 and chromatin compaction facilitate gene 
repression13,48,49. The corepressor Trim28 can also interact with HP1 and SetDB1 to 
facilitate formation of repressive chromatin75,76, but the mechanisms are not fully 
understood. 
 
PcG protein complexes can associate with nucleosomes with histone H3K9me3 
and further contribute to repression77. These proteins occupy most of the 
transcriptionally repressed lineage-specific genes targeted by Oct4, Sox2, and 
Nanog13,14,78. The PcG proteins form multiple polycomb repressive complexes 
(PRCs), the components of which are conserved from Drosophila to humans 
(reviewed in ref. 79). Prc2 catalyzes histone H3 lysine 27 (H3K27) methylation, an 
enzymatic activity required for Prc2-mediated gene silencing. Methylation of 
histone H3K27 is thought to provide a binding surface for Prc1, which facilitates 
oligomerization, condensation of chromatin structure, and inhibition of chromatin 
remodeling activity in order to maintain gene silencing. Prc1 also contains a 
histone ubiquitin ligase, Ring1b, whose activity appears likely to contribute to 
silencing in ES cells80.  
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Various models have been proposed to explain how PcG proteins silence genes 
encoding key regulators of development yet allow them to remain in a state that is 
poised for activation during differentiation13,14,78,81-84,85-90. A particularly intriguing 
model involves a dynamic balance between TrxG and PcG proteins at promoters of 
developmental genes91. Recruitment of TrxG complexes and transcription initiation 
at promoters of developmental regulators results in catalyzation of H3K4me3 and 
production of short CG-rich RNAs that recruit PcG proteins. These proteins then 
catalyze histone H3K27 methylation and histone H2A ubiquitylation, and then 
spread beyond the nucleation site to establish repression. This repression prevents 
RNA Pol2 pause release, elongation, and recruitment of Dot1L and Set2 proteins. 
How this repression is achieved is not fully understood, but likely involves a 
variety of mechanisms58. Prc2-mediated methylation of histone H3K27 might 
directly interfere with transcriptional activation by counteracting TrxG-associated 
proteins and the histone modifications they mediate, including acetylation of 
histone H3K27 (H3K27ac) by p300 (refs. 92,93) and histone H3K4me3 (refs. 94-
96). Prc1 binding and ubiquitylation of histone H2A has been suggested to induce 
chromatin compaction and interfere with nucleosome-remodeling activities to 
prevent RNA Pol2 transcriptional elongation and prevent H3K36 methylation by 
Set2 (ref. 97).  
 
In conclusion, Oct4, Sox2 and Nanog may recruit SetDB1 through protein-protein 
interactions, and PcG complexes via interactions with both histone H3K9me3 and 
RNA transcripts produced as a consequence of local transcription activation. These 
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complexes may serve to pause RNA polymerase machinery at key regulators of 
development in pluripotent cells (Fig 2b, middle panel). At genes where the 
transcription apparatus is continuously recruited by activating transcription factors 
(Fig 2a, upper panel), activities associated with TrxG proteins predominate, 
reducing PcG complexes and their associated histone modifications.  
 
Gene silencing 
Oct4, Sox2 and Nanog are not bound at a subset of genes that are silenced and 
show little to no evidence of transcription initiation and elongation (Fig 2b, lower 
panel). These genes are occupied by DNA methyltransferases (Fig 2a), among 
other chromatin regulators. DNA methylation is essential for mammalian 
development98,99, and is established and maintained by three catalytically active 
enzymes100. DNA methyltransferase (Dnmt)3a and Dnmt3b are responsible for de 
novo methylation, and Dnmt1 functions as a maintenance methyltransferase, 
ensuring newly synthesized DNA is methylated during DNA replication. Though 
ES cells can be established and maintained in the absence of Dnmts and DNA 
methylation101,102, recent evidence suggests a subset of these silent genes are 
regulated by DNA methylation. For example, the silent trophectodermal gene Elf5 
is highly methylated, and cells deficient in Dnmt1 show hypomethylation of the 
Elf5 promoter and gain the ability to differentiate into trophectoderm103.  
 
There are various mechanisms by which these genes may be silenced by DNA 
methylation. One possibility is that DNA methylation can directly block 
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transcription factor binding. A more likely scenario is that DNA methylation 
represses gene expression through several methyl-CpG-binding proteins (MECPs) 
that recognize and subsequently bind to methylated DNA. For example, in somatic 
cells MECP2 forms a complex with histone deacetylases and a corepressor protein, 
Sin3a, to repress transcription in a methylation-dependent manner104,105. The 
methyl-CpG-binding protein MBD2 forms a complex with the CHD family 
member CHD3/4 to form the nucleosome remodeling and deacetylase (NuRD) 
complex, which contains histone deacetylase (HDAC) activity. The NuRD 
complex can occupy methylated promoters and remodel methylated chromatin to 
repress genes106,107. The Sin3a and NuRD complexes provide a mechanistic link 
between DNA methylation and histone deacetylation in gene silencing.  
 
In summary, models exist for the functions of chromatin regulators in the control 
of the pluripotent state (Fig 2). These regulators can be found at active, poised, and 
silent genes. At active genes (Fig 2b, upper panel), enhancers are typically bound 
by multiple transcription factors, which recruit cofactors that can interact with 
RNA Pol2 at the core promoter. RNA Pol2 generates a short transcript and pauses 
until pause-release and elongation factors allow further transcription. Chromatin 
regulators, which include nucleosome-remodeling complexes such as CHD 
complexes and histone-modifying complexes such as TrxG, Dot1, and Set2, are 
recruited by transcription factors or the transcription apparatus and mobilize or 
modify local nucleosomes. At poised genes (Fig 2b, middle panel), transcription 
initiation and recruitment of TrxG can occur, but pause release, elongation, and 
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recruitment of Dot1 and Set2 do not occur. SetDB1 and PcG proteins can 
contribute to this repression, and these can be recruited by transcription factors and 
by non-coding RNAs. These genes are rapidly activated when ES cells are 
stimulated to differentiate. At silent genes (Fig 2b, lower panel), there is little or no 
evidence of transcription initiation and elongation, and these genes are often 
occupied by chromatin regulators that methylate DNA and H3K9. Together, these 
regulators regulate the ES cell gene expression program to control the pluripotent 
state. 
 
Exit from the Pluripotent State 
Upon ES cell differentiation and establishment of new cell states, at least three 
things must occur (Fig 3): (1) Certain genes of the prior gene expression program 
must be silenced. (2) Genes of the new gene expression program must be activated. 
(3) Genes of alternative gene expression programs must be silenced. Recent 
evidence in ES cells indicates that a large fraction of genes that are either active or 
poised for activation upon differentiation are co-occupied by chromatin regulators 
with opposing activities—those that modify or mobilize nucleosomes to facilitate 
chromatin accessibility and gene activity, and those that modify or mobilize 
nucleosomes to reduce chromatin accessibility and gene activity.  
 
At least two models that are not mutually exclusive emerge from these findings. 
Such opposing activities at genes may allow for precise tuning of gene expression 
in ES cells. A more intriguing view is that a dynamic balance exists in ES cells 
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between regulators of opposing functions at enhancers and core promoters of 
genes, and this balance poises genes to become either silenced or activated upon 
differentiation. In ES cells, chromatin regulators with opposing functions occupy 
enhancer elements and core promoters of a subset of active genes, where the 
actions of chromatin regulators responsible for maintained gene activation  
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Figure 3 
 
 
 
_____________________________________________________________________ 
Figure 3: Models for chromatin regulators during ES cell differentiation 
Chromatin regulators play important roles during ES cell differentiation, where 
they participate in the silencing of certain active genes of the ES cell gene 
expression program, the activation of genes of the new gene expression program, 
and silencing of genes of alternative gene expression programs. 
Upper panel – Chromatin regulators participate in the silencing of certain active 
genes of the ES cell gene expression program. In ES cells, LSD1 and NuRD 
complexes are recruited to active enhancer elements containing H3K4 methylation. 
LSD1 is unable to demethylate histones, however, due to the presence of 
acetylated histones that are catalyzed by HATs such as p300. During 
differentiation, when the levels of Oct4 and associated HATs are lost, acetylated 
histones are reduced and LSD1 is able to demethylate H3K4, resulting in enhancer 
decommissioning and gene silencing. 
Middle panel – Chromatin regulators participate in the selective activation of genes 
encoding lineage-specific transcription factors. In ES cells, these genes are 
occupied by TrxG and RNA Pol2, but these genes are not fully transcribed and are 
repressed by PcG complexes that catalyze H3K27 methylation. During 
differentiation, Utx removes H3K27 methylation, and the TrxG member Dpy30 is 
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responsible for increased H3K4 methylation at promoters of certain lineage-
specific genes that become activated. 
Lower panel – Chromatin regulators are also responsible for silencing genes of 
alternative gene expression programs. In ES cells, a pioneer factor binds the 
endoderm-specific enhancer of the Alb1 gene and protects it from DNA 
methylation. The surrounding regions are DNA methylated, and Alb1 is silent. 
During differentiation of ES cells down mesodermal and ectodermal lineages, the 
pioneer factor is lost at the Alb1 enhancer and the DNA is methylated, facilitating 
stable silencing of Alb1. The NuRD complex contributes to this silencing. During 
differentiation of ES cells down the endodermal lineage, transcription factors bind 
the Alb1 enhancer to facilitate activation. HATs and the nucleosome remodeling 
complex SWI/SNF are believed to facilitate gene activation. 
_____________________________________________________________________ 
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predominate. Upon differentiation, when the high levels of regulators associated 
with gene activation are reduced, the competitive balance shifts and these genes 
are repressed by the chromatin regulators associated with gene repression. At 
lineage-specific genes in ES cells, the chromatin regulators responsible for gene 
repression predominate. When cells are triggered to differentiate, the levels or 
functions of chromatin regulators associated with repression are reduced at 
selected genes, and lineage-specific transcription factors are selectively activated. 
Hence, in ES cells a set of active genes are poised for repression upon 
differentiation, and a set of lineage-specific genes are poised for activation upon 
differentiation. We discuss new insights into how chromatin regulators might 
facilitate this dynamic control.  
 
Silencing genes of the old gene expression program 
Chromatin regulators control at least two major steps in the silencing of genes of 
the old gene expression program (Fig 3, upper panel)44,108-110. Some chromatin 
regulators are required in the initial silencing of genes by occupying enhancer 
elements and core promoters of genes, where they either modify or mobilize 
nucleosomes and facilitate gene repression. Other chromatin regulators are 
required to stably maintain the silent state by methylating DNA.  
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The histone-demethylating protein LSD1 is responsible for removal of mono- and 
dimethylation of histone H3K4 (ref. 111), two modifications typically found at 
active enhancer elements112. In ES cells, LSD1 and members of the NuRD ATP-
dependent nucleosome remodeling complex, including HDACs and the ATPase 
CHD4, interact with Oct4 (refs. 113,114), and occupy Oct4-regulated active 
enhancer elements108. LSD1 proteins do not substantially demethylate histone 
H3K4 because the H3K4 demethylase activity of LSD1 is inhibited in the presence 
of acetylated histones115,116. Enhancers occupied by Oct4, Sox2 and Nanog are also 
occupied by the HAT p300 and nucleosomes with acetylated histones9. Thus, as 
long as the enhancer-bound transcription factors recruit HATs to enhancers, the net 
effect of having both HATs and NuRD-associated HDACs present is to have 
sufficient levels of acetylated histones to suppress LSD1 demethylase activity. 
During ES cell differentiation, the levels of Oct4 and p300 are decreased, thus 
decreasing the level of acetylated histones, which in turn permits the 
demethylation of H3K4 by LSD1. This model would explain why key components 
of LSD1 and NuRD complexes are not essential for the maintenance of ES cell 
state but are essential for normal differentiation, when the active enhancers and 
associated genes must be silenced. Several lines of evidence demonstrate that 
LSD1 is required for differentiation of multiple cell types108,117-121, suggesting that 
LSD1 is likely to be generally involved in gene silencing during differentiation 
(Fig 3a).  
To stably maintain gene silencing, a different set of chromatin regulators are 
required. Following histone deacetylation and H3K4 demethylation at the Oct4 
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gene, the histone-modifying enzyme G9a methylates histone H3K9, leading to 
HP1 recruitment and chromatin compaction109. G9a-mediated methylation is 
required for de novo DNA methylation by Dnmt3a and Dnmt3b, resulting in stable 
gene repression110,122. In summary, during ES cell differentiation, certain genes of 
the old gene expression program undergo a multi-step, tightly regulated form of 
repression that requires the activities of various chromatin regulators to enforce a 
stable form of silencing that is maintained by DNA methylation. 
 
Activating genes of the new gene expression program 
Recent studies reveal that histone-modifying and nucleosomal-remodeling 
enzymes play critical roles in the activation of gene expression programs important 
for differentiation and establishment of new cell states. From these studies, a 
dynamic model is emerging for the functions of PcG/TrxG complexes and 
associated proteins in the regulation of genes encoding lineage-specific 
transcription factors during differentiation. In ES cells, transcription initiation and 
recruitment of TrxG and associated coactivators to promoters of lineage-specific 
genes can occur, but pause release and elongation do not occur, due in part to PcG-
mediated repression. This dynamic balance is lost when cells are stimulated to 
differentiate, as PcG proteins are reduced from a subset of these promoters and 
increased occupancy and stabilization of TrxG proteins facilitate gene activation.  
The mechanisms involved in the loss of PcG proteins during differentiation is 
unclear, but likely involve the removal of H3K27 methylation by histone-
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demethylating proteins (Fig 3, middle panel). The histone-demethylating enzyme 
Utx is responsible for demethylating histone H3K27 (refs. 96,123,124) at certain 
PcG-occupied promoters of developmental genes125. During ES cell differentiation, 
master lineage-specific transcription factors bind to a subset of developmental 
genes that contain H3K27 methylation and are occupied by PcG proteins. These 
factors then bind to Utx, which catalyzes the removal of H3K27 methylation at 
these genes to facilitate transcriptional activation. How demethylation of H3K27 
contributes to gene activation is not fully understood but likely involves loss of 
Prc1 proteins. Brg1, the SWI/SNF ATPase and member of the ES-specific 
nucleosome remodeling complex esBAF (ref. 126), is also targeted to these 
promoters, presumably to facilitate chromatin accessibility125. H3K27 
demethylation has also been linked to increased acetylation of H3K27 by p300, 
which can facilitate activation of PcG-target genes (ref. 92). Considering Utx is 
broadly expressed in multiple tissues (reviewed in ref. 127), the interaction 
between Utx and master lineage-specific transcription factors likely plays an 
important role in the specific activation of Utx targets. 
Activation of lineage-specific transcription factors not only requires the loss of 
PcG proteins, but also increased occupancy of TrxG proteins and associated 
cofactors that facilitate gene activity. Utx associates with Mll TrxG proteins that 
catalyze the methylation of H3K4 (refs. 94-96). Therefore, it is likely that Utx is 
required for the activity or the targeting of TrxG proteins at genes encoding 
lineage-specific transcription factors genes, and contributes to gene activation94,96. 
The mammalian TrxG member Dpy30 is part of the Mll complex of proteins 
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responsible for catalyzing H3K4 methylation. In ES cells, Dpy30 occupies 
promoters of PcG-targeted genes, where it regulates H3K4 methylation128. Loss of 
Dpy30 has limited effects on H3K4 methylation levels and gene expression, 
presumably due to the presence of PcG proteins that repress gene activity. During 
differentiation, Dpy-30 occupancy increases at a subset of genes whose promoters 
lose PcG-mediated H3K27 methylation. H3K4 methylation levels are also 
increased at these genes, which facilitates gene activation128. In summary, the 
dynamic balance between PcG and TrxG proteins affects expression of genes that 
become activated during differentiation (Fig 3, middle panel). Loss of PcG 
proteins by demethylases like Utx, and increased activity of TrxG proteins such as 
Dpy30 contribute to the activation of the new gene expression program during 
differentiation.  
Silencing genes of alternative programs 
During differentiation and establishment of a new cell type, genes encoding 
lineage-specific master transcription factors of alternative gene expression 
programs must be silenced, because forced expression of these factors is associated 
with establishment and control of new cell states129-131. PcG proteins occupy 
promoters of lineage-specific genes whose promoters contain H3K27me3 and are 
repressed. Upon differentiation, a subset of these genes maintain H3K27 
methylation and are not activated, providing a model that PcG targets are specified 
early in development, and continue to be repressed until activated. ES cells lacking 
several PcG subunits fail to silence several key regulators of development, and 
have differentiation defects132. 
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Loss of DNA methylation impairs ES cell differentiation, also suggesting an 
important role for DNA methyltransferases during differentiation101. Most of the 
changes in DNA methylation associated with differentiation occur at regions distal 
from known promoters133, suggesting gene enhancers of alternative gene 
expression programs may be methylated and silenced during differentiation134 (Fig 
3, lower panel). For example, the Alb1 gene is repressed in ES cells and the 
endoderm-specific Alb1 enhancer is protected from DNA methylation. During 
differentiation into endodermal cells, the pioneer transcription factor FoxA1 binds 
to the Alb1 enhancer and facilitates chromatin remodeling and transcriptional 
activation135. This activation is likely accompanied by specific transcription factor 
recruitment and increased histone acetylation and H3K4 methylation, as well as by 
recruitment of SWI/SNF remodeling complexes136-138. During differentiation into 
mesoderm or ectoderm lineages, however, the endoderm-specific Alb1 enhancer 
becomes DNA methylated and the Alb1 gene is silenced, likely by Dnmts and the 
NuRD complex134. Hence, methylation of enhancer elements controlling 
developmental regulators might be a key feature of silencing alternative gene 
expression programs during differentiation (Fig 3, lower panel).  
 
In summary, chromatin regulators with opposing functions co-occupy a large 
subset of active and poised genes in ES cells, providing a more dynamic view on 
the mechanisms controlling ES cell maintenance and differentiation. This model 
describes a dynamic competition that exists at genes between regulators that 
promote gene activity and those that promote gene silencing. At most active genes, 
	   43	  
the activities of chromatin regulators responsible for maintained gene activation 
predominate, and the net effect of having regulators of opposing activities is to 
keep genes poised for repression during differentiation. At lineage-specific genes, 
the chromatin regulators responsible for gene repression predominate, and the net 
effect of having regulators of opposing activities at these genes is to keep genes 
poised for activation during differentiation. When ES cells are triggered to 
differentiate, the levels or functions of chromatin regulators associated with gene 
activation are reduced at a set of active genes, allowing these genes to become 
silenced. At lineage-specific genes, the levels or functions of chromatin regulators 
associated with repression are reduced at selected genes, and lineage-specific 
transcription factors are selectively activated. 	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Box 1: The Embryonic Stem Cell State 
Embryonic stem (ES) cells are pluripotent, self-renewing cells that are derived 
from the ICM of the developing blastocyst1-3. Pluripotency is the capacity of a 
single cell to generate all cell lineages of the developing and adult organism. Self-
renewal is the ability of a cell to proliferate in the same state. ES cells have a gene 
expression program that allows them to self-renew yet remain poised to 
differentiate into essentially all cell types in response to developmental cues. The 
ES cell gene expression program is governed by transcription factors, signaling 
pathways, chromatin regulators, and noncoding RNAs. These four classes of 
regulators control the embryonic stem cell state4. 
 
Transcription factors recognize and bind specific DNA sequences to either activate 
or prevent transcription5. In ES cells, the gene expression program is largely 
governed by the core transcription factors Oct4, Sox2, and Nanog6-8. The core 
transcription factors function together to positively regulate their own promoters, 
forming an interconnected autoregulatory loop. This keeps ES cells in a state that 
is maintained by a positive-feedback-controlled gene expression program when the 
transcription factors are expressed at normal levels. This state is no longer 
maintained and differentiates when one of the core transcription factors is no 
longer functioning.  
 
The core transcription factors activate a large fraction of the actively transcribed 
protein-coding and miRNA genes in ES cells9,10. Oct4, Sox2 and Nanog also 
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occupy repressed genes encoding lineage-specific transcription factors, and the 
repression of these genes is essential for ES cells to maintain a stable pluripotent 
state10-17. The loss of these core transcription factors leads to activation of these 
developmental genes, indicating that these genes are poised for activation.  In 
addition to Oct4, Sox2 and Nanog, other transcription factors have been shown to 
play important roles in control of ES cell state18-28. Thus, the functions of the core 
transcription factors are augmented by the functions of many transcription factors 
implicated in control of ES cell state at actively transcribed genes.  
 
For ES cells, maintenance of the pluripotent state is dependent on the absence of 
signal that stimulate differentiation8,29. Murine ES cells are initially cultured on a 
layer of fibroblasts in order to obtain factors necessary for self-renewal and 
pluripotency30,31. LIF, Wnt, and ligands of the TGF-β/BMP signaling pathway are 
among factors supplied by the fibroblasts and found to influence the murine ES 
cell state32-36. The transcription factors associated with the LIF, Wnt, and BMP4 
signaling pathways (Stat3, Tcf3, and Smad1) tend to co-occupy enhancers bound 
by Oct4, Sox2, and Nanog, thereby allowing direct control of genes within the core 
circuitry by these signaling pathways9,22,23,37-39. Loss of Oct4 leads to a loss of these 
signaling transcription factors at Oct4-bound enhancers.  
 
Transcription factors can bind to chromatin regulators that alter chromatin 
structure and influence gene expression40-45. Chromatin regulators generally fall 
into three classes: histone-modifying proteins, ATP-dependent nucleosome 
	   62	  
remodeling protein complexes, and DNA methyltransferases. These regulators 
play important roles in ES cells, and is the focus of my thesis. 
 
Non-coding RNAs (ncRNAs) have long been implicated in the regulation of gene 
expression5,46, and are critical in the control of ES cell state10,47,48. These include 
miRNAs, which can regulate messenger RNAs and play essential roles in self-
renewal and differentiation10. They also include longer ncRNAs of various types, 
which have been implicated in recruitment of chromatin regulators such as the PcG 
complexes47-53. 
 
ES cells provide a powerful system for discovering the regulators and mechnasms 
that control cell states, and serve as a resource for understanding the changes that 
occur as cells differentiate. 
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Table 1: Key chromatin regulators implicated in control of ES cell state  
 
  
Family Complex or protein Function* Key 
References 
Histone-modifying complexes and proteins   
Polycomb (PcG) PRC2 Differentiation 1-3 
 PRC1 Maintenance 4-7 
 Jarid2 Differentiation 8-12 
 Pcl2 Differentiation 13 
    
Trithorax (TrxG) MLL Differentiation 14,15 
 Wdr5 Maintenance 16 
 Ash2L Maintenance 16 
 Dpy30 Differentiation 17 
    
Eset SetDB1 Maintenance 18-20 
    
G9a/Glp Ehmt2 Differentiation 21,22 
 Ehmt1 Maintenance 22 
    
Dot1 Dot1L Differentiation 23 
    
Set2 Setd2 Differentiation 24 
    
Histone Deacetylase Hdac1 Differentiation 25 
    
Histone Demethylase LSD1 Differentiation 26-30 
 Jmjd1a Maintenance 31 
 Jmjd2c Maintenance 31 
 Jarid1a Differentiation 32 
 UTX Differentiation 33 
    
Histone Arginine Methylation Carm1/Prmt4 Maintenance 34,35 
 Prmt5 Maintenance 36 
 Prmt6 Differentiation 37 
    
Histone Clipping Cathepsin L Differentiation 38,39 
    
 	   	   	  
ATP-dependent Nucleosome Remodeling     
SWI/SNF esBAF Maintenance 40-44 
    
CHD NuRD Differentiation 26,45,46 
 Chd1 Maintenance 47 
    
ISWI NURF Differentiation 48 
	   71	  
  	   	  
INO80 Tip60-p400 Maintenance	   49	  
  	   	  
DNA Methyltransferases    
DNMT Dnmt3a/b Differentiation 
 
50,51 
 Dnmt1 Differentiation 50,51 
  	   	  
Cofactors 	   	   	  
Mediator Mediator Maintenance 21,52 
    
SMC Cohesin Maintenance 21,49,52 
    
KAP 
 
PAF 
Trim28 
 
Paf1 
Maintenance 
 
Maintenance 
21,49 
 
53 
    
CBP/p300 p300 Differentiation 54,55 
  	   	  
* - Reduced levels or activity of these regulators result in either loss of the ES cell gene expression program (and  
therefore these regulators function in the maintenance of cell state) or defects in ES cell differentiation. 
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Summary 
Transcription factors and chromatin modifiers play important roles in 
programming and reprogramming of cellular states during development1,2. 
Transcription factors bind to enhancer elements and recruit coactivators and 
chromatin modifying enzymes to facilitate transcription initiation3,4. During 
differentiation, a subset of these enhancers must be silenced, but the mechanisms 
underlying enhancer silencing are poorly understood. Here we show that the 
H3K4/K9 histone demethylase LSD1 (ref. 5) plays an essential role in 
decommissioning enhancers during differentiation of embryonic stem cells 
(ESCs).  LSD1 occupies enhancers of active genes critical for control of ESC 
state.  However, LSD1 is not essential for maintenance of ESC identity.  Instead, 
ESCs lacking LSD1 activity fail to fully differentiate and ESC-specific enhancers 
fail to undergo the histone demethylation events associated with differentiation. 
At active enhancers, LSD1 is a component of the NuRD complex, which contains 
additional subunits that are necessary for ESC differentiation.  We propose that 
the LSD1-NuRD complex decommissions enhancers of the pluripotency program 
upon differentiation, which is essential for complete shutdown of the ESC gene 
expression program and the transition to new cell states. 
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The histone H3K4/K9 demethylase LSD1 (Lysine-specific-demethylase-1, 
KDM1A) is among the chromatin regulators that have been implicated in control of 
early embryogenesis6-8.  Loss of LSD1 leads to embryonic lethality and ESCs lacking 
LSD1 function fail to differentiate into embryoid bodies6-8. These results suggest that 
LSD1 contributes to changes in chromatin that are critical to differentiation of ESCs, 
but LSD1’s role in this process is not yet understood. To investigate the function of 
LSD1 in ESCs, we first identified the sites it occupies in the genome using chromatin 
immunoprecipitation coupled with massively parallel DNA sequencing (ChIP-Seq; 
Fig. 1, and Supplementary Fig. 1).  The results revealed that LSD1 occupies the 
enhancers and core promoters of a substantial population of actively transcribed and 
bivalent genes (Fig. 1a, b, and Supplementary Table 1).  Inspection of individual gene 
tracks showed that LSD1 co-occupies well-characterized enhancer regions with the 
ESC master transcription factors Oct4, Sox2 and Nanog and the Mediator coactivator 
(Fig. 1b, and Supplementary Fig. 1). Loci bound by Oct4, Sox2 and Nanog are 
generally associated with Mediator and p300 coactivators and have enhancer 
activity9,10. A global view of Oct4, Sox2, Nanog and Mediator -occupied enhancer 
regions confirmed that 97% of the 3,838 high confidence enhancers were co-occupied 
by LSD1 (p < 10-9) (Fig. 1c, and Supplementary Table 2). This is consistent with 
evidence that LSD1 can interact with Oct4 (refs. 11,12). LSD1 signals were also 
observed at core promoter regions with RNA Polymerase II (Pol II) and TBP (Fig. 1d).  
The density of LSD1 signals at enhancers was higher than at core promoters (p < 10-16; 
Supplementary Fig. 1), indicating that LSD1 is associated predominantly with the 
enhancers of actively transcribed genes in ESCs. 
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It was striking to find that LSD1 is associated with active genes in ESCs 
because previous studies have shown that LSD1 is not essential for maintenance of 
ESC state, but is required for normal differentiation6-8.  We used an ESC 
differentiation assay to further investigate the involvement of LSD1 in cell state 
transitions (Fig. 2a, b).  Prolonged depletion of Oct4 in ZHBTc4 ESCs using 
doxycycline causes loss of pluripotency and differentiation into trophectoderm13.  As 
expected, loss of Oct4 expression led to a rapid loss of ESC morphology and a marked 
reduction in SSEA-1 and alkaline phosphatase, two markers of ESCs (Fig. 2c, and 
Supplementary Fig. 2).  When these ESCs were treated with the LSD1 inhibitor 
tranylcypromine (TCP) during Oct4 depletion, they failed to undergo the 
morphological changes associated with differentiation of ESCs (Fig. 2c).  Instead, the 
TCP-treated cells formed small colonies resembling those of untreated ESCs and 
maintained expression of SSEA-1 and alkaline phosphatase (Fig. 2c, and 
Supplementary Fig. 3).  Very similar results were obtained in LSD1 knockout ESCs 
(Supplementary Fig. 4, 5), and in cells treated with another LSD1 inhibitor, pargyline 
(Prg), or an shRNA against LSD1 (Supplementary Fig. 2, 3).  LSD1 inhibition also 
caused an increase in cell death during differentiation, as has been observed with cells 
lacking LSD1 in other assays7,8. These results suggest that LSD1 may be required for 
ESCs to completely silence the ESC gene expression program. 
 
Further analysis of ESCs forced to differentiate in the absence of LSD1 activity 
confirmed that these cells failed to fully transition from the ESC gene expression 
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program; while key genes of the trophectoderm gene expression program were 
activated, including Cdx2 and Esx1 (ref. 14), there was incomplete repression of many 
ESC genes, including Sox2 and Fbox15 (Fig. 2d).  A global analysis confirmed that a 
set of genes neighboring LSD1-occupied enhancers in ESCs are repressed upon 
differentiation, and that repression of this set of genes is partially relieved in the 
presence of TCP (Fig. 2e, and Supplementary Table 3).  Similar results were obtained 
with LSD1 knockout cells (Supplementary Fig. 4, 5), and cells treated with either 
pargyline or an shRNA against LSD1 (Supplementary Fig. 3). These results indicate 
that the trophectoderm differentiation program can be induced in cells lacking LSD1 
function, but the ESC program is not fully silenced in these cells. 
 
To gain further insight into the role of LSD1 in ESC differentiation, we 
investigated whether LSD1 is associated with previously described complexes, 
including NuRD (Nucleosome remodeling and histone deacetylase), CoREST 
(Cofactor of REST) and the AR/ER (Androgen receptor/ Estrogen receptor) 
complexes8,15-17.  We first studied whether the LSD1 found at Oct4-occupied genes is a 
component of NuRD because Oct4 and Nanog have been reported to interact with 
several components of NuRD11,12,18.  ChIP-Seq experiments confirmed that NuRD 
subunits Mi-2β, HDAC1 and HDAC2 co-occupy sites with LSD1 at enhancers (p < 
10-9; Fig. 3 and Supplementary Table 1). Immunoprecipitation of LSD1 confirmed its 
association with Mi-2β, HDAC1 and HDAC2 (Fig. 3b, c). We then investigated 
whether LSD1 is associated with CoREST; ChIP-Seq data revealed that a minor 
fraction of LSD1 co-occupies sites with CoREST and Rest (2% and 6%, 
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respectively)(Supplementary Fig. 6 and Supplementary Table 1).  As expected, LSD1-
REST sites were frequently found associated with neuronal genes (Supplementary Fig. 
7 and Supplementary Table 4). Immunoprecipitation experiments confirmed that 
LSD1 is associated with CoREST (Fig. 3b, c).  AR and ER are not expressed in ESCs 
based on the lack of histone H3K79me2 and H3K36me3 (modifications associated 
with transcriptional elongation) at the genes encoding these proteins (Supplementary 
Table 1).  Further examination of the ChIP-Seq data revealed that enhancers were 
significantly more likely to be occupied by the LSD1 and NuRD proteins as compared 
to REST and CoREST (p < 10-9) (Fig. 3d and Supplementary Fig. 8).  Multiple 
components of NuRD are dispensable for ESC state but required for normal 
differentiation6,19-21. ESCs with reduced levels of the core NuRD ATPase Mi-2β failed 
to differentiate properly and partially maintained expression of SSEA-1, alkaline 
phosphatase and ESC genes (Supplementary Fig. 9), which are the same phenotypes 
we observed with reduced levels of LSD1.  These results indicate that LSD1 at 
enhancers is associated with a NuRD complex that is essential for normal cell state 
transitions. 
 
Nucleosomes with histone H3K4me1 are commonly found at enhancers of 
active genes, and are a substrate for LSD1 (refs. 5,22).  If LSD1-dependent H3K4me1 
demethylase activity is involved in enhancer silencing during ESC differentiation, 
LSD1 inhibition should cause retention of H3K4me1 levels at active ESC enhancers 
when differentiation is induced.  During trophectoderm differentiation with control 
ESCs, we found p300 and H3K27ac levels reduced at a set of active ESC enhancers, 
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suggesting these enhancers were being silenced (Supplementary Fig. 10).  The levels 
of H3K4me1 at enhancers were also reduced, as seen for example at Lefty1 (Fig. 4a, 
and Supplementary Table 5), while the levels of H3K4me1 increased at newly active 
trophectoderm genes such as Gata2 (Fig. 4b).  In contrast, H3K4me1 signals were 
higher at LSD1- occupied enhancers in differentiating ESCs treated with TCP than in 
control cells, including Lefty1 and Sox2 (Fig. 4a, c). The majority of enhancers (1,722 
of 2,755) that were occupied by LSD1 and that experienced reduced levels of 
H3K4me1 during differentiation retained H3K4me1 in TCP-treated ESCs compared to 
untreated control differentiating ESCs (Fig. 4d, e).  These results are consistent with 
the model that LSD1 demethylates H3K4me1 at the enhancers of ESC-specific genes 
during differentiation, and that this activity is essential to fully repress the genes 
associated with these enhancers.    
 
Our results indicate that an LSD1-NuRD complex is required for silencing of 
ESC enhancers during differentiation, which is essential for complete shutdown of the 
ESC gene expression program and the transition to new cell states.  These results, 
together with those of previous studies on NuRD function18,21,23,24, suggest the 
following model for LSD1-NuRD in enhancer decommissioning.  LSD1-NuRD 
complexes occupy Oct4-regulated active enhancers in ESCs, but do not substantially 
demethylate histone H3K4 because LSD1’s H3K4 demethylase activity is inhibited in 
the presence of acetylated histones23,24.  Enhancers occupied by Oct4, Sox2 and Nanog 
are co-occupied by the HAT p300 and nucleosomes with acetylated histones 
(Supplementary Fig. 10 and ref. 10).  Thus, as long as the enhancer-bound 
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transcription factors recruit HATs to enhancers, the net effect of having both HATs 
and NuRD-associated HDACs present is to have sufficient levels of acetylated 
histones to suppress LSD1 demethylase activity.  During ESC differentiation, the 
levels of Oct4 and p300 are reduced, thus reducing the level of acetylated histones, 
which in turn permits demethylation of H3K4 by LSD1.  Consistent with this model, 
we find that the shutdown of Oct4 leads to reduced levels of p300 and histone 
H3K27ac at enhancers that are occupied by Oct4 and LSD1 (Supplementary Fig. 10, 
11), and this is coincident with reduced levels of methylated H3K4 (Fig. 4, and 
Supplementary Figs. 12, 13). This model would explain why key components of 
LSD1-NuRD complexes are not essential for maintenance of ESC state, but are 
essential for normal differentiation, when the active enhancers must be silenced. 
Additional HATs expressed in ESCs may also contribute to the dynamic balance of 
nucleosome acetylation. Future biochemical analysis of HAT, HDAC and demethylase 
complexes at enhancers will be valuable for testing this model and for further 
understanding how enhancers are regulated during differentiation.   
 
We conclude that LSD1-NuRD complexes present at active promoters in ESCs 
are essential for normal differentiation, when the active enhancers must be silenced. 
Given evidence that LSD1 is required for differentiation of multiple cell types6,25,26, 
LSD1 is likely to be generally involved in enhancer silencing during differentiation. 
The ESC gene expression program can be maintained in the absence of many other 
chromatin regulators2, and it is possible that some of these also play key roles in the 
transition from one transcriptional program to another during differentiation. 
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Methods Summary 
ESC Cell Culture Conditions 
ESCs were grown on irradiated murine embryonic fibroblasts (MEFs) and passaged as 
previously described9. In drug treatment experiments, ESCs were split off MEFs and 
treated with tranylcypromine (TCP, 1mM) or pargyline (Prg, 3mM) to inhibit LSD1 
activity. Lentiviral constructs were purchased from Open Biosystems and produced 
according to the Trans-lentiviral shRNA Packaging System (TLP4614). 
 
Differentiation assay, Immunofluorescence, and Alkaline Phosphatase Staining 
ZHBTc4 ESCs were split off MEFs in ESC media containing 2μg/ml doxycycline to 
reduce Oct4 expression levels. For Immunofluorescence, ESCs were crosslinked, 
blocked and permeabilized before incubation with Oct4 (Santa Cruz, sc-9081x; 1:200 
dilution) or SSEA1 (mc-480, DHSB, 1:20 dilution) antibodies.  Alexa-conjugated 
secondary antibodies were used for detection. Staining of ESCs for alkaline 
phosphatase was achieved using the Alkaline Phosphatase Detection Kit (Millipore, 
SCR004). Cells were harvested at indicated time points for ChIP-Seq, qPCR or 
expression array analyses. 
 
ChIP-Seq 
Chromatin immunoprecipitations (ChIPs) were performed and analyzed as previously 
described9. The following antibodies were used: LSD1 (Abcam, ab17721), Mi-2b 
(Abcam, ab72418), HDAC1 (Abcam, ab7028), HDAC2 (Abcam, ab7029), REST 
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(Millipore, 07-579), CoREST (Abcam, ab32631), H3K4me1 (Abcam, ab8895), p300 
(Santa-Cruz, sc-584) and H3K27Ac (Abcam, ab4729).  
For ChIP-Seq analyses, reads were aligned with Bowtie and analyzed as described in 
Supplemental Information. 
 
Full Methods and any associated references are available in Supplementary 
Information of the paper at www.nature.com/nature. 
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FIGURE LEGENDS 
 
Figure 1: LSD1 is associated with enhancer and core promoter regions of active 
genes in ESCs  
a, LSD1 occupies a substantial population of actively transcribed genes in murine 
ESCs. Pie charts depict active (green), bivalent (yellow) and silent (red) genes, and the 
proportion (black lines) occupied by either LSD1, Pol II, or the Polycomb protein 
Suz12 (Supplementary Table 1, and Supplementary Information). The numbers depict 
the number of genes bound over the total number of genes in each of the active, 
bivalent, and silent classes. LSD1 ChIP-Seq data is from combined biological 
replicates using an antibody specific for LSD1 as determined by knockdown 
experiments (Supplementary Fig. 1). The p-value for each category was determined by 
a hypergeometric test.  
b, LSD1 occupies enhancers and core promoter regions of actively transcribed genes. 
ChIP-Seq binding profiles (reads/million) for ESC transcription factors (Oct4, Sox2, 
Nanog), coactivator (Med1), chromatin regulator (LSD1), the transcriptional apparatus 
(Pol II, TBP) and histone modifications (H3K4me1, H3K4me3, H3K79me2, 
H3K36me3) at the Oct4 (Pou5f1) and Lefty1 loci in ESCs, with the y-axis floor set to 
1. Gene models, and previously described enhancer regions27-29 are depicted below the 
binding profiles.  
c, LSD1 occupies enhancer sites. Density map of ChIP-Seq data at Oct4, Sox2, Nanog, 
and Med1 co-occupied enhancer regions.  Data is shown for ESC regulators (Oct4), 
coactivators (Med1 and p300) and a chromatin regulator (LSD1) in ESCs. Enhancers 
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were defined as Oct4, Sox2, Nanog and Mediator co-occupied regions.  Over 96% of 
the 3,838 high confidence enhancers were co-occupied by LSD1 (p < 10-9).  Color 
scale indicates ChIP-seq signal in reads per million. 
d, LSD1 occupies core promoter sites. Density map of ChIP-Seq data at transcriptional 
start sites (TSS) of genes neighboring the 3,838 previously defined enhancers (Fig. 
1c). Data is shown for components of the transcription apparatus (Pol II and TBP) and 
the chromatin regulator LSD1 in ESCs. Core promoters were defined as the closest 
TSS from each enhancer. Color scale indicates ChIP-Seq signal in reads per million. 
 
Figure 2: LSD1 inhibition results in incomplete silencing of ESC genes during 
differentiation 
a, Schematic representation of trophectoderm differentiation assay using doxycycline-
inducible Oct4 shutdown murine ESC line ZHBTc4. Treatment with doxycycline for 
48 hours leads to depletion of Oct4 and early trophectoderm specification. Cells were 
treated with DMSO (control) or the LSD1 inhibitor tranylcypromine (TCP) for 6 hours 
before 2μg/ml doxycycline was added for an additional 24 or 48 hours. 
b, Treatment of ZHBTc4 ESCs with doxycycline leads to loss of Oct4 proteins. Oct4 
and LSD1 protein levels in nuclear extracts (NE) determined by Western blot (WB) 
before and after treatment of ZHBTc4 ESCs with 2μg/ml doxycycline. Tubulin served 
as loading control. 
c, Doxcycline-treated cells treated with TCP maintained SSEA-1 cell surface marker 
expression. Cells were stained for Hoechst (Hoe), Oct4 and SSEA-1. Scale bar = 
100μM  
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d, Expression of selected ESC and trophectodermal genes 48 hours after Oct4 
depletion in DMSO- versus TCP-treated cells (black versus grey bars, respectively). 
Treatment of TCP partially relieved repression of ESC genes, but did not affect 
upregulation of trophectodermal genes. Error bars reflect standard deviation from 
biological replicates. 
e, Genes neighboring LSD1-occupied enhancers are less downregulated during ESC 
differentiation following TCP treatment. Mean fold change in expression of the 630 
downregulated (at least 1.25 fold; p < 0.01) genes nearest LSD1- occupied enhancers 
(Fig. 1c) during differentiation of TCP-treated and untreated control cells. Alleviation 
of repression is significantly higher (p < 0.005) for LSD1 enhancer-bound repressed 
genes compared to all repressed genes. 
 
Figure 3: LSD1 is associated with a NuRD complex at active enhancers in ESCs 
a, NuRD components occupy enhancers and core promoter regions of actively 
transcribed genes. ChIP-Seq binding profiles (reads/million) for transcription factors 
(Oct4, Sox2, Nanog), coactivator (Med1), and chromatin regulators (LSD1, Mi-2β, 
HDAC1, HDAC2), at the Oct4 (Pou5f1) and Lefty1 loci in ESCs, with the y-axis floor 
set to 1.  Gene models, and previously described enhancer regions27-29 are depicted 
below the binding profiles.  
b, LSD1 is associated with NuRD components Mi-2β, HDAC1, HDAC2, as well as 
CoREST. LSD1 and HDAC1 are detected by Western blot (WB) after 
immunoprecipitation of crosslinked chromatin using LSD1, HDAC1, HDAC2, Mi-2β, 
or CoREST antibodies. IgG is shown as a control. 
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c, LSD1 and HDAC1 are detected by Western blot (WB) after immunoprecipitation of 
uncrosslinked nuclear extracts (NE) using LSD1, HDAC1, HDAC2, Mi-2β, or 
CoREST antibodies. IgG is shown as a control. 
d, The occupancy of enhancers by NuRD proteins (Mi-2β, HDAC1 and HDAC2) is 
significantly greater than the occupancy by CoREST or REST (p < 10-9). The height of 
the bars represents the percentage of the 3,838 enhancers co-occupied by LSD1, 
NuRD proteins (Mi-2β, and either HDAC1 or HDAC2), CoREST and REST. 
 
Figure 4: LSD1 is required for H3K4me1 removal at ESC enhancers 
a, H3K4me1 levels are reduced at LSD1-occupied enhancers upon ESC 
differentiation, and this effect is partially blocked upon TCP treatment. b, TCP 
treatment does not affect the increase in H3K4me1 levels at trophectodermal genes 
during differentiation. ChIP-Seq binding profiles (reads/million) for Oct4 and LSD1 at 
the Lefty1 and Gata2 loci in ESCs.  Below these profiles, histone H3K4me1 levels are 
shown for ZHBTc4 control ESCs, cells treated with doxycycline for 48 hours to 
repress Oct4 and induce differentiation (ESCs +Dox), and ESCs treated with 
doxycycline and TCP (ESCs +Dox,TCP). For appropriate normalization, ChIP-Seq 
data for histone H3K4me1 is shown as rank normalized reads/million with the y-axis 
floor set to 1 (Supplementary Information). Gene models, and previously described 
enhancer regions29,30	  are depicted below the binding profiles. 
c, Sum of the normalized H3K4me1 density +/- 250 nucleotides surrounding LSD1-
occupied enhancer regions before and during trophectoderm differentiation in the 
presence or absence of TCP. The associated genes were identified based on their 
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proximity to the LSD1-occupied enhancers.  
d,  Sum of the normalized H3K4me1 density +/- 250 nucleotides surrounding 1,722 
LSD1-occupied enhancers before and during differentiation in the presence or absence 
of TCP. Of the 2,755 LSD1-occupied enhancers having reduced levels of H3K4me1 
upon differentiation, 63% (1,722) display higher H3K4me1 levels after TCP treatment 
(p < 10-16). 
e, Heatmap displaying the sum of the normalized H3K4me1 density +/- 250 
nucleotides surrounding the 1,722 LSD1-occupied enhancers that retained H3K4me1 
in TCP-treated ESCs compared to untreated control differentiating ESCs. Color scale 
indicates ChIP-Seq signal in normalized reads per million.  
 
 
 	  	  
	   102	  
 
	   103	  
 
  
0! 24! 48! 0! 24! 48!
Control! 2-PCPA!
WB: Oct4!
WB: LSD1!
WB: Tubulin!
Time (hrs.):!
B: Tubulin!
a!
Oct4ON! Oct4OFF!
Doxycycline!
TCP!
0 hrs! 24 hrs! 48 hrs!-6 hrs!
ZHBTc4 ESCs!
b!
0!
-24!
-16!
-8!
Zic3! Sox2! Fbox15! Dppa5! Oct1! Nanog!
-9!
-6!
-3!
-4.5!
-3.0!
-1.5!
-3!
-2!
-1!
-2.1!
-1.4!
-0.7!
!
Fo
ld 
Ch
an
ge
!
Ex
pr
es
sio
n!
log
2!
Figure 2!
!
ESC Genes!d!
0! 24! 48! 0! 24! 48!
ontrol! 2- !
: ct4!
: L 1!
: Tubulin!
Time (hrs.):! ! ! ! ! ! !
C tr l! -PCPA!
B: Oct !
B: SD !
B: li !
Ti e (hrs.):! 0! 24! 48! 0! 24! 48!
ontrol! 2- !
W : ct4!
W : L 1!
W : Tubulin!
Time (hrs.):! ! ! ! ! ! !
tr l! - !
: t4!
: L 1!
: ub lin!
i  ( rs.):!
+!-!
0! 24!
li
i ! 4
TCP:!
Time (hrs):!
B: Oct4!
B: LSD1!
Early  Trophectoderm!
-2.5!
-1.5!
-0.5!
M
ea
n 
!
Fo
ld 
Ch
an
ge
!
log
2!  !
0!
e! !Repressed !
Genes!
*!
ESCs +Dox!
!ESCs +Dox,TCP!
Tead2! Cldn4! Plac1! Dkkl1! Cdx2! Esx1!
1!
2!
3!
1.5!
3.0!
4.5!
2!
4!
6!
5!
10!
15!
!
Trophectoderm Genes!
Phase!
ES
Cs
!
+D
ox
,T
CP
!
 0 hrs!
Hoe! Oct4! SSEA1! Phase! Hoe! Oct4! SSEA1! Phase! Hoe! Oct4! SSEA1!
ES
Cs
!
+D
ox
!
ES
Cs
!
 24 hrs!  48 hrs!
c!
	   104	  
a!
Ig
G
!
L
S
D
1
!
C
o
R
E
S
T
!
M
i-
2
"
!
10%!
Crosslinked!
H
D
A
C
1
!
H
D
A
C
2
!
WCE!
b!
WB: LSD1!
WB: HDAC1!
Core Promoter!
Oct4! Lefty1!
Figure 3!
d!
Enhancers!
E
n
h
a
n
c
e
rs
 !
O
c
c
u
p
ie
d
 (
%
) 
!
100!
L
S
D
1
!
50!
0!
c!
Transcription Factors!
Chromatin Regulators!
70!
Coactivator!
70!
70!
15!
10!
5!
5!
5!
15kb! 15kb!
LSD1!
CHD4!
HDAC1!
HDAC2!
Oct4!
Sox2!
Nanog!
Med1!
M
i-
2
"
!
H
D
A
C
1
/2
!
C
o
R
E
S
T
!
R
E
S
T
!
Ig
G
!
L
S
D
1
!
C
o
R
E
S
T
!
M
i-
2
"
!
10%!
Uncrosslinked!
H
D
A
C
1
!
H
D
A
C
2
!
NE!
WB: LSD1!
WB: HDAC1!
	   105	  
  
ESC!
ESC !
+Dox     !
ESC!
+Dox +TCP!
a!
Figure 4!
10!
7!
7!
7!
Enhancers!
Chromatin Regulator!
b!
Transcription Factor!
c! d!
Lefty1!
80!
40!
60!
20!
0!
Dox:!
H
3
K
4
m
e
1
!
D
e
n
s
it
y
!
TCP:!
+!+!-!
-!+!-!
e!
Core Promoter!
1
,7
2
2
 L
S
D
1
 o
c
c
u
p
ie
d
 !
e
n
h
a
n
c
e
r 
re
g
io
n
s
!
H3K4me1!
100!
Gata2!Lefty1!
15kb!
LSD1!
Oct4!
H3K4me1!
H3K4me1!
H3K4me1!
70!
10!
7!
7!
7!
20kb!
LSD1!
Oct4!
H3K4me1!
H3K4me1!
H3K4me1!
70!
Sox2!
120!
60!
90!
30!
0!
+!+!-!
-!+!-!
Sall4!
160!
80!
120!
40!
0!
+!+!-!
-!+!-!
Trim28!
160!
100!
130!
70!
0!
+!+!-!
-!+!-!
Esrrb!
120!
80!
100!
60!
0!
+!+!-!
-!+!-!
Phc3!
80!
40!
60!
20!
0!
+!+!-!
-!+!-!
Akt2!
160!
80!
120!
40!
0!
+!+!-!
-!+!-!
LIFR!
120!
60!
90!
30!
0!
+!+!-!
-!+!-!
Dppa5!
140!
70!
105!
35!
0!
+!+!-!
-!+!-!
1,722 LSD1 !
Occupied Enhancers!
100!
50!
75!
25!
0!
+!+!-!
-!+!-!
Dox:!
H
3
K
4
m
e
1
!
D
e
n
s
it
y
!
TCP:!
+! +!-!
-! +!-!
Dox:!
TCP:!
	   106	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
	   107	  
Chapter 3 
 
Summary And Future Perspectives 
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Cellular differentiation is the developmental process by which cells become more 
specialized.  Differentiation depends on changes in gene expression programs that 
are associated with changes in chromatin.  In previous chapters, I described how 
deciphering the molecular mechanisms controlling differentiation is paramount to 
understanding development. Specifically, I discussed new insights revealing that 
chromatin regulators of opposing functions share a common set of active genes in 
embryonic stem (ES) cells, suggesting a model of a dynamic balance in the 
transcriptional control of cell state and differentiation. I described the mechanisms 
by which chromatin regulators contribute to the control of the ES cell state and 
differentiation, where these regulators play critical roles both in activating new 
gene expression programs and in silencing old programs.  
In this chapter, I discuss how reprogramming is another valuable method for 
studying the molecular mechanisms involved in cell transitioning. I then discuss 
how these mechanisms can go awry and lead to diseased states. I then conclude by 
offering future challenges and possible approaches to test this dynamic model in 
other cell types. 
Insights into Reprogramming to a Pluripotent State 
The study of chromatin regulators in ES cell control has provided new insights into 
mechanisms that are involved in generation of induced pluripotent stem (iPS) cells 
(Box 2). These cells can been generated from a broad range of somatic cell types 
by using forced expression of Oct4, Sox2 and other transcription factors1-4, and are 
apparently equivalent to ES cells in their ability to generate all cell types of the 
developing organism5-8, and in gene expression7,9.  
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Chromatin regulators play critical roles in either the reactivation of the pluripotent 
gene expression program or the silencing of the somatic gene expression program 
during iPS cell generation (reviewed in ref. 4)(Fig 1). Reactivation of the 
pluripotent gene expression program requires the removal of the DNA methylation 
and H3K9 methylation that normally occurs during differentiation when active ES 
cell genes are silenced. The mechanisms by which DNA methylation is lost at the 
promoters of ES cell transcription factors in iPS cells have not been elucidated, but 
the removal of H3K9 methylation likely involves H3K9 histone-demethylating 
proteins such as Jmjd1a and Jmjd2c10. Reprogramming of somatic cells to iPS cells 
is accompanied by increased expression of Jmjd1a and Jmjd2c. These two proteins 
occupy active genes in ES cells, where they remove H3K9 methylation and 
positively regulate gene expression10. 
 
Silencing of the somatic cell gene expression program during the generation of iPS 
cells requires a different set of regulators (Fig 1). Repressive chromatin regulators, 
which include histone-modifying proteins such as SetDB1 and PcG, are important 
for heterochromatin formation and transcriptional silencing of somatic genes. 
Interestingly, the H3K79 methyltransferase Dot1L inhibits this process, as 
prolonged H3K79 methylation at  
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Figure 1 
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Figure 1: Chromatin regulators participate in reprogramming of fibroblasts 
to induced pluripotent stem (iPS) cells 
Reprogramming of murine somatic cells is a multistep process by which 
transcription factors or small molecules induce a pluripotent stem cell state. During 
generation of iPS cells, chromatin regulators participate in the reactivation of 
certain genes of the pluripotent gene expression program. In somatic fibroblast 
cells, many of the enhancers and promoters of genes associated with pluripotency 
such as Oct4 and Nanog contain nucleosomes with H3K9 and H3K27 
trimethylation. These genes are DNA methylated and are silent. During 
reprogramming, enhancer and promoter regions lacking DNA methylation gain 
H3K4 dimethylation, but pluripotency-associated genes remain silent until later 
steps when the histone modifications associated with repression are lost. How 
DNA methylation is lost from these genes is not fully understood, but loss of 
H3K9 and H3K27 methylation likely involves the activities of histone-
demethylating enzymes such as Jmjd1a and Jmjd2c. Chromatin regulators also 
participate in the silencing of the somatic gene expression program. Recently, 
Dot1L was shown to prevent silencing of fibroblast genes such as Snai1. In 
fibroblasts, a subset of somatic genes are active and contain nucleosomes with 
H3K79 dimethylation (H3K79me2). Removal of Dot1L leads to loss of 
H3K79me2, and facilitates the repression of these genes by PcG proteins and 
H3K9-methyltransferases. 
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somatic genes during the initial phases of reprogramming prevents silencing and 
delays activation of the pluripotent gene expression program. Reduction in the 
function or levels of Dot1L enhances reprogramming, at least in part, by 
facilitating the removal of H3K79 methylation at somatic genes that need to be 
silenced. Hence, Dot1L and H3K79 methylation antagonizes the efficient 
repression of the somatic gene expression program during reprogramming11. Given 
this antagonistic function is observed in other systems12, Dot1L inhibition may 
enhance reprogramming in a broad range of somatic cell types by facilitating the 
silencing of lineage-specific gene expression programs. In summary, the levels of 
specific chromatin regulators can be modulated to increase the efficiency by which 
iPS cells are generated.  
 
Insights into Disease States 
The study of chromatin regulators in ES cell control has also provided new insights 
into mechanisms that are involved in several human diseases (Fig 2). For example, 
improved understanding of the functions of nucleosome remodeling complexes 
such as the NuRD complex in cell transitioning has provided new insights into the 
molecular pathways affected by deregulation of this complex. 
Of the various NuRD subunits, the metastasis-associated (MTA) subunits have 
been extensively studied in the context of human disease. Deregulation of MTA-
containing NuRD complexes have been implicated in a variety of cancers, 
including breast, colorectal, gastric, oesophageal, endometrial, pancreatic, ovarian, 
non-small-cell lung, prostate, hepatocellular carcinoma, and diffuse large  
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Figure 2 
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Figure 2: NuRD participates in an epithelial-mesenchymal transition (EMT) 
in breast cancer 
Non-metastatic breast cancer cells express epithelial markers such as E-cadherin 
and estrogen-receptor alpha (ER-a). During EMT, expression of certain epithelial 
genes are lost as cells acquire mesenchymal characteristics and metastatic ability. 
The oncogenic transcription factor Twist binds to the E-Box motif at the ER-a 
gene, where it binds to NuRD to facilitate gene silencing. Reduced levels of 
histone H3 acetylation by NuRD is accompanied by increased H3K9 methylation 
and chromatin compaction. DNA methyltransferases catalyze DNA methylation to 
enforce stable silencing. 
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B cell lymphoma (reviewed in ref. 13). Recently, NuRD was found to interact with 
the oncogene Twist14-16, a master transcription factor that, when overexpressed, 
promotes an epithelial-mesenchymal transition (EMT) in various cancers17. During 
EMT, cells lose expression of certain epithelial genes and gain expression of 
certain mesenchymal genes, which is crucial for initiation of cancer metastasis18. In 
breast cancer cells expressing high levels of Twist, NuRD is associated with the 
oncogene in silencing of the epithelial markers E-cadherin and Estrogen Receptor-
alpha (ER-a)14-16. During EMT, the NuRD complex deacetylates histones, which 
results in increased H3K9 methylation and chromatin condensation. Twist also 
interacts with Dnmt3b to methylate DNA and facilitate gene repression16. Reduced 
expression of these genes contributes to an EMT in these cells and cancer 
metastasis (Fig 2).   
Knowledge that LSD1 and NuRD associate with master transcription factors in ES 
cells and promote the multi-step silencing of the ES cell gene expression program 
during differentiation suggests therapies that might compensate for the loss of the 
epithelial gene expression program during EMT and cancer metastasis. Histone 
deacetyltransferases reside within the NuRD complex19-21, so it is conceivable that 
small molecule antagonists of HDACs would lead to an increase in transcriptional 
activity of NuRD target genes. Alternatively, as the NuRD complex frequently 
associates with oncogenic transcription factors to repress transcription (reviewed in 
ref. 13), drugs interfering with the interactions of these proteins may represent a 
more selective approach to inhibiting NuRD functions in cancer cells. Chromatin 
regulators with enzymatic activities are a new class of targets for small-molecule 
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drug discovery, and we can expect new developments in this field in the near 
future. 
Future Perspective 
Chromatin regulators play important roles in controlling the ES cell gene 
expression program to either maintain self-renewing cells in a pluripotent state, or 
to allow them to differentiate into all cell types of the developing and adult 
organism. Master transcription factors recruit chromatin regulators to contribute to 
the activation of a large fraction of active genes, and to the poised activation of 
lineage-specific genes. At actively transcribed genes, chromatin regulators 
implicated in maintenance of cell state occupy enhancer elements and core 
promoters and modulate RNA expression levels through mechanisms that include 
creating accessible binding sites, looping in of enhancer elements to core 
promoters, and releasing paused RNA polymerase. At lineage-specific genes, 
chromatin regulators occupy promoter regions and help create a poised state by 
pausing RNA polymerase and creating repressive chromatin architecture. During 
differentiation, chromatin regulators facilitate the silencing of genes encoding ES 
cell transcription factors and the selective activation of specific lineage-specific 
genes.  
 
An interesting regulatory feature of ES cells is that chromatin regulators of 
opposing functions share common target genes in ES cells, suggesting a more 
dynamic view on the mechanisms governing ES cell state. An intriguing model is 
that in ES cells a dynamic balance exists at genes between regulators that promote 
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gene activity and those that promote gene silencing. At active genes, the activities 
of chromatin regulators responsible for maintained gene activation predominate, 
and the net effect of having regulators of opposing activities is to keep genes 
poised for repression. At lineage-specific genes, the chromatin regulators 
responsible for gene repression predominate, and the net effect of having 
regulators of opposing activities at these genes is to keep genes poised for 
activation. During ES cell differentiation, the levels or functions of chromatin 
regulators associated with gene activation are reduced at a set of active genes, 
allowing these genes to become silenced. At lineage-specific genes, the levels or 
functions of chromatin regulators associated with repression are reduced at 
selected genes, and lineage-specific transcription factors are selectively activated. 
ES cells are a powerful model system for discovering regulatory features of the 
control of cell state, and it would be important to test if this model is true in other 
cell types, such as adult stem and progenitor cells that can also differentiate, to 
improve our understanding on the regulation of cell identity, the process of 
mammalian development, and how regulation goes awry in disease. Insights from 
ES cells, reprogramming and disease support the idea that chromatin regulators are 
important in the control of cell state in various cell types. Therefore, if this model 
holds true for most cell types, then identifying the functions and localization of all 
chromatin regulators in all cell types would significantly improve our 
understanding of the mechanisms involved in cell state control and differentiation. 
For example, the concept that some regulators activate transcription and others 
repress transcription is almost certainly operative in all cell types, suggesting that 
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improved understanding of global control on gene expression will depend on 
ascertaining which of these functions applies to each chromatin regulator in each 
cell type. With emerging evidence that signaling cues can transmit information 
about the surrounding environment to genes occupied by master transcription 
factors and associated regulators in a cell type-specific-manner22, better perspective 
on the cell-type-specific recruitment of chromatin regulators to genes in each cell 
type will be crucial to elucidating the potential roles for these regulators in control 
of cell state and differentiation.  
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Box 2: Changes in Chromatin Structure During Reprogramming to a Pluripotent 
State  
Since 2006 (ref. 1), the stepwise mechanism by which transcription factors or small 
molecules induce a pluripotent state has been well studied (reviewed in ref. 2)(Fig 1). 
For example, reprogramming of mouse fibroblast cells requires the stepwise transition 
through key intermediate steps, with fewer and fewer cells advancing. Increase in 
proliferation rate and decrease in cell size are the first noticeable changes in the 
reprogramming of fibroblasts3. These changes are accompanied by the induction of 
proliferation genes and silencing of the somatic gene expression program4-6. 
Mesenchymal cells such as fibroblasts need to acquire epithelial characteristics similar 
to ES cells, and thus undergo a mesenchymal-epithelial transition (MET) by 
upregulating epithelial genes such as CDH1 (encodes E-cadherin), and downregulating 
mesenchymal genes such as Snai1 (refs. 5,7). After these characteristics have been 
established, other ES cell markers such as SSEA1 are induced7-9, as well as many 
embryonic genes involved in housekeeping functions5,6,10. Expression of the 
pluripotency-related genes Oct4, Sox2 and Nanog, and the jump-start of the 
pluripotency gene expression program, are considered to be the final step of 
reprogramming8. 
 
Alterations in the levels or functions of chromatin regulators affect reprogramming 
efficiency, suggesting that changes in chromatin are crucial for inducing a pluripotent 
state11. In fibroblasts and other somatic cells, promoters of key pluripotency-related 
genes such as Oct4 and Nanog lack histone H3K4me3, the surrounding DNA is 
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methylated, and these genes are silenced1,6. Histones H3K27 and H3K9 methylation 
can also often be found at many of these promoters6,10,12,13. It is unclear when DNA 
demethylation and the loss of these histone methylation marks occur during 
reprogramming, however recent evidence suggests that specific chromatin changes 
precede the activation of pluripotency-related genes4,10. During the initial steps of 
reprogramming, enhancer elements and promoter regions of certain pluripotency-
related genes that lack DNA methylation in fibroblasts gain histone H3K4 
dimethylation (H3K4me2). Increased H3K4 methylation does not affect the levels of 
H3K27 methylation at these genes, which remain silent until later steps of 
reprogramming when H3K27 methylation levels are reduced4. Changes in chromatin 
structure also occur at enhancer elements and core promoters of fibroblast genes that 
must be silenced. H3K4 methylation is lost early from core promoters of these genes, 
while DNA methylation of enhancer elements occurs much later in reprogramming4. 
Given DNA methylation is required to stably silence genes during ES cell 
differentiation13, this observation would explain why some cells in the intermediate 
steps of reprogramming can return to a fibroblast-like cell state upon removal of 
reprogramming factors8,9.  
 
In summary, knowledge of the mechanisms underlying reprogramming, including the 
changes in chromatin structure that occur during this process, is critical for advancing 
therapeutic application of induced pluripotent stem (iPS) cells.  
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Supplementary Data File 1 
 
Supplementary Data File 1 contains ChIP-Seq data in compressed WIG format 
(WIG.GZ) for upload into the UCSC genome browser1.  This file contains data for 
mES_H3K4me1, DMSO_H3K4me1, DMSO_48HR_H3K4me1, 
TCP_48HR_H3K4me1, mES_H3K4me3, mES_H3K79me2, mES_H3K36me3, 
mES_Oct4, mES_Sox2, mES_Nanog, mES_Pol II, mES_TBP, mES_LSD1, 
mES_p300, mES_REST, mES_CoREST, mES_Suz12, mES_H3K27ac, 
mES_HDAC1, mES_HDAC2, mES_Mi-2b, mES_DMSO_H3K27ac, 
mES_DMSO_H3K4me1, mES_C646_H3K27ac, mES_C646_H3K4me1, 
WCE_DMSO, WCE_48HR_DMSO, WCE_48HR_TCP, and WCE_mES. 
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The first track for each data set contains the ChIP-Seq density across the genome in 
25bp bins.  The minimum ChIP-Seq density shown in these files is 1.0 reads per 
million total reads.  For DMSO_H3K4me1, DMSO_48HR_H3K4me1, and 
TCP_48HR_H3K4me1 datasets, the minimum ChIP-Seq density is 1 normalized read 
per million total reads. Subsequent tracks identify genomic regions identified as 
enriched at a p-value threshold of 10-9.  
 
Supplementary Discussion 
 
To address LSD1 function in ESCs and during ESC differentiation, cells were treated 
with the monoamine oxidase inhibitors (MAOIs) tranylcypromine (TCP) or pargyline 
(Prg). Mechanistically, LSD1 is unique relative to other demethylases, as it 
demethylates lysine residues via a flavin–adenine dinucleotide–dependent reaction2,3. 
This reaction is inhibited by MAOIs, which are used in the treatment of certain 
psychiatric and neurological disorders4-8. Furthermore, TCP inhibits LSD1 at levels 
comparable to MAO inhibition of clinical mitochondrial MAOI targets6,7. Finally, the 
effects of inhibition by TCP and Prg were highly similar in our assays. Therefore, we 
found TCP and Prg suitable to study LSD1 activity during differentiation of ES cells. 
 
Previous studies demonstrated that LSD1 is required for mouse development beyond 
e6.5 (ref. 9). The differentiation defect is recapitulated in vitro in embryoid body (EB) 
formation assays, where ESCs are plated in suspension in media lacking leukemia 
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inhibitory factor (LIF), causing ESC differentiation.  In these assays, deletion of LSD1 
leads to considerable cell death and formation of small EBs, with the remaining cells 
expressing markers of all three germ layers9,10. The differentiation defect is also 
recapitulated in vitro in the Oct4 depletion assay used in the present study, where 
ESCs preferentially differentiate into the trophectodermal lineage. In this assay, 
inhibition of LSD1 with either TCP or Prg leads to considerable cell death, and 
surviving cells express trophectodermal differentiation markers. Thus, very similar 
effects are observed in these two assays. 
 
In the Oct4 depletion assay used in the present study, full repression of key ESC 
regulators such as Nanog is not achieved in the presence of LSD1 inhibitors 48 hours 
after Oct4 depletion is initiated.  Similar results were obtained for Nanog in the assay 
used by Foster et al. (2010) with LSD1 mutant ESCs 48 hours after LIF removal9. In 
this latter assay, Nanog levels were ultimately fully reduced in ESCs lacking LSD1. 
Our interpretation of all these data is that inhibition of LSD1 delays differentiation 
because there is a delay in reducing levels of key ESC regulators whose enhancers are 
occupied by LSD1.    
 
Previous studies also report that deletion of LSD1 protein destabilizes Co-REST, 
which leads to a less active LSD1-CoREST-HDAC complex9. Accordingly, 
developmental regulators targeted by the LSD1-CoREST-HDAC complex are de-
repressed, and this may explain the defect observed in ESC differentiation.  In 
experiments using small molecule inhibitors of LSD1 activity, we did not observe 
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significant changes in genes associated with LSD1-REST co-occupied sites. One 
explanation for this discrepancy may be that loss of LSD1 proteins destabilizes the 
CoREST-HDAC complex, while small molecules inhibiting LSD1 enzymatic activity 
may not alter the stability of the complex, thereby giving a different transcriptional 
phenotype. Thus, the different methods (gene deletion versus enzymatic inhibition) of 
LSD1 inhibition may explain the discrepancy in gene expression. 
 
Differences were observed for LSD1 function in mouse and human ESCs. Although 
mouse ESCs fail to differentiate into embryoid bodies in absence of LSD1 (refs. 9-11), 
human ESCs differentiate when LSD1 levels are reduced12. In both mouse and human 
ESCs, LSD1 is found at Oct4 and Nanog -occupied regions. Similar to our 
observations in the Oct4 depletion assay, a subpopulation of differentiating human 
ESCs with reduced LSD1 levels retained the expression of pluripotency markers12.  
 
Supplementary Experimental Procedures 
 
Cell Culture Conditions and Differentiation Assays 
 
Embryonic Stem Cells 
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V6.5, ZHBTc4, and E14 murine ESCs were grown on irradiated murine embryonic 
fibroblasts (MEFs), unless otherwise stated. Cells were grown under standard ESC 
conditions as described previously13. Briefly, cells were grown on 0.2% gelatinized 
(Sigma, G1890) tissue culture plates in ESC media; DMEM-KO (Invitrogen, 10829-
018) supplemented with 15% fetal bovine serum (Hyclone, characterized SH3007103), 
1000 U/mL LIF (ESGRO, ESG1106), 100 μM nonessential amino acids (Invitrogen, 
11140-050), 2 mM L-glutamine (Invitrogen, 25030-081), 100 U/mL penicillin, 100 
μg/mL streptomycin (Invitrogen, 15140-122), and 8 nL/mL of 2-mercaptoethanol  
(Sigma, M7522). 
 
Generation of LSD1 knockout ESC lines (Supplementary Fig. 4, 5) 
An E14 ESC line expressing a Cre-estrogen receptor fusion protein from the ROSA26 
locus was used to generate cells in which LSD1 can be inactivated conditionally. 
Briefly, LSD1 Lox/Δ3 ESCs were generated as previously described12, in which one 
LSD1 allele has exon 3 flanked by LoxP sites (floxed) and the second has exon 3 
deleted. Induction of Cre activity by addition of 4-hydroxytamoxifen (4-OHT, Sigma, 
H7904) to the growth medium resulted in complete recombination of the remaining 
floxed allele (to generate LSD1 Δ3/Δ3) within 6 hours. Cells were grown in the 
absence of irradiated MEFs under standard ESC conditions as described previously13.  
 
Generation and Expression of LSD1 Expression Constructs in ESCs (Supplementary 
Fig. 5) 
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Two forms of human LSD1 were generated by PCR with primers containing tails of 
family D vector homology for cloning into pCAGGs expression vectors. An enhanced 
green fluorescent protein (EGFP) tag was added to the N-terminus of either the full-
length LSD1 protein, or the catalytically inactive form of LSD1 with a lysine to 
alanine mutation introduced at residue 661 by site-directed mutagenesis14. 
 
For expression of LSD1 constructs in ESCs, LSD1 Lox/Δ3 and Δ3/Δ3 E14 ESCs 
were plated in 6-well culture plates. The following day, cells were transfected with 
2μg pCAGGs construct and 2μg of the pMONO-hygro plasmid containing the 
hygromycin resistance gene (Invivogen, pmonoh-mcs) using 10μl Lipofectamine 2000 
(Invitrogen, 11668-019). After 24 hours, the media was removed and replaced with 
ESC media containing 400μg/ml hygromycin. 24 hours after hygromycin addition, 
hygromycin concentration was reduced to 200μg/ml for the duration of the 
experiment. 
 
Differentiation of ESCs (Fig. 2, 4, and Supplementary Fig. 2, 3, 9, and 10) 
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For immunofluorescence, monitoring H3K4me1 levels and ESC expression analysis 
during differentiation following either DMSO, TCP or Prg treatment, ZHBTc4 ESCs 
were split off MEFs, placed in a tissue culture dish for 45 minutes to selectively 
remove the MEFs, and plated on either 6-well or 15cm cell culture plates. The 
following day, cells were treated with either DMSO, 1mM TCP or 3mM Prg for 6 
hours in ESC media. After 6 hours, the media was removed and replaced with ESC 
media containing 2μg/ml doxycyline and either DMSO, TCP or Prg. 24 hours after 
doxycycline addition, the media was replaced with ESC media containing doxycycline 
and either DMSO, TCP or Prg for another 24 hours (48 hours total). 
 
Inhibition of p300 using HAT inhibitor C-646 (Supplementary Fig. 12) 
During differentiation, it is presently unclear which acetylated histone residue(s) need 
to be deacetylated to trigger activation of LSD1 demethylation activity. While p300 
and H3K27Ac are very good candidates at enhancers, many other HATs (CBP, GCN5, 
Tip60, Elp3, Myst3, Myst4) are active in ESCs 15-17. Therefore, regulation of 
acetylation levels at enhancers is most likely to be the result of a combination of HATs 
and HDACs complexes.   
 
To test if acetylation of H3K27 prevents demethylation of H3K4 by LSD1, we 
treated ESCs with the p300-specific acteyltransferase inhibitor C-646 (ref. 18). V6.5 
ESCs were split off MEFs, placed in a tissue culture dish for 45 minutes to selectively 
remove the MEFs, and plated in 15cm cell culture plates. The following days, cells 
were treated with either DMSO (control) or C-646 (Tocris, 4200) for 24 hours. Cells 
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were then crosslinked and collected to generate ChIP-seq datasets for H3K27ac and 
H3K4me1. 
 
Lentiviral Production and Infection (Supplementary Fig. 2, 3, 4, 5, and 9) 
Lentivirus was produced according to Open Biosystems Trans-lentiviral shRNA 
Packaging System (TLP4614). The shRNA constructs targeting LSD1, Oct4, CoREST 
and Mi-2b are listed below.  The shRNAs targeting either GFP (RHS4459) or 
Luciferase (SHC007) were used as controls.  
 
GFP  RHS4459 
Luciferase SHC007 
LSD1  TRCN0000071373 
Oct4  TRCN0000009611 
Mi-2b #1 TRCN0000086143 
Mi-2b #2 TRCN0000086145 
CoREST TRCN0000071371 
 
For GFP, LSD1 and Mi-2b, ZHBTc4 ESCs were split off MEFs, placed in a tissue 
culture dish for 45 minutes to selectively remove the MEFs, and plated on either 6-
well or 12-well cell culture plates. The following day, cells were infected in ESC 
media containing 8 µg/ml polybrene (Sigma, H9268-10G).  After 24 hours the media 
was removed and replaced with ESC media containing 3.5 µg/mL puromycin (Sigma, 
P8833).  ESC media with puromycin was changed daily.  Three days post infection, 
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the media was removed and replaced with ESC media containing 2μg/ml doxycycline 
to shutdown Oct4 and induce differentiation. Cells were harvested 48 hours later. 
 
For Luciferase and Oct4, LSD1 Lox/Δ3 or Δ3/Δ3 E14 ESCs were plated on 6-well 
culture plates. The following day, cells were infected in ESC media containing 8 
µg/ml polybrene. Cells transfected with LSD1 expression constructs were infected in 
ESC media lacking antibiotics and polybrene. After 16 hours the media was removed 
and replaced with ESC media containing 3.5 µg/mL puromycin (Sigma, P8833).  The 
media of ESCs transfected with the LSD1 expression constructs also contained 
hygromycin, as described earlier. ESC media with either puromycin, or puromycin and 
hygromycin, was changed daily. Cells were harvested 72 hours later. 
 
Immunofluorescence (Fig. 2b and Supplementary Fig. 3, 4, 5, and 9) 
Following crosslinking, the cells were washed once with PBS, twice with blocking 
buffer (PBS with 0.25% BSA, Sigma, A3059-10G) and then permeabilized for 15 
minutes with 0.2% Triton X-100 (Sigma, T8797-100ml).  After two washes with 
blocking buffer cells were stained overnight at 4 degrees C for either Oct4 (Santa Cruz 
Biotechnology, sc-9081x; 1:200 dilution) or SSEA1 (mc-480, DHSB, 1:20 dilution) 
and washed twice with blocking buffer.  Cells were incubated for 1 hour at room 
temperature with either goat anti-rabbit-conjugated Alexa Fluor 488, goat anti-rabbit-
conjugated Alexa Fluor 647 or goat anti-mouse conjugated 568 (Invitrogen; 1:1000 
dilution) and Hoechst 33342 (Invitrogen; 1:2000 dilution).  Finally, cells were washed 
twice with blocking buffer and twice with PBS before imaging. Images were acquired 
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on either Nikon Inverted TE300 or Zeiss Axiovert 200m Inverted microscopes with a 
Hamamatsu Orca camera. Openlab (http://www.improvision.com/products/openlab/) 
was used for image acquisition.  
 
Alkaline Phosphatase Staining (Supplementary Fig. 2, 4, 5, and 9) 
Staining of ZHBTc4 cells for alkaline phosphatase was achieved using the Alkaline 
Phosphatase Detection Kit (Millipore, SCR004). Briefly, cells were crosslinked at 
various timepoints before addition of Fast Red Violet solution and Napthol AS-BI 
phosphate solution. Cells were visualized on a Nikon Inverted TE300 with a 
Hamamatsu Orca camera.  Openlab (http://www.improvision.com/products/openlab/) 
was used for image acquisition.  
 
RNA Extraction, cDNA, and TaqMan Expression Analysis (Supplementary Fig. 1, 3, 5, 
and 9) 
RNA utilized for real-time qPCR was extracted with TRIzol according to the 
manufacturer protocol (Invitrogen, 15596-026).  Purified RNA was reverse transcribed 
using Superscript III (Invitrogen) with oligo dT primed first-strand synthesis following 
the manufacturer protocol. 
 
Real-time qPCR were carried out on the 7000 ABI Detection System using the 
following Taqman probes according to the manufacturer protocol (Applied 
Biosystems). 
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Gapdh Mm99999915_g1 
LSD1  Mm01181030_g1 
Mi-2b  Mm01190896_m1 
CoREST Mm03053471_s1 
Sox2  Mm00488369_s1 
Nanog  Mm02019550_s1 
Lefty1  Mm00438615_m1 
Lefty2  Mm00774547_m1 
Esrrb  Mm00442411_m1 
Trim28 Mm00495594_m1 
Klf4  Mm00516104_g1 
Oct4  Mm03053917_g1 
Apobec1 Mm00482895_m1 
Dppa3  Mm01184198_g1 
Tcl1  Mm00493477_m1 
 
Expression levels were normalized to Gapdh levels.  All comparisons were made 
relative to either DMSO (control)-treated, Luciferase, or GFP-infected cells. 
 
Chromatin Immunoprecipitation (ChIP) 
 
Antibody Specificity (Supplementary Fig. 1, 6, and 9) 
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For LSD1 (AOF2/KDM1A)-occupied genomic regions, we performed ChIP-Seq 
experiments using Abcam ab17721 rabbit polyclonal antibody.  The antibody was 
raised with a synthetic peptide conjugated to KLH derived from within residues 800 to 
the C-terminus of human LSD1. Antibody specificity was determined by shRNA-
mediated knockdown (Open Biosystems) of LSD1 proteins, followed by Western blot 
analysis. Knockdowns were carried out using the following shRNAs according to the 
manufacturer protocol (Open Biosystems). Cells were infected with indicated short 
hairpins for 5 days, followed by protein extraction and Western blotting. 
 
GFP  RHS4459 
LSD1  TRCN0000071374 
 
For Mi-2b (CHD4)-occupied genomic regions, we performed ChIP-Seq experiments 
using Abcam ab72418 rabbit polyclonal antibody.  The antibody was raised with a 
synthetic peptide conjugated to KLH derived from within residues 25 to 75 of human 
CHD4. Antibody specificity was determined by shRNA-mediated knockdown (Open 
Biosystems) of Mi-2b proteins, followed by Western blot analysis. Knockdowns were 
carried out using the following shRNAs according to the manufacturer protocol (Open 
Biosystems). Cells were infected with indicated short hairpins for 5 days, followed by 
protein extraction and Western blotting. 
 
GFP  RHS4459 
shMi-2b #1 TRCN0000086143 
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shMi-2b #2 TRCN0000086147 
 
For HDAC1-occupied genomic regions, we performed ChIP-Seq experiments using 
Abcam ab7028 rabbit polyclonal antibody.  The antibody was raised with a synthetic 
peptide conjugated to KLH derived from within residues 466 to 482 of human 
HDAC1. Antibody specificity was previously determined19. 
 
For HDAC2-occupied genomic regions, we performed ChIP-Seq experiments using 
Abcam ab7029 rabbit polyclonal antibody.  The antibody was raised with a synthetic 
peptide conjugated to KLH derived from within residues 471 to 488 of human 
HDAC2. Antibody specificity was previously determined19. 
 
For REST (NRSF)-occupied genomic regions, we performed ChIP-Seq experiments 
using Millipore 07-579 rabbit polyclonal antibody.  The antibody was raised with a 
GST fusion protein corresponding to residues 801-1097 of human REST. Antibody 
specificity was previously determined20. 
 
For CoREST-occupied genomic regions, we performed ChIP-Seq experiments using 
Abcam ab32631 rabbit polyclonal antibody. The antibody was raised with a 
synthetic peptide conjugated to KLH derived from within residues 450 to the C-
terminus of human CoREST. Antibody specificity was determined by shRNA-
mediated knockdown (Open Biosystems) of CoREST proteins, followed by Western 
blot analysis. Knockdowns were carried out using the following shRNAs according to 
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the manufacturer protocol (Open Biosystems). Cells were infected with indicated short 
hairpins for 5 days, followed by protein extraction and Western blotting. 
 
GFP  RHS4459 
CoREST TRCN0000071371 
 
For H3K4me1-occupied genomic regions, we performed ChIP-Seq experiments using 
Abcam ab8895 rabbit polyclonal antibody. The antibody was raised with a synthetic 
peptide conjugated to KLH derived from within residues 1 to 100 of human 
H3K4me1. Antibody specificity was previously determined21. 
 
For p300-occupied genomic regions, we performed ChIP-PCR experiments using 
Santa Cruz sc-584 rabbit polyclonal antibody. The antibody was raised with a 
synthetic peptide derived from the N-terminus of human p300. Antibody specificity 
was previously determined22. 
 
For H3K27Ac-occupied genomic regions, we performed ChIP-PCR experiments using 
Abcam ab4729 rabbit polyclonal antibody. The antibody was raised with a synthetic 
peptide conjugated to KLH derived from within residues 1 - 100 of human histone H3, 
acetylated at K27. Antibody specificity was previously determined23. 
 
ChIP Protocol 
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Protocols describing chromatin immunoprecipitation materials and methods have been 
previously described24. v6.5 or ZHBTc4 ESCs were grown to a final count of 5-10 x 
107 cells for each ChIP experiment. Cells were chemically crosslinked by the addition 
of one-tenth volume of fresh 11% formaldehyde solution for 15 minutes at room 
temperature. Cells were rinsed twice with 1X PBS and harvested using a silicon 
scraper and flash frozen in liquid nitrogen. Cells were stored at –80oC prior to use. 
Cells were resuspended, lysed in lysis buffers and sonicated to solubilize and shear 
crosslinked DNA. Sonication conditions vary depending on cells, culture conditions, 
crosslinking and equipment. 
 
For LSD1, Mi-2b, HDAC1, HDAC2, REST, CoREST, p300, H3K27Ac, and 
H3K4me1 the sonication buffer was 20mM Tris-HCl pH8, 150mM NaCl, 2mM 
EDTA, 0.1% SDS, 1% Triton X-100. We used a Misonix Sonicator 3000 and 
sonicated at approximately 24 watts for 10 x 30 second pulses (60 second pause 
between pulses). Samples were kept on ice at all times.  The resulting whole cell 
extract was incubated overnight at 4 degrees C with 100ul of Dynal Protein G 
magnetic beads that had been pre-incubated with approximately 10 ug of the 
appropriate antibody. Beads were washed 1X with the sonication buffer, 1X with 
20mM Tris-HCl pH8, 500mM NaCl, 2mM EDTA, 0.1% SDS, 1%Triton X-100, 1X 
with 10mM Tris-HCl pH8, 250mM LiCl, 2mM EDTA, 1% NP40 and 1X with TE 
containing 50 mM NaCl.  
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Bound complexes were eluted from the beads (50 mM Tris-Hcl, pH 8.0, 10 mM 
EDTA and 1% SDS) by heating at 65 degrees C for 1 hour with occasional vortexing 
and crosslinking was reversed by overnight incubation at 65°C. Whole cell extract 
DNA reserved from the sonication step was also treated for crosslink reversal. 
 
Gene Specific ChIPs (Supplementary Fig. 9, 10, and 11) 
For gene specific ChIPs carried out in ZHBTc4 ESCs, approximately 5x107 ES cells 
were grown on two 15cm plates. Plates were treated or not treated with 2ng/ml 
doxycyline for 12 hours, and crosslinked.  SYBR Green real-time qPCR was carried 
out on the 7000 ABI Detection System according to the manufacturer protocol 
(Applied Biosystems).  Data was normalized to the whole cell extract and control 
regions.  Primer pairs are listed below. 
 
Lefty1 
5’-GTAGCCAGCAGACAGGACAA-3’ 
5’-ATCCCCAATCCACATTCACT-3’ 
 
Lefty2 
5’-AGGCCTAGCTTTTGCATCAC-3’ 
5’-TCTCCCAGAGTCGATCTTCC-3’ 
 
Sall4 
5’- GAAATAAACATCTGGGAGAAGGA-3’ 
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5’- GGAAACCCCAGATTGAGAGA-3’ 
 
Sox2 
5’- TGGCGAGTGGTTAAACAGAG-3’ 
5’- TAGCGAGAACTAGCCAAGCA-3’ 
 
Trim28 
5’- GGTCTGCAATTGAAGGAAGG-3’ 
5’- TTAAACAGCAGGGGGTAAGG-3’ 
 
Esrrb 
5’- CGAGCTTCAGCTGGCTATTT-3’ 
5’- GAGCTCCAGATCCCCTACAC-3’ 
 
Nanog 
5’-GGAATTTCCTTCCCAGGTTT-3’ 
5’- GGTTGGAACTAGCTGTGTGG-3’ 
 
Ctrl (Olfr460) 
5’-AACTGTTATTGTGCCCGTGA -3’ 
5’-CATTGCTCCAAGCAAAGAAA -3’ 
 
ChIP-Seq Sample Preparation and Analysis 
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All protocols for Illumina/Solexa sequence preparation, sequencing and quality control 
are provided by Illumina (http://www.illumina.com/pages.ilmn?ID=203). A brief 
summary of the technique and minor protocol modifications are described below. 
 
Sample Preparation 
Purified chromatin immunoprecipitated (ChIP) DNA was prepared for sequencing 
according to a modified version of the Illumina/Solexa Genomic DNA protocol. 
Approximately 200 ng of ChIP DNA was prepared for ligation of Solexa linkers by 
repairing the ends and adding a single adenine nucleotide overhang to allow for 
directional ligation. A 1:200 dilution of the Adaptor Oligo Mix (Illumina) was used in 
the ligation step. A subsequent PCR step with 18 amplification cycles added additional 
linker sequence to the fragments to prepare them for annealing to the Genome 
Analyzer flow-cell. Amplified material was purified by Qiaquick MinElute (Qiagen, 
Valencia, CA) and a narrow range of fragment sizes was selected by separation on a 
2% agarose gel and excision of a band between 150-300bp, representing ChIP 
fragments between 50 and 200 nt in length and ~100bp of primer sequence. The DNA 
was purified from the agarose and diluted to 10nM for loading on the flow cell. 
 
For multiplexed samples, libraries were prepared using the Illumina TruSeq adapters 
(to enable multiplexing) and prepared using Beckman-Coulter’s SPRIworks system. 
For library preparations, ChIP samples were used in their entirety and whole-cell 
extracts control samples were prepared using 100ng. Adapters were diluted to 1:200. 
	   149	  
Size selection was 200–400bp before PCR, and the samples were amplified using 
KAPA Hi-Fi polymerase and 18 cycles of PCR according to manufacturer’s cycling 
recommendations. Amplified material was purified using Agencourt Ampure XP 
beads using a 0.93 ratio of beads to sample. 
  
Polony Generation and Sequencing 
The DNA library (2–5pM) was applied to the flow-cell (8 samples per flow-cell) using 
the Cluster Station device from Illumina. The concentration of library applied to the 
flow-cell was calibrated such that polonies generated in the bridge amplification step 
originate from single strands of DNA. Multiple rounds of amplification reagents were 
flowed across the cell in the bridge amplification step to generate polonies of 
approximately 1,000 strands in 1mm diameter spots. Double-stranded polonies were 
visually checked for density and morphology by staining with a 1:5000 dilution of 
SYBR Green I (Invitrogen) and visualizing with a microscope under fluorescent 
illumination. Validated flow-cells were stored at 4°C until sequencing. Flow-cells 
were removed from storage and subjected to linearization and annealing of sequencing 
primer on the Cluster Station. Primed flow-cells were loaded into the Illumina 
Genome Analyzer II or Hi-seq. After the first base was incorporated in the Sequencing 
by-Synthesis reaction the process was paused for a quality control checkpoint. A small 
section of each lane was imaged and the average intensity value for all four bases was 
compared to minimum thresholds. Flow-cells with low first base intensities were 
reprimed and if signal was not recovered the flow-cell was aborted. Flow-cells with 
signal intensities meeting the minimum thresholds were resumed and sequenced for 26 
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cycles. For multiplexed samples Truseq V2.5 kits were used to cluster them on the 
cBot and Truseq V2 were used to do a multiplex 40+7 cycle run on the Hi-seq 
 
ChIP-Seq Data Analysis 
Images acquired from the Illumina/Solexa sequencer were processed through the 
bundled Solexa image extraction pipeline which identified polony positions, 
performed base-calling and generated QC statistics. 
 
ChIP-Seq reads were aligned using the software Bowtie25 to NCBI build 36 (mm8) of 
the mouse genome with default settings. Sequences uniquely mapping to the genome 
with zero or one mismatch were used in further analysis 
 
When multiple reads mapped to the same genomic position, a maximum of two reads 
mapping to the same position were used.  ChIP-Seq datasets profiling the genomic 
occupancy of H3K36me2 (ref. 26), H3K79me2 (ref. 26), H3K4me3 (ref. 26), 
H3K27me3 (ref. 27), Oct4 (ref. 26), Sox2 (ref. 26), Nanog26, RNA Polymerase 2 (ref. 
28), TBP29, Med1 (ref. 29), p300 (ref. 22), H3K4me1 (ref. 21), H3K27ac23 and 
Suz12 (ref. 26) in mouse ESCs were obtained from previous publications. Below is the 
list of ChIP-Seq datasets used and corresponding GEO Accession numbers. 
 
Dataset GEO Accession Numbers 
H3K27ac GSM594578, GSM594579 
H3K27me3 GSM307619 
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H3K36me3 GSM307152, GSM307153 
H3K4me1 GSM281695 
H3K4me3 GSM307146 
H3K79me2 GSM307150, GSM307151 
Med1 GSM560347, GSM560348 
WCE mES GSM307154, GSM307155, GSM560357 
WCE mES (matching H3K4me1 mES) GSM307625 
Nanog GSM307140, GSM307141 
Oct4 GSM307137 
p300 GSM288359 
RNA Pol II GSM318444 
Sox2 GSM307138, GSM307139 
Suz12 GSM307144, GSM307145 
TBP GSM555160, GSM555162 
DMSO H3K4me1  This Paper 
48HR DMSO H3K4me1  This Paper 
48HR TCP H3K4me1  This Paper 
HDAC1 This Paper 
HDAC2 This Paper 
LSD1 This Paper 
Mi-2b This Paper 
REST GSM656525, This Paper 
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CoREST This Paper 
WCE – DMSO This Paper 
WCE – 48HR DMSO This Paper 
WCE – 48HR TCP This Paper 
 
 All ChIP-Seq datastsets, including those obtained elsewhere, were analyzed using the 
methods described below. 
 
Analysis methods were derived from previously published methods26,27,30,31. Sequence 
reads from multiple flow cells for each IP target and/or biological replicates were 
combined.  For all datasets, excluding H3K4me1, H3K4me3, H3K79me2, H3K36me3, 
H3K27ac, and H3K27me3 each read was extended 200bp, towards the interior of the 
sequenced fragment, based on the strand of the alignment. For H3K4me1, H3K4me3, 
H3K79me2, H3K36me3, H3K27ac, and H3K27me3 datasets, each read was extended 
600bp towards the interior and 400bp towards the exterior of the sequenced fragment, 
based on the strand of the alignment. Across the genome, in 25 bp bins, the number of 
extended ChIP-Seq reads was tabulated.  The 25bp genomic bins that contained 
statistically significant ChIP-Seq enrichment were identified by comparison to a 
Poissonian background model.  Assuming background reads are spread randomly 
throughout the genome, the probability of observing a given number of reads in a 
genomic bin can be modeled as a Poisson process in which the expectation can be 
estimated as the number of mapped reads multiplied by the number of bins (8 for all 
sequences datasets except H3K4me1, H3K4me3, H3K79me2, H3K36me3, H3K27ac, 
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and H3K27me3, which was 40) into which each read maps, divided by the total 
number of bins available (we estimated 70% of the genome).  Enriched bins within 
200bp of one another were combined into regions.  
 
The Poissonian background model assumes a random distribution of background 
reads, however we have observed significant deviations from this expectation.  Some 
of these non-random events can be detected as sites of apparent enrichment in negative 
control DNA samples and can create many false positives in ChIP-Seq experiments. 
To remove these regions, we compared genomic bins and regions that meet the 
statistical threshold for enrichment to a set of reads obtained from Solexa sequencing 
of DNA from whole cell extract (WCE) in matched cell samples.  We required that 
enriched bins and enriched regions have five-fold greater ChIP-Seq density in the 
specific IP sample, compared with the control sample, normalized to the total number 
of reads in each dataset.  This served to filter out genomic regions that are biased to 
having a greater than expected background density of ChIP-Seq reads. A summary of 
the bound regions and genes for each antibody is provided (Supplementary Table 1). 
 
Assigning ChIP-Seq Enriched Regions to Genes (Supplementary Table 1) 
The complete set of RefSeq genes was downloaded from the UCSC table browser 
(http://genome.ucsc.edu/cgi-bin/hgTables) on June 1, 2010. For all datasets except 
H3K4me1, H3K4me3, H3K79me2, H3K36me3, H3K27ac, and H3K27me3, genes 
with enriched regions within 10kb of their transcription start site were called bound. 
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For H3K4me1, H3K4me3, H3K79me2, H3K36me3, H3K27ac, and H3K27me3 
datasets, genes with enriched regions within the gene body were called bound. 
 
Enrichment of LSD1, Pol II, and Suz12 at genes (Fig. 1) 
Each gene in the mouse genome was classified into active, bivalent, or silent groups 
based on the presence of co-occupancy of H3K4me3 (GSE11724), H3K79me2 
(GSE11724), and H3K27me3 (GSM307619). See the table below for a description of 
the number of genes in each category as well as the classification rules. Using a 
hypergeometric test, the p-value for enrichment of LSD1, Pol II, and Suz12 binding to 
the genes in each of these classes was determined.  
 
  Classification rules    
 H3K4me3 
within +/- 2kb 
of the TSS 
H3K79me2 
within first 
5kb of gene 
body 
H3K27me3 
within +/- 
5kb of the 
TSS 
Number 
of genes 
Active Required Required - 7339 
Bivalent Required - Required 3094 
Silent Absent Absent - 6976 
 
Definition of Enhancer and Core Promoter (Fig. 1, 4, Supplementary Fig. 8, 13, and 
Supplementary Table 1) 
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An enhancer was defined as a Med1 high-confidence enriched region that is 
overlapped at least 1bp by enriched regions of Oct4, Sox2, and Nanog in mES cells. 
Using this definition we identified 3,838 enhancers, and the genomic locations of 
those enhancers are listed in Supplementary Table 1. These enhancers were assigned 
to the nearest genes to determine the neighboring core promoter regions. 
 
Determining LSD1 density at Enhancer and Core Promoter (Supplementary Fig. 1) 
The mean LSD1 density at enhancers (15.91) and core promoters (13.46) was 
determined by calculating the sum of LSD1 density within 5kb of each enhancer and 
core promoter, and then taking the average across the 3,838 enhancers and core 
promoters. A t-test was then performed to obtain a p-value (p < 10-16) indicating that 
LSD1 density was statistically larger at enhancers compared to core promoters. 
 
ChIP-Seq Density Heatmaps (Fig. 1, 4, Supplementary Fig. 8, and 13) 
Selected enriched regions were aligned with each other according to the position of 
either Med1 (Fig. 1c, 4e, and Supplementary Fig. 5b) or the TSS (Fig. 1d). For each 
experiment, the ChIP-Seq density profiles were normalized to the density per million 
total reads. Heatmaps were generated using Java Treeview 
(http://jtreeview.sourceforge.net/) with color saturation as indicated.  
 
Calculation of the Statistical Significance of the Overlap Between Sets of Genomic 
Regions (Fig. 1, 3, 4, and Supplementary Fig. 8) 
In the manuscript, when assessing the overlap between two sets of genomic regions, 
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we report p-values calculated using a Monte Carlo method. In order to make this type 
of comparison, a number of different statistical methods could be applied.  One could 
use a chi-square test, and compare the total size of the overlap of two sets of genomic 
regions to the size of this overlap that would be expected at random based on the total 
size of the genome and the total size of the genomic regions in each group. This 
method accurately models the expected overlap between two datasets if they were 
truly randomly associated. Unfortunately, since the genome is so large, this method 
will call the overlap between two datasets statistically significant even if it is not much 
larger than would be expected at random. 
 
Another way to assess the statistical significance of the overlap between two sets of 
genomic regions is to use a Monte Carlo method. In Monte Carlo methods, a 
tremendous number of simulated datasets are created and the overlaps between the 
simulated datasets are tabulated. The statistical significant of the actual overlap is then 
estimated based on the frequency of an overlap at least that large occurring in the 
simulated datasets. We used a Monte Carlo method to assess the statistical significance 
of the overlap between two sets of genomic regions in this manuscript. To create the 
simulated datasets, we shifted each of the genomic regions in one of the datasets a 
random distance between -2,000bp and +2,000bp from its original position.  For this 
manuscript, Monte Carlo simulations were run one billion times. 
 
We noted that, if two sets of genomic regions that tend to occur in the same place, then 
this overlap is statistically significant. This will be true whether the regions occur 
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together 10% of the time, or 100% of the time. Thus, the test for statistical significance 
is not a very good at describing the degree of overlap between to datasets. 
Consequently, in each instance that we assessed the statistical significance of the 
overlap between two set of genomic regions, we also calculated the fold enrichment of 
the overlap between the two datasets. This was calculated as the total size of the actual 
overlap between the two sets of regions and the overlap between the two datasets that 
would be expected at random. 
 
Rank Normalization of H3K4me1 ChIP-Seq Data (Fig. 4, Supplementary Fig. 13, and 
Supplementary Table 5) 
In order to compare the levels of H3K4me1 between three conditions a rank 
normalization method was used. The three cells types and conditions in which 
H3K4me1 occupancy was profiled were ZHBTc4 ESCs, ZHBTc4 ESCs treated with 
doxycycline for 48 hours, and ZHBTc4 ESCs treated with doxycycline for 48 hours 
and TCP for 54 hours.  In each of the three datasets, the genomic bin with the greatest 
ChIP-Seq signal was identified. The average of these three values was calculated, and 
the greatest bin in each dataset was assigned this average value. This was repeated for 
all genomic bins from the greatest signal to the least, assigning each the average ChIP-
Seq signal for all bins of that rank across all datasets. Subsequently, the total number 
of ChIP-Seq reads in the three H3K4me1 datasets was calculated, and this value was 
used to scale each dataset to the units, rank normalized reads/million. 
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Using this method, we computed the rank normalized reads/million density in each of 
the three datasets in 10 bp bins across the genome. The H3K4me1 signal at an 
enhancer was then calculated as the sum of the observed densities in the 50 bins (+/- 
250bp) surrounding each of the 3,838 identified enhancers. This number captures the 
normalized H3K4me1 signal in dataset, and the value for each enhancer in each of the 
three datasets is reported in Supplementary Table 5. 
 
Gene Ontology (GO) Analysis (Supplementary Fig. 7) 
Gene ontology analysis was performed using the web tool David Bioinformatics 
Database (http://david.abcc.ncifcrf.gov/home.jsp)32,33. The complete set of all RefSeq 
genes was used as a background.  
 
Public availability of ChIP-Seq datasets 
ChIP-Seq data have been submitted to the Gene Expression Omnibus Database 
(http://www.ncbi.nlm.nih.gov/geo/) with accession number GSE27844 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=jfcvlkoimyymyzm&acc=GSE
27844). 
 
Microarray Analysis (Fig. 2) 
Cell Culture and RNA isolation 
For ESC expression analysis during differentiation following either DMSO or TCP 
treatment, ZHBTc4 ESCs were split off MEFs, placed in a tissue culture dish for 45 
minutes to selectively remove the MEFs and plated in 6-well plates. The following day 
	   159	  
cells were treated with either DMSO or 1mM TCP for 6 hours in ESC media. After 6 
hours a subset of cells from DMSO treated wells was removed for TRIzol RNA 
isolation, the media was removed and replaced with ESC media containing 2μg/ml 
doxycyline and either DMSO or 1mM TCP. 24 hours after doxycycline addition, a 
subset of cells was removed for RNA isolation and the media was replaced with ESC 
media containing doxycycline and either DMSO or TCP. After another 48 hours, RNA 
was isolated using TRIzol (Invitrogen, 15596-026) from all time points (at indicated 
times), further purified with RNeasy columns (Qiagen, 74104) and DNase treated on 
column (Qiagen, 79254) following the manufacturer’s protocols. 
 
Micorarray hybridization and Analysis 
For microarray analysis, Cy3 and Cy5 labeled cRNA samples were prepared using 
Agilent’s QuickAmp sample labeling kit starting with 1ug total RNA. Briefly, double-
stranded cDNA was generated using MMLV-RT enzyme and an oligo-dT based 
primer. In vitro transcription was performed using T7 RNA polymerase and either 
Cy3-CTP or Cy5-CTP, directly incorporating dye into the cRNA. 
 
Agilent mouse 4x44k expression arrays were hybridized according to our laboratory’s 
standard method, which differs slightly from the standard protocol provided by 
Agilent. The hybridization cocktail consisted of 825 ng cy-dye labeled cRNA for each 
sample, Agilent hybridization blocking components, and fragmentation buffer. The 
hybridization cocktails were fragmented at 60 degrees C for 30 minutes, and then 
Agilent 2X hybridization buffer was added to the cocktail prior to application to the 
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array. The arrays were hybridized for 16 hours at 60 degrees C in an Agilent rotor 
oven set to maximum speed. The arrays were treated with Wash Buffer #1 (6X SSPE / 
0.005% n-laurylsarcosine) on a shaking platform at room temperature for 2 minutes, 
and then Wash Buffer #2 (0.06X SSPE) for 2 minutes at room temperature. The arrays 
were then dipped briefly in acetonitrile before a final 30 second wash in Agilent Wash 
3 Stabilization and Drying Solution, using a stir plate and stir bar at room temperature. 
 
Arrays were scanned using an Agilent DNA microarray scanner. Array images were 
quantified and statistical significance of differential expression for each hybridization 
was calculated using Agilent’s Feature Extraction Image Analysis software with the 
default two-color gene expression protocol. For each gene in the RefSeq gene list (see 
ChIP-Seq analysis section), the log10 ratio values (ESC+Dox  / ESC, or 
ESC+DOX+TCP / ESC) and p-value for that gene were determined by averaging 
log10 ratios and p-values of all Agilent Features annotated to that gene. Genes with no 
annotated features were reported as NA (Supplementary Table 3). Genes with a log10 
ratio of at least 0.0969 (1.25x) and a p-value less than or equal to 10-2 were determined 
to have a significant change in expression. 
 
Public availability of microarray gene expression datasets 
Microarray gene expression data have been submitted to the Gene Expression 
Omnibus Database (http://www.ncbi.nlm.nih.gov/geo/) with accession number 
GSE27844 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=jfcvlkoimyymyzm&acc=GSE
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27844). 
 
Protein Extraction and Western Blot Analysis (Fig. 2, Supplementary Fig. 1, 4, 5, 
6, and 9) 
ESCs were lysed with CelLytic Reagent (Sigma, C2978-50ml) containing protease 
inhibitors (Roche). After SDS-PAGE, Western blots were revealed with antibodies 
against Oct4 (Santa Cruz Biotechnology, sc-5279), LSD1 (Abcam, ab17721), Mi-2b 
(Abcam, ab72418), CoREST (Abcam, ab32631), p300 (Santa Cruz, sc-584), GAPDH 
(Abcam, ab9484) or Tubulin (Millipore, 05-661).  
 
ChIP-Western and Co-Immunoprecipitation (Fig. 3) 
For ChIP-Western, same conditions as for ChIP-Seq were used. For co-
immunoprecipitation, murine ES cells were harvested in cold PBS and extracted for 30 
min at 4 degrees C in TNEN250 (50 mM Tris pH 7.5, 5 mM EDTA, 250 mM NaCl, 
0.1% NP-40) with protease inhibitors. After centrifugation, supernatant was mixed to 
2 volumes of TNENG (50 mM Tris pH 7.5, 5 mM EDTA, 100 mM NaCl, 0.1% NP-
40, 10% glycerol). Protein complexes were immunoprecipitated overnight at 4 degrees 
C using 5 micrograms of either LSD1 (Abcam, ab17721), HDAC1 (Abcam, ab7028), 
HDAC2 (Abcam, ab7029), Mi-2b (Abcam, ab72418), CoREST (Abcam, ab32631) or 
Rabbit IgG (Upstate, 12-370), bound to 50ul of Dynabeads®. Immunoprecipitates 
were washed three times with TNEN125 (50 mM Tris pH 7.5, 5 mM EDTA, 125 mM 
NaCl, 0.1% NP-40). For both ChIP-Western and co-immunoprecipitation, beads were 
boiled for 10 minutes in XT buffer (Biorad) containing 100mM DTT to elute proteins. 
	   162	  
After SDS-PAGE, Western blots were revealed with antibodies against either LSD1 
(Abcam, ab17721), or HDAC1 (Abcam, ab7028). 
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Supplementary Fig. 1: Validation and characterization of LSD1 ChIP-Seq 
dataset 
a, Validation of shRNA targeting LSD1. qPCR of LSD1 transcripts in v6.5 ESCs 
infected with short hairpins (Open Biosystems) against either LSD1 or GFP 
(control) for 5 days. The data is normalized to Gapdh. The error bars represent 
the standard deviation of triplicate PCR reactions. b, LSD1 antibody is specific. 
Western blot of LSD1 protein levels in GFP or LSD1 knockdown cells, showing a 
decrease in signal of one band corresponding to LSD1 molecular weight (MW = 
92.9 kDa). Tubulin served as loading control. c, LSD1 ChIP-Seq signals are 
above experimental noise. ChIP-Seq binding profiles (reads/million) for LSD1 at 
the Oct4 (Pou5f1) and Lefty1 loci in ESCs, with the y-axis floor set to 1. Gene 
models, and previously described enhancer regions1-3 are depicted below the 
binding profiles. d, ChIP-Seq data, at high resolution, showing coincidental 
binding of Oct4, Sox2, and Nanog with LSD1. High-resolution ChIP-Seq binding 
profiles (reads/million) at the Oct4 (Pou5f1) and Lefty1 enhancer loci in ESCs, 
with y-axis floor at 1.0 reads/million. e, Metagene showing mean LSD1 density is 
significantly higher at the 3,838 ESC enhancers compared to 3,838 neighboring 
core promoters (p<10-16). 
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Supplementary Fig. 2: LSD1 is required for doxcycline-induced 
differentiation of ZHBTc4 ESCs   
a, Schematic representation of trophectoderm differentiation assay using 
doxycycline-inducible Oct4 depletion murine ESC line ZHBTc4. Treatment with 
doxycyline for 48 hours leads to depletion of Oct4 and early trophectoderm 
specification. ZHBTC4 cells were treated with DMSO (control) or the LSD1 
inhibitors Tranylcypromine (TCP) and Pargyline (Prg) for 6 hours before 2g/ml 
doxycycline was added for an additional 48 hours. b, c, ESCs treated with either 
(b) 1mM tranylcypromine (TCP) or (c) 3mM pargyline (Prg) maintained ESC 
colony morphology and alkaline phosphatase (AP) staining in doxycycline-treated 
cells despite depletion of Oct4 protein levels. Scale bar = 20M. d, Schematic 
representation of trophectoderm differentiation assay using doxycycline-inducible 
Oct4 depletion murine ESC line ZHBTc4. ESCs were infected with a GFP or 
LSD1 shRNA for 72 hours before 2g/ml doxycycline was added for an additional 
48 hours. e, ESCs infected with an shRNA targeting LSD1 maintained ESC 
colony morphology and alkaline phosphatase (AP) staining in doxycycline-treated 
cells despite depletion of Oct4 protein levels. Scale bar = 20M. 
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Supplementary Fig. 4: Characterization of LSD1 knockout ESCs 
a, Beginning with an E14 ESC line (WT), cells were engineered to express an 
inducible Cre-ER fusion protein from the endogenous ROSA26 locus12. 
Sequential gene targeting produced cells in which one LSD1 allele has exon 3 
flanked by LoxP sites (floxed) and the second has exon 3 deleted (Lox/3). 
Induction of Cre activity by addition of 4-hydroxytamoxifen (4-OHT) to the growth 
medium resulted in complete recombination of the remaining floxed LSD1 allele, 
generating LSD1 homozygous null (3/3) cells. Loss of exon 3 disrupts the 
open reading frame of LSD1 such that a premature stop codon is introduced into 
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exon 4, resulting in the progressive loss of LSD1 protein by 48 hours, as detected 
by Western blot (WB). Gapdh served as a loading control. b, LSD1 heterozygous 
(Lox/Δ3) and homozygous null (Δ3/Δ3) ESCs maintain Oct4 and SSEA-1 cell 
surface marker expression compared to E14 wild type (WT) cells. Cells were 
stained for Hoechst (Hoe), Oct4 and SSEA-1. Scale bar = 100μM. c, LSD1 
heterozygous (Lox/Δ3)  or homozygous null (Δ3/Δ3) ESCs maintain ESC 
morphology and alkaline phosphatase (AP) staining compared to E14 wild type 
(WT) ESCs. Scale bar = 100μM. LSD1 Lox/Δ3 ESCs are used as a control 
throughout the remainder of the study. d, Schematic representation of 
trophectoderm differentiation assay. LSD1 Lox/Δ3 cells were treated for 48 hours 
with either ethanol (control) or 4-OHT to generate LSD1 Δ3/Δ3 ESCs before 
being infected with a GFP (shRNAGFP, control) or Oct4 (shRNAOct4) shRNA to 
knockdown Oct4 and induce differentiation. e, LSD1 Δ3/Δ3 ESCs partially 
maintained SSEA-1 cell surface marker expression when Oct4 levels are 
decreased. Cells were stained for Hoechst (Hoe), Oct4 and SSEA-1. Scale bar = 
100μM. f, LSD1 Δ3/Δ3 ESCs partially maintained ESC colony morphology and 
alkaline phosphatase (AP) staining when Oct4 levels are decreased. 
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of trophectoderm differentiation assay. LSD1 Lox/Δ3 cells were treated for 48 
hours with either ethanol (control) or 4-OHT to generate LSD1 Δ3/Δ3 ESCs 
before transfected with either an LSD1 wildtype or catalytic mutant (K661A) 
transgene fused to EGFP (EGFP-LSD1wt or EGFP-LSD1mut). Cells were 
transduced with an shRNA targeting either Luciferase (control) or Oct4 
(shRNAOct4) to knockdown Oct4 and induce differentiation. f, Validation of shRNA 
targeting Oct4. qPCR of Oct4 transcripts in LSD1 heterozygous (Lox/Δ3) ESCs 
infected with a short hairpin (Open Biosystems) against either Oct4 or Luciferase 
(control) for 72 hours. The data is normalized to Gapdh. The error bars represent 
the standard deviation of triplicate PCR reactions. g, Western blot of Oct4 protein 
levels in Luciferase (control) or Oct4 knockdown cells, showing a decrease in 
signal of one band corresponding to Oct4 molecular weight (MW = 38 kDa). 
Tubulin served as loading control. h, Expression of ESC genes was 
downregulated during differentiation when wildtype, but not the catalytic mutant, 
LSD1 was introducted into homozygous null (Δ3/Δ3) cells. Expression of ESC 
genes was maintained in differentiating LSD1 null cells compared to control cells. 
Overexpression of wildtype LSD1, but not the catalytic mutant, rescued this 
phenotype. Error bars reflect standard deviation of triplicate PCR reactions. 
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Supplementary Fig. 6: Validation of CoREST antibody 
a, Validation of shRNA targeting CoREST. qPCR of CoREST transcripts in v6.5 
ESCs infected with short hairpins (Open Biosystems) against either CoREST or 
GFP (control) for 5 days. The data is normalized to Gapdh. The error bars 
represent the standard deviation of triplicate PCR reactions. b, CoREST antibody 
is specific. Western blot of CoREST protein levels in GFP or CoREST knockdown 
cells showing a decrease in signal of one band corresponding to CoREST 
molecular weight (MW = 70 kDa). Gapdh served as loading control. 
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Supplementary Fig. 7: LSD1 occupies a subset of genomic sites with REST 
a, LSD1 occupies a subset of genomic sites with REST. ChIP-Seq binding 
profiles (reads/million) for transcription factors (Oct4, Sox2, Nanog, REST), 
chromatin regulator (LSD1), the transcriptional apparatus (Pol II, TBP) and 
histone modifications (H3K4me1, H3K4me3, H3K79me2, H3K36me3) at the 
NeuroD4 and VGF loci in ESCs. Gene models are depicted below the binding 
profiles. b, GO analysis on the top 500 (based on peak height) REST bound 
genes co-occupied by LSD1 reveals significant enrichment for genes involved in 
neurogenesis. 
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Supplementary Fig. 8: LSD1 occupies ESC enhancers with NuRD 
LSD1 occupies ESC enhancer sites with Mi-2b and either HDAC1 or HDAC2. 
Density map of ChIP-Seq data at Oct4, Sox2, Nanog, and Med1 co-occupied 
enhancer regions.  Data is shown for chromatin regulators (LSD1, Mi-2b, and 
either HDAC1 or HDAC2) in ESCs. Over 70% of the 3,838 high confidence 
enhancers were co-occupied by LSD1 and NuRD (p < 10-9).  Color scale 
indicates ChIP-seq signal in reads per million. 
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Supplementary Fig. 9: NuRD is required for doxcycline-induced 
differentiation of ZHBTc4 ESCs   
a, Validation of shRNAs targeting Mi-2b. qPCR of Mi-2b  transcripts in v6.5 ESCs 
infected with short hairpins (Open Biosystems) against either Mi-2b or GFP 
(control) for 5 days. The data is normalized to Gapdh. The error bars represent 
the standard deviation of triplicate PCR reactions. b, Mi-2b antibody is specific. 
Western blot of Mi-2b protein levels in GFP or Mi-2b knockdown cells, showing a 
decrease in signal of two bands corresponding to Mi-2b molecular weight (MW = 
280 and 218 kDa). Gapdh served as loading control. c, ESCs infected with 
shRNAs targeting Mi-2b partially maintained ES cell colony morphology and 
alkaline phosphatase (AP) staining in doxycycline-treated cells despite depletion 
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of Oct4 protein levels. Scale bar = 20μM. d, ESCs with decreased Mi-2b  levels 
partially maintained SSEA-1 cell surface marker expression in doxycycline-
treated cells. ESCs were infected with Mi-2b shRNA as represented in 
Supplementary Fig. 2d and were stained for Hoechst (Hoe), Oct4 and SSEA-1. 
Scale bar = 20μM. e, Mi-2b is required for downregulation of ESC genes. 
Expression of ESC genes was maintained 48 hours after Oct4 depletion in GFP- 
versus Mi-2b shRNA treated cells. Error bars reflect standard deviation of either 
duplicate or triplicate PCR reactions. 
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Supplementary Fig. 10: Reduced p300 and H3K27Ac levels at ESC 
enhancers during differentiation 
a, b, Reduced levels of transcriptional coactivator p300 and H3K27Ac at 
enhancers during ESC differentiation. ChIP–PCR analysis of p300 and H3K27Ac 
enrichment at enhancer loci in doxycycline-treated (+dox) and untreated (-dox) 
ZHBTc4 cells. Error bars reflect standard deviation of either duplicate or triplicate 
PCR reactions.  
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Supplementary Fig. 11: LSD1 occupies ESC enhancers during 
differentiation 
a, b, LSD1 is approximately 0-5% reduced at 12 hours and 30-50% at 48 hours 
following Oct4 depletion and differentiation of ESCs. ChIP–PCR analysis of LSD1 
enrichment at enhancer loci in doxycycline-treated (+dox) and untreated (-dox) 
ZHBTc4 cells. Error bars reflect standard deviation from biological replicates.  
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Supplementary Figure 12: p300 inhibition results in reduced H3K27ac and 
H3K4me1 levels at ESC enhancers 
a, Reduced levels of H3K27ac and H3K4me1 at enhancers of ESCs treated with 
p300 inhibitor C-646. ChIP-Seq binding profiles (reads/million) for chromatin 
regulators (p300, LSD1) at the Lefty1 locus in ESCs. Below these profiles, 
histone H3K27ac and H3K4me1 levels are shown for DMSO treated (control) 
ESCs, and cells treated with p300 inhibitor C-646 for 24 hours. For appropriate 
normalization, ChIP-Seq data for histone H3K27ac and H3K4me1 is shown as 
rank normalized reads/million with the y-axis floor set to 1 (Supplementary 
Information). Gene models, and previously described enhancer regions3 are 
depicted below the binding profiles. b, Mean of the normalized H3K27ac and 
H3K4me1 density +/- 250 nucleotides surrounding LSD1-occupied enhancer 
regions in the presence or absence of C-646. The associated genes were 
identified based on their proximity to the LSD1-occupied enhancers 
(Supplementary Information). c, Mean of the normalized H3K27ac and H3K4me1 
density +/- 250 nucleotides surrounding 1,234 LSD1-occupied enhancers 
showing reduced levels of H3K27ac in the presence of C-646. Of the 1,234 
LSD1-occupied enhancers having reduced levels of H3K27ac upon C-646 
treatment, 63% (773) display reduced H3K4me1 levels after C-646 treatment (p 
< 10-3).  
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Supplementary Fig. 13: LSD1 is required for H3K4me1 removal at ESC 
enhancers  
Heatmap of normalized H3K4me1 density +/- 250 nucleotides surrounding the 
2,755 LSD1 occupied enhancers having reduced levels of H3K4me1 upon 
differentiation. Of the 2,755 LSD1 occupied enhancers having reduced levels of 
H3K4me1 upon differentiation, 63% (1,722) display higher H3K4me1 levels after 
TCP treatment (p < 10-16). Color scale indicates ChIP-Seq signal in normalized 
reads per million. 
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Appendix B: 
Embryonic Stem Cell-Based System For Discovery Of 
Developmental Transcriptional Programs 
  
Esteban O. Mazzoni1, Shaun Mahony2, Jun-An Chen1, Michelina Iacovino3, Carolyn 
A. Morrison1, George Mountoufaris1, Yuan-Ping Huang1, Warren Whyte4, Rick A. 
Young4,  Michael Kyba3, David K. Gifford2 and Hynek Wichterle1. 
 
1.Departments of Pathology, Neurology, and Neuroscience, Center for Motor 
Neuron Biology and Disease, Columbia University Medical Center, 630 168 street, 
New York, NY 10032, USA. 2.Computer Science and Artificial Intelligence 
Laboratory, Massachusetts Institute of Technology, 32 Vassar Street, Cambridge, 
MA 02139, USA. 3. Lillehei Heart Institute and Department of Pediatrics, 
University of Minnesota, 312 Church St. SE, Minneapolis, MN 55455, USA. 4. 
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, 
MA 02142, USA.	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Personal Contribution to the Project 
This chapter is the result of a collaboration with Esteban Mazzoni on work that was 
published in 2011 in Nature Methods. Esteban requested assistance in the tagging of 
lineage-specific transcription factors and determining their genome-wide localization 
in ES-cell-derived motor neurons and their progenitor cells. I conducted ChIP-seq 
experiments, and performed some data analysis, which is described in this appendix.  	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Study of developmentally regulated transcription factors by chromatin 
immunoprecipitation and sequencing (ChIP-seq) faces two major obstacles: 
availability of ChIP grade antibodies and access to sufficient number of cells.  We 
describe a versatile method for genome-wide analysis of transcription factor 
binding sites by combining directed differentiation of embryonic stem cells and 
inducible expression of tagged proteins.  We demonstrate its utility by mapping 
transcription factors involved in motor neuron specification.  
 
The study of transcriptional networks provides an opportunity to gain fundamental 
insight into complex molecular processes that govern cell fate specification and 
embryonic development. While numerous transcription factors controlling cell 
differentiation have been functionally characterized, their cell type specific patterns of 
DNA binding remain largely unknown. 
The method of choice for genome-wide mapping of transcription factor binding sites is 
chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) 1.   Although 
powerful, current ChIP-seq technology is limited by two critical factors when applied 
to developmental studies.  First, ChIP-seq profiling demands a large number of cells 
(20-50 million) separated from other cell types expressing the transcription factor of 
interest, and second, it requires antibodies with high affinity and specificity that 
recognize transcription factors in their native form bound to DNA.   To overcome 
these two hurdles, we combined a versatile system for generating mouse embryonic 
stem cell (ESC) lines harboring inducible and epitope-tagged transcription factors with 
directed differentiation of ESCs along defined cellular lineages. 
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To overcome the inconsistency and inefficiency of classical transgenic ESC line 
production, we relied on a recently developed inducible cassette exchange (ICE) 
system 2. The resulting transgenic lines harbor a single copy of the transgene 
recombined into a defined expression-competent locus. To further streamline the 
generation of inducible cell lines, we introduced Gateway (Invitrogen) landing sites 
into the shuttle vector and a short epitope tag either at the amino- (Flag-Bio) or 
carboxy-terminus (His-V5) of the protein (Fig. 1a).    Because of the high efficiency of 
all steps, parallel production of multiple inducible tagged lines can be accomplished in 
as little as three weeks. 
Differentiation of mouse ESCs to spinal motor neurons yields scalable and largely 
homogeneous populations of cells mirroring developmentally relevant motor neuron 
differentiation states in mouse 3. To test our approach, we first investigated genome-
wide binding of the bHLH transcription factor Olig2 in motor neuron progenitors 
(pMNs) 4, a rare population of cells (<1% of spinal cells on e9.5) found in the 
embryonic ventral spinal cord 5.We generated an inducible Olig2 ESC line in which 
Olig2 protein is carboxy-terminal tagged with the V5 epitope (iOlig2-V5).  To mimic 
the normal Olig2 pattern of expression, doxycycline (Dox) was administered late on 
Day 3 and the expression of the transgene was analyzed on Day 4 (Fig. 1b) when cells 
reach pMN stage. The transgenic Olig2-V5 protein was expressed uniformly in pMNs, 
exhibited correct nuclear localization is ~4 fold higher than native Olig2 (Suppl. Fig. 
1a-b).  The V5 sequence did not perturb the function of the tagged Olig2-V5 protein.  
As expected, ectopic expression of Olig2-V5 resulted in the repression of Nkx2.2 in 
ventral interneuron progenitors (Fig. 1c) 4 and in the repression of Pax6 and Irx3 in 
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dorsal interneuron progenitors (Fig. 1d) 6.   Therefore, a tagged version of Olig2 
recapitulates in differentiating ESCs the normal function of native Olig2 during spinal 
cord development 7.  
To profile Olig2 binding, we induced Olig2-V5 in pMNs and performed a ChIP-seq 
experiment with an anti-V5 antibody.  We observed that Olig2-V5 binds in the 
proximity of the downregulated genes Irx3, Nkx2.2 and Pax6 (Fig 2a and Suppl. Fig. 
1c), indicating that Olig2 specifies pMN identity by direct repression of interneuron 
transcriptional programs.  
The overexpression of the Olig2 transgene or the addition of the short tag sequence 
might affect the genomic binding pattern of the Olig2-V5 protein. For comparison, we 
therefore performed a ChIP-seq experiment in ESC-derived pMNs with antibodies 
against the native Olig2 protein in the absence of Dox.  The endogenous Olig2 and 
inducible Olig2-V5 ChIP-seq experiments revealed a remarkable level of agreement.  
The proteins bind to the same regulatory sequences of Irx3, Nkx2.2 and Pax6 (Fig 2a 
and Suppl. Fig. 1c).  As expected for a bHLH transcription factor, motif discovery 
within the ChIP-enriched sites revealed an E-box motif consensus (Fig 2b) that is 
present at 58.8% of Olig2-V5 and 60.4% of native Olig2 binding sites (10% false 
discovery rate (FDR) motif scoring threshold 8).  To determine whether enriched 
sequences lacking E-box motif represent real binding events we employed an in vitro 
ELISA based DNA-protein interaction assay.  We demonstrate that Olig2 transcription 
factor can be recruited to all tested ChIP-seq identified sequences regardless whether 
they contain E-box motif or not (Suppl. Fig.1d), supporting the notion that ChIP-seq 
data reflect Olig2 binding events. 
	   189	  
The distribution of binding sites found in both experiments is also highly coincident 
(Fig. 2c). Comparing the read counts at enriched peaks shows that only 0.2 % and 
1.1% are differentially enriched in the native Olig2 and Olig2-V5 ChIP experiments, 
respectively (Fig. 2c). Globally, the levels of ChIP-seq enrichment are highly 
correlated between experiments with a Pearson’s correlation coefficient of 0.83, 
indicating that neither the overexpression of Olig2-V5 in Olig2+ pMNs, nor the 
addition of an epitope tag, affects Olig2 activity or DNA binding preference.  
Next we compared the binding site preference of tagged transcription factors in a 
postmitotic motor neuron stage. We have previously demonstrated that Hoxc9 
represses cervical programs and promotes specification of thoracic motor neurons 9; 
the study of Hoxc9-V5 (iHoxc9-V5) (Fig. 1e) revealed a direct repression of cervical 
Hox genes 9.  We compared binding sites of C- and N-terminally epitope tagged 
Hoxc9, reasoning that overlapping sites are most likely to reflect native Hoxc9 binding 
events.  We modified the inducible system to accommodate a Flag-Bio (FlagB) amino-
terminal tag (Fig. 1a) that can be used for ChIP pull-downs either with anti-Flag 
antibodies or streptavidin-based purification in combination with the biotinylation 
enzyme BirA 10. We determined that FlagB tagged Hoxc9 retained its ability to repress 
cervical Hoxc4 and Hoxa5 genes (Fig. 3e and data not shown).    Importantly, the 
genome-wide binding of the iFlagB-Hoxc9 with anti-Flag antibodies shows a high 
degree of agreement with the Hoxc9-V5 binding profile.  Both Hoxc9 proteins 
associate with rostral Hox genes regulatory elements, indicating their direct repression 
(Fig. 2d).  At the genomic level, both proteins share an identical sequence preference, 
depicted by a typical Hox binding primary motif (Fig. 2e).  Moreover, 47.1% of the 
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peaks in the V5-tagged and 39.1% in the Flag-tagged experiments contain the primary 
motif at a 10% FDR scoring threshold (Suppl. Fig. 2). Although we estimate that the 
proportion of ChIP-seq reads located in enriched regions is approximately three times 
higher in the FlagB-Hoxc9 experiment than in the Hoxc9-V5 experiment, the detected 
peaks are highly coincident across experiments (Fig. 2f). Out of 22,458, only 156 
peaks (0.7%) are differentially enriched in V5 ChIP and 799 peaks (3.6%) are 
differentially enriched in the Flag experiment (Fig. 2f). We conclude that genomic 
regions shared between C- and N- terminally tagged ChIP-seq experiments are likely 
to represent native Hoxc9 binding events.   
The high degree of overlap between ChIP-seq experiments for one transcription factor 
contrasts with the binding profiles of two unrelated transcription factors. The 
comparison of the Olig2-V5 and Hoxc9-V5 ChIP experiments revealed a large fraction 
of non-overlapping peaks, which is in striking contrast to biological replicates of 
Hoxc9-V5 ChIP-seq experiments that are virtually indistinguishable (Suppl. Fig 3a-c). 
Detailed analysis of predicted binding positions by the GPS algorithm 8 in co-bound 
peaks reveals that Olig2 and Hoxc9 occupy proximal but distinct sites within the peaks 
(Suppl. Fig 2e and f). Because a typical ChIP-seq peak covers ~200 bp, these 
experiments might be revealing enhancers that are active in both motor neuron 
progenitors and postmitotic motor neurons. 
The system we present here is robust and allows the generation of multiple inducible 
cell lines in parallel.  Of twenty-four generated lines, only three exhibited problems 
with inducible protein expression, likely due to the inherent toxicity of introduced 
transgenes (data not shown). While the system is versatile and can be employed to 
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study both progenitors and differentiated cells, we observed that the efficiency and 
homogeneity of transgene induction declines in postmitotic neurons. Inducing the 
transgene at late progenitor stage results in maintained and homogenous expression in 
postmitotic neurons, offering a reasonable workaround for this problem. Some 
transcription factors control their targets in a concentration dependent manner. In those 
instances, it will be important to first establish the Dox concentration and timing of the 
treatment that result in desired phenotypes, to ensure that the transcription factor 
binding studies produce biologically relevant information.   
In summary, we provide a set of tools for rapid generation of ESC lines and 
production of unlimited quantities of isogenic differentiated cells that enable 
identification of developmentally relevant transcription factor binding sites in a 
genome-wide manner. The cell lines can also be utilized for other biochemical studies, 
including the isolation and identification of transcription factor binding partners by 
coimmunoprecipitation followed by mass spectrometry 11.  We believe that the 
combination of these powerful techniques will pave the way to a detailed mechanistic 
understanding of transcriptional networks that govern mammalian development.  
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Methods 
Cell culture  
ES cells were cultured over a layer of Mitomycin-C treated fibroblast resistant to 
Neomycin (Fisher) in EmbryoMax D-MEM (Fisher) supplemented with 10% ES-FBS 
(Invitrogen), L-Glutamine (Gibco), 0.1 mM b-mercaptoethanol and 100 U/ml LIF. 
Motor neuron differentiation of ES cells was performed as previously described1.  
Briefly, ES cells were trypsinized (Invitrogen) and seeded at 5x105 cells/ml in ANDFK 
medium (Advanced DMEM/F12:Neurobasal (1:1) Medium, 10% Knockout-SR, 
Pen/Strep, 2 mM L-Glutamine, and 0.1 mM 2-mercaptoethanol) to initiate formation 
of embryoid bodies (Day 0). Medium was exchanged on Day 1, Day 2 and Day 5 of 
differentiation.  Patterning of embryoid bodies was induced by supplementing media 
on Day 2 with 1 µM all-trans-Retinoic acid (RA, Sigma) and 0.5 µM agonist of 
hedgehog signaling (SAG, Calbiochem). For ChIP experiments, the same conditions 
were used but scaled to seed 1x107 cells on Day 0. Doxycycline (Sigma) was added to 
the culture medium at 1ug/ml when required. 
Generation of inducible lines 
The p2Lox-V5 plasmid was generated by replacing GFP with the L1-L2 Gateway 
cassette from pDEST-40 (Invitrogen) in the p2Lox plasmid. The cassette contains a 
V5-His double epitope tag in frame downstream of the L2 recombination site. p2Lox-
FlagB was generated by replacing GFP in the p2Lox plasmid with the L1-L2 Gateway 
cassette from pDEST-40 without the V5-His sequence but with the addition of a Flag-
Biotin sequence2 in frame and upstream the L1 recombination site. 
	   195	  
Open reading frames of genes are cloned by polymerase chain reaction (PCR). To 
minimize the introduction of mutations during PCR amplification, Phusion polymerase 
was used (New England Biolabs). Open reading frames were directionally inserted 
into pENTR/D-TOPO vector (Invitrogen) following manufacturer instructions. The 5’ 
primer always contains the addition of the CACC sequence to ensure directional 
integration. For each coding sequence, two alternative 3’ primers were used: with and 
without STOP codon, generating two pENTR plasmids for each gene.  
The LR recombination scheme is as follow: 1) When constructing a V5-His C-
terminal fusion protein the pENTR plasmid with NO STOP codon is recombined with 
the p2Lox-V5. 2) Non-tagged proteins are generated by recombining the pENTR 
plasmid with STOP codon with the p2Lox-V5 plasmid. 3) To generate N-terminal 
tagged proteins, the pENTR plasmid with STOP codon is recombined with p2Lox-
FlagB. 
Inducible lines were generated by treating the recipient ESCs for 16 hours with 
doxycycline to induce Cre followed by electroporation of either p2Lox-V5 and p2Lox-
FlagB plasmids harboring the desired construct. After G418 selection, on average 
three resistant clones were picked, characterized and expanded. 
Immunocytochemistry 
Embryoid bodies were fixed with 4% paraformaldehyde in PBS, embedded in OCT 
(Tissue-Tek) and sectioned for staining: 24 hours at 4C for primary antibodies and 4 
hours at RT for secondary antibodies. After staining, samples were mounted with 
Aqua Poly Mount (Polyscience). Images were acquired with a LSM 510 Carl Zeiss 
confocal microscope. Antibodies used in this study include: Rabbit anti-Olig2 
	   196	  
(Millipore); mouse anti-V5 (Invitrogen); mouse anti-Flag M2 (Sigma); rabbit anti-
Hoxc4 are gifts from T Jessell. Alexa488-, FITC-, Cy3- and Cy5-conjugated 
secondary antibodies were obtained from either Invitrogen or Jackson 
Immunoresearch. 
ChIP-seq 
Differentiating embryoid bodies were washed with PBS and then dissociated by mild 
Trypsinization (Invitrogen) followed by mechanical dissociation until single-cell 
suspension was obtained. Cells were fixed with 1% formaldehyde for 15 minutes at 
room temperature. Pellets containing ~40 x106 cells were flash frozen and stored at -80 
oC. Cells were thawed on ice, resuspended in 5ml of Lysis Buffer A and incubated for 
10 minutes at 4 oC in a rotating platform. Samples were spun down for 5 minutes at 
1,350g, resuspended in 5ml Lysis Buffer B and incubated for 10 minutes at 4 oC in a 
rotating platform. Samples were spun down for 5 minutes at 1,350g, resuspended in 
3ml of Sonication Buffer (SB). 
Nuclear extracts were sonicated using a Misonix 3000 model sonicator to sheer cross-
linked DNA to an average fragment size of approximately 500bp. Sonicated chromatin 
was incubated for 16 hours at 4C with Protein-G beads (Invitrogen) conjugated with 
either rabbit anti-V5 (Abcam, ab15828), mouse anti-Flag M2 (Sigma, ab15828) or 
rabbit anti-Olig2 (Millipore, AB15328). After incubation and with the aid of a 
magnetic device, beads were washed once with SB+500nM NaCl, once with LiCl 
Wash Buffer (LiClB) and 1ml of TE. Then, beads were centrifugated at 950g for 3 min 
and residual TE removed with a pipette. 210 ul of Elution Buffer was added to the 
beads followed by incubation at 65 oC for 45 minutes with a brief pulse of vortex 
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every 10 minutes. 200 ul of supernatant was removed after a 1 minute centrifugation at 
16,000g. The crosslink was reversed by 16 hours incubation at 65 oC. 
RNA was digested by the addition of 200 ul of TE and RNAseA (Sigma) at a final 
concentration of 0.2mg/ml and incubated for 2 hours at 37C.  Protein was digested by 
the addition of Proteinase K (0.2 mg/ml final, Invitrogen) supplemented with CaCl2 
followed by a 30 minutes incubation at 55 oC. DNA was extracted with 
phenol:chloroform:isoamyl alcohol (25:24:1) and then recovered with an ethanol 
precipitation with glycogens as carrier. The pellets were suspended in 70 ul of water. 
Purified DNA fragments were processed according to the Illumina/Solexa sequencing 
protocol using a Genome Analyzer II (Illumina, 
http://www.illumina.com/pages.ilmn?ID=252).     
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Lysis Buffer A (50 mM Hepes-KOH, pH 7.5; 140 mM NaCl; 1 mM EDTA; 10% 
Glycerol; 0.5%  Igepal; 0.25% Triton X-100). Lysis Buffer B (10 mM Tris-HCl, pH 
8.0; 200 mM NaCl; 1 mM EDTA, pH 8.0; 0.5 mM EGTA, pH 8.0). Sonication Buffer 
(50mM Hepes pH 7.5; 40mM NaCl; 1mM EDTA; 1mM EGTA; 1% Trition X-100; 
0.1% Na-deoxycholate; 0.1% SDS). Sonication Buffer High Salt (50mM Hepes pH 
7.5; 500mM NaCl; 1mM EDTA; 1mM EGTA; 1% Trition X-100; 0.1% Na-
deoxycholate; 0.1% SDS). IgG LiCl Wash Buffer (20mM Tris-HCL pH8.0; 1mM 
EDTA; 250mM LiCl; 0.5% NP-40; 0.5% Na-deoxycholate). Elution Buffer (50 mM 
Tris-HCl, pH 8.0; 10 mM EDTA, pH 8.0; 1% SDS).   
ChIP-seq analysis 
Sequence reads were aligned to the mouse genome (version mm9) using Bowtie3 
version 0.12.5 with options "-q --best --strata -m 1 -p 4 --chunkmbs 1024". Only 
uniquely mapping reads were analyzed further. Binding events were detected using 
GPS4. In GPS, the scaling ratio between IP and control channels was estimated using 
the median ratio of all 10Kbp windows along the genome. The GPS binding model 
was initialized to the default and iteratively updated over up to 3 training rounds. In 
this study, we require that reported peaks contain a ChIP-seq enrichment level that is 
significantly greater than 1.5 times the control level with p-value <0.01 as tested using 
the Binomial distribution. Signal-to-noise ratios are estimated by comparing the ChIP-
seq read count occurring at any peak found for a given transcription factor in any 
condition to the count of remaining reads in that experiment.  
When comparing enrichment levels between two ChIP-seq experiments, we first scale 
the read counts assigned to each peak using the median ratio of observed read counts 
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across all peaks. The read counts of one experiment are always scaled down to match 
the scale of the other experiment. We define differentially enriched sites as those that 
have a scaled read count in one experiment that is significantly greater than 1.5 times 
the scaled read count from the other experiment (p<0.01, Binomial test, adjusted for 
multiple testing using Benjamini & Hochberg’s method). All microarray and ChIP-seq 
data are available from the 
GEO database under accession number GSE31456 
DNA motif analysis	  
De-novo motif-finding was performed in 200bp windows centered on the 2,000 top-
ranked peaks for each examined ChIP-seq experiment. GimmeMotifs5 was used to 
discover motifs by running and combining results from the motif-finders MDmodule, 
MEME, GADEM, MotifSampler, trawler, Improbizer, MoAn, and BioProspector. The 
settings “-w 200 -a large -g mm9 -f 0.5 -l 500” were used with GimmeMotifs. 
STAMP6 was used to determine the similarity of discovered motifs to known DNA-
binding preferences. Log-likelihood scoring thresholds for the discovered motifs were 
calculated by simulating 1,000,000 200bp sequences using a 3rd-order Markov model 
of the mouse genome. The motif scoring thresholds that yield false discovery rates of 
10% in this set of sequences were recorded and used to scan 200bp sequences centered 
on the Olig2 and Hoxc9 GPS-predicted peak positions. 	  
ELISA DNA Binding 
PCR amplified and biotin-labeled genomic fragments are gel purified. The fragments 
are between 500 and 600 bp with the 5’ primers containing a single biotin molecule at 
the 5’end. Streptavidin coated 96 well plates (Fisher, PI-15500) are washed three times 
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with 200 μl of Wash Buffer. The biotin-labeled PCR reaction is loaded into each well 
in Blocking Buffer up to 125 μl final volume to saturate the binding capacity of each 
well (Plates can bind ~125pmol/well). The plates were incubated overnight at 4ºC then 
washed each well three times with 200 μl of Wash Buffer. Serial dilutions of the cell 
extract in PBS were added to each well and incubated for 3 hrs with shaking at room 
temperature. After washing each well three times with 200 μl with Wash Buffer the 
primary antibody in 0.5% BSA in PBS was added to final volume of 100 μl to each 
well and incubate plate for 2 hours with shaking at room temperature. After washing 
each well three times with 200μl of Wash Buffer, HRP-conjugated secondary antibody 
diluted in 0.5% BSA in PBS to final volume of 100 μl to was added to each well for 
30-45 minutes with shaking at room temperature. The wells were washed three times 
with 200 μl of Wash Buffer. 100 µl of equilibrate the TMB (Fisher EN-N301) to room 
temperature was added to each well. After 10 minutes incubation, the reaction was 
stopped by adding 100 μl of 2 M sulfuric acid to each well. The absorbance was 
measured of each well at 450 nm using a plate reader. 	  
Wash Buffer: 0.05% Tween-20 + .1% BSA in PBS.	  
Blocking Buffer: 0.5% BSA in PBS.	  	  
Primers to amplify the ChIp-seq identified genomic regions in Suppl. Table 1. 
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Figure 1   
Characterization of Olig2-V5 expression and in 
vitro binding. 
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Figure 2   
Primary motif distribution of ChIp-seq binding 
data. 
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Figure 3   
Comparison of Olig2-V5 vs. Hoxc9-V5 and 
Hoxc9-V5 vs. Flag-Hoxc9 ChIP-seq 
experiemtns. 
Supplementary 
Table 1   
 Primer sequence for in vitro binding 
experiemtns. 
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Figure legend 
Figure 1: Generation of inducible cell lines 
(a) The schematic depicts the cloning strategy to generate inducible lines with 
epitope tagged genes. Coding sequences lacking the STOP codon are V5-tagged at 
the C-terminus. (b) Overview of embryonic stem cell (ESC) directed 
differentiation. Differentiating cells become motor neuron progenitors (pMNs) at 
Day 4 and produce motor neurons (MNs) from Day 5-7. Doxycyline (Dox) is 
added late on Day 3 or Day 4 to mimic the expression pattern of the endogenous 
Olig2 and Hoxc9 respectively. Olig2-V5 is analyzed at Day 4 and Hoxc9-V5 or 
FlagB-Hoxc9 at Day 5. (c)  Nkx2.2 staining in control or Olig2-V5 expressing 
cells at Day 4 of differentiation under high Hh concentration (500 nM). (d)  Pax6 
staining in control or Olig2-V5 expressing cells at Day 4 of differentiation under 
low Hh (5 nM). (e) iHoxc9-V5 and iFlagB-Hoxc9 day 5 embryoid bodies stained 
with anti-Hoxc4, V5 and Flag antibodies.  
Figure 2: Native and tagged ChIP comparisons 
(a) ChIP signal tracks over Nkx2.2 genomic loci for endogenous and V5-tagged 
Olig2. Red peaks represent significant (p<0.01) enrichment over control. (b) The 
most over-represented motifs discovered under ChIP-seq peaks for native Olig2 
and Olig2-V5 ChIP experiments. (c) The plots show a comparison of read 
enrichment from native and V5-tagged Olig2 ChIP-seq experiments at all detected 
peaks. Blue dots in the scatterplot represents peaks significantly differentially 
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enriched in one experiment over the other. Pie chart represents numbers of sites 
differentially enriched between native Olig2 and V5 tagged ChIP experiments as a 
percentage of total sites. (d) ChIP signal tracks over Hoxc5 genomic locus for V5- 
and Flag- tagged Hoxc9 experiments. Red peaks represent significant enrichment 
over control (p<0.01). (e) The most over-represented motifs discovered under 
ChIP-seq peaks for Hoxc9-V5 and FlagB-Hoxc9 ChIP.  (f) The plots show a 
comparison of read enrichment from FlagB and V5-tagged Hoxc9 ChIP-seq 
experiments at all detected peaks. Blue points in the scatterplot represent peaks 
significantly differentially enriched in one experiment over the other. The pie chart 
shows numbers of sites differentially enriched between Hoxc9-V5 and FlagB-
Hoxc9 ChIP experiments as a percentage of total sites. 
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Personal Contribution to the Project 
This chapter is the result of a collaboration with Marion Dejosez on work that was 
published in 2010 in Genes and Development. Marion requested assistance in 
determining the genome-wide localization of the ES cell transcription factor Ronin in 
ES cells. I conducted ChIP-seq experiments, and performed some data analysis, which 
is described in this appendix.  
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Summary 
 
Embryonic stem (ES) cells have an exceptional need for timely biomass 
production, yet the transcriptional control mechanisms responsible for meeting 
this requirement are largely unknown.  We report here that the transcription 
factor Ronin (Thap11), which is essential for the self-renewal of ES cells, controls 
a key set of genes necessary for accommodating the biosynthetic and bioenergetic 
demands of self-renewing mouse ES cells. Genome-wide analysis revealed that 
Ronin occupies an exceptionally conserved regulatory motif in mammals, a DNA 
sequence that previously lacked a recognized binding factor. Ronin, together with 
the transcriptional coregulator Hcf-1, was generally observed to be an activator 
of genes essential to protein biosynthesis and energy production.  We propose 
that Ronin activity is essential to the unimpeded growth of ES cells. 
 
In contrast to all other mammalian cells, embryonic stem (ES) cells are characterized 
by a truncated cell cycle, relative autonomy from extracellular signal-regulated kinase 
(Erk) signaling and an unusually rapid growth rate, analogous to that of cancer cells 
and primitive unicellular organisms including bacteria (1-3).  Thus, the task of 
replicating the genome, proteome and other cellular components (biomass) to keep 
pace with this rapid growth imposes stringent metabolic demands on ES cells.  
Emerging evidence indicates that such requirements are met not by a self-correcting, 
homeostatic system of housekeeping enzymes, but by a dynamically regulated genetic 
network (4).  Although much has been learned about the factors governing the 
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pluripotency of ES cells (5-10), the molecular mechanisms that facilitate their efficient 
self-renewal are only beginning to be explored.  A better understanding of the link 
between ES cell metabolism and pluripotency is fundamental to realizing the full 
potential of these cells in genetic engineering and regenerative medicine. 
 
We recently discovered a novel zinc-finger transcriptional regulator, Ronin (also 
Thap11), that is essential for the self-renewal of ES cells (11). Conditional knockout of 
the Ronin gene induces ES cell death, while its forced expression enables the cells to 
proliferate transiently without differentiation under conditions that normally do not 
promote self-renewal. While studying Ronin-overexpressing mouse ES cells, we 
noticed that they possessed a strikingly enlarged nucleolus (Fig. 1A), the prime site of 
ribosome synthesis and assembly, suggesting that Ronin overexpression may alter the 
production of a key growth-related body in ES cells. This observation, coupled with 
our previous finding that Ronin can interact with the cell growth factor Hcf-1 (11-13), 
led us to investigate its contribution to the biosynthetic needs of mouse ES cells.   
 
We first sought to identify the DNA-binding sites of Ronin using chromatin 
immunoprecipitation and DNA sequencing (ChIP-seq). Our mapping results revealed 
866 Ronin-bound regions (Table S1), most of which were located at or immediately 
upstream of transcription start sites (Fig. 1B and C), suggesting that Ronin participates 
in transcriptional initiation.  Alignment analysis identified a Ronin-binding motif 
(CTGGGARWTGTAGTY, designated here as RBM) in 844 of the target gene 
promoters (Fig 1D).  This functional element was highly enriched compared with 
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random sequences (P << 10-100).  Intriguingly, the Ronin target sequence closely 
matched an orphan promoter sequence (ACTAYRNNNCCCR, so-called M4 motif; 
Fig. 1D), whose conservation rate in humans (61%) is the fourth highest among the 
top 50 conserved motifs described by Xie et al. (14).  This sequence is notable for 
another reason: in contrast to most highly conserved regulatory motifs in the human 
genome, it lacked a recognized binding factor until this analysis. The RBM was 
present within 70% of all regions enriched for Ronin binding. When we examined the 
22 sites that were bound by Ronin but lacked the full length RBM (P>0.05), we found 
that a substantial proportion of these targets contained at least half of the conserved 
motif (fig. S2A), suggesting that similar to other zinc-finger proteins, such as Rest 
(15), Ronin can occupy half-sites. Gel-shift experiments (Fig. S1A) and ChIP with a 
Ronin-specific antibody, followed by PCR analysis of selected target gene regions 
(fig. S1B and C), confirmed the identity of each site we had found to be specifically 
targeted by Ronin. 
 
Because Ronin lacks a transactivation domain and can interact directly with a known 
transcriptional regulator, the Hcf-1 protein (11), we considered that both factors might 
be needed at the RBM to initiate gene transcription.  We therefore performed ChIP-seq 
with an Hcf-1 antibody (16), identifying 743 genomic loci occupied by Hcf-1 at a high 
confidence level (see Table S2). These regions overlapped 176 target promoters that 
were also bound by Ronin (Table S2 and Fig. 1E). Even when the Hcf-1 signal did not 
attain significance by our conservative cut-off point, we were still able to detect a 
substantial binding peak, indicating that Hcf-1 generally co-occupies Ronin-bound 
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target sites. To study functional significance of the interaction between Ronin and Hcf-
1 at a common regulatory motif we created ES cells overexpressing a Ronin mutant 
deficient in Hcf-1 binding (EF1α-RoninDHSA) (figs. S3 and S4A, B). As previously 
reported (11) Ronin made Lif nonessential for ES cells under our experimental 
conditions, while EF1α-RoninDHSA ES cells still differentiated (fig. S4C, D), suggesting 
that Ronin must interact with Hcf-1 to block differentiation. 
 
Approximately 40% of the 866 promoters bound by Ronin were also occupied by one 
or more of the ES cell transcription factors Oct4, Sox2 and Nanog, which have central 
roles in pluripotency control (5-10, 17).  It was interesting that Ronin consistently 
occupied sites within promoter regions that were only 50 to 100 bp upstream of 
transcription start sites, in contrast to the more distant sites occupied by Oct4 (Fig. 1F) 
and other core transcription factors.  Most promoters bound by Ronin were not 
occupied by Oct4, Sox2, Nanog, and Tcf3.  Indeed, Ronin and Hcf-1 clustered 
together rather than with the canonical factors in a hierarchical clustering analysis 
based on target similarity scores for genomic regions that were highly enriched in 
ChIP-seq experiments (7, 17-19) (Fig. 1G).  
 
We next considered the possibility that the genes occupied by Ronin and Hcf-1, but 
not the canonical factors, are involved in biomass production supporting ES cell 
growth.  To test this hypothesis, we focused on the subset of genes whose promoters 
were solely bound by Ronin and Hcf-1. Using the Panther tool for classifying 
biological processes, we determined the functional categories of all genes defined by 
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independent binding of Ronin/Hcf-1 to promoters.  Transcription initiation, mRNA 
splicing and protein metabolism were among the most overrepresented categories, 
whereas cell signaling and cell development were underrepresented (Fig. 2A). Close 
inspection of the individual genes within these categories (Table S3) yielded a more 
informative functional portrait (Fig. 2B).  Ronin bound as many as 30% of the 
ribosomal protein-encoding genes, including Rplp2, Rps12 and Rpl36, and two key 
subunits of RNA polymerase I, Rpo1-2 and Rpo1-4 (all involved in protein 
biosynthesis);  Ctd, Cnot4/8 and Med4 (transcription initiation); and Rab1b, Nup133 
and Timm22 (protein trafficking).  These results are important because alterations in 
ribosomal biosynthesis, transcriptional initiation and protein transport can have 
profound effects on the metabolome of any cell, including stem cells (20-22).  Ronin 
also bound specifically to a subset of genes encoding mitochondrial ribosomal proteins 
(Mrpl19, 32, 50 and 54), mitochondrial translation factors (Tufm) and rate-limiting 
members of the oxidative phosphorylation cascade (Atp5e, NADH dehydrogenase and 
Atp5e), suggesting its involvement in the control of energy production in ES cells. 
Finally, Ronin occupied genes encoding threonine catabolic enzymes (Mtr), whose 
increased expression in ES cells facilitates a high-flux metabolic state characterized by 
enhanced threonine catabolism (3). Ronin did not bind to any of the classical cell cycle 
genes, suggesting that it influences self-renewal without affecting cell cycle 
progression. Thus, Ronin occupies a relatively small number of genes with specific 
functions in protein biosynthesis and energy production, but not cell development or 
mitosis (Fig. 2B).  
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To explore the nature of target gene regulation by Ronin/Hcf-1, we conducted gene set 
enrichment analysis (GSEA) of RNA from Ronin-targeted genes in ES cells compared 
with that from embryoid bodies (Fig. 3A, top). The result indicates that Ronin-
occupied genes are generally highly transcribed, and the transcripts are significantly 
overrepresented in ES cells. We also compared the Ronin transcriptional program in 
wild-type ES cells with that in cells ectopically and stably overexpressing Ronin 
(EF1α-Ronin ES cells). Again, GSEA showed an overrepresentation of Ronin target 
genes (Fig. 3A, middle), suggesting that Ronin indeed positively affects the expression 
of many but not all of its target genes, consistent with the ability of Hcf-1 to either 
positively or negatively regulate transcription depending on the cellular context (13).  
To test the reverse prediction, we transfected RoninloxP/-  ES cells with the gene 
encoding Cre recombinase, sorted Cre-positive cells at 18 hours post-transfection, 
extracted the RNA and performed microarray analysis of gene expression. 
Interestingly, the entire subset of 133 genes found to be upregulated in Ronin knockout 
cells (Fig. 3B, right) were downregulated in our Ronin-overexpressing clones, whereas 
in the converse situation only 43 of 99 genes found to be downregulated after 
knockout (Fig. 3B, left) were upregulated in the Ronin-overexpressing clones.  
Additional evidence for direct transcriptional control of Ronin targets was obtained in 
experiments in which we cloned a set of the Ronin-targeted promoters and performed 
luciferase reporter assays. As shown in Fig. 3C, Ronin gain-of-function had a positive 
effect on gene expression, while loss of the RBM modulated the regulatory effects of 
Ronin on its targets. To track the expression of Ronin-controlled genes more closely, 
we analyzed the results of DNA microarrays over 14 days of ES cell differentiation 
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(Fig. 3D).  As expected, the largest class of genes showed rapid downregulation after 
induction of differentiation, while the two remaining classes were either upregulated 
or demonstrated complex regulation. Taken together, our findings show that Ronin 
binding to target sites can lead to either gene repression or activation, with the latter 
being more common.  These findings revise our earlier suggestion that Ronin is 
primarily a global repressor, based on the assumption that acute upregulation of Ronin 
under otherwise steady-state conditions would exert a dominant-negative effect on 
Ronin function, similar to observations on other proteins that harbor a Thap domain 
(23).  Thus, Ronin is most frequently an activator of genes involved in protein 
biosynthesis and energy production. 
 
To further validate the apparent role of Ronin in meeting the metabolic requirements 
of rapidly dividing ES cells, we focused our attention on cell size, reasoning that this 
property might be highly sensitive to fluctuations in Ronin activity.  In experiments to 
determine the diameters of EF1α-Ronin and EF1α-RoninDHSA ES cells compared with 
wild-type controls, we found that EF1α-Ronin ES cells were significantly enlarged (> 
6.4% increase in size, P=5.63x10-4; Fig. 4A, top), a change that was clearly visible in 
cell pellets adjusted for cell number (Fig. 4A, bottom). Importantly, ES cells 
expressing EF1α-RoninDHSA did not show an increase in cell size, confirming the 
requirement for Hcf-1 in optimal Ronin function. We also measured the amount of 
protein per cell (Fig. 4B, top) as well as protein translation capacity per cell (Fig. 4B, 
bottom), demonstrating that Ronin-overexpressing cells have significantly more 
protein content and translational activity per cell than do RoninDSHA or wild-type cells 
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(P=1.64x10-2). Finally, we found that the amount of ATP per cell was significantly 
higher (P=3.92x10-3) in EF1α-Ronin ES cells compared with wild-type or EF1α-
RoninDHSA ES cells (Fig. 4C).  This increase in cell size and protein metabolism was not 
due to a difference in cell cycle kinetics, as the proliferative rates of these cells did not 
differ over 96 hours of culture (Fig. 4D) and similar numbers of control and EF1α-
Ronin ES cells were in S phase (fig. S5A and B).  
 
Recently, the life cycle of ES cells was compared to that of yeast cells and other 
unicellular metazoans, in the sense that it follows a relatively primitive set of 
behavioral rules that differ from those of more mature cells (2, 3, 24).  In yeast, 
changes in certain exogenous factors, such as temperature and the sugar composition 
of the environment, profoundly affect the ability of the cells to produce protein and 
therefore to grow and to metabolize different energy sources (20).   Similarly, we 
suggest that fluctuations in the growth and metabolic capacity of ES cells may 
represent a previously unrecognized mechanism of pluripotency control.  Thus, for 
example, a shortfall in protein biosynthesis could cause ES cells to lose their full self-
renewal capacity, leading to apoptotic death or perhaps a rapid transition to 
differentiation.  This model is supported by recent observations establishing a 
correlation between the translational capacity of ES cells and the likelihood of 
differentiation (25). Our results indicate that Ronin participates in pluripotency control 
by directly stimulating a genetic program that ensures sufficiently robust protein 
biosynthesis and energy production to sustain the rapid self-renewal of ES cells until 
they exit the undifferentiated state. A deeper understanding of the links between 
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Ronin- and canonical transcription factor-controlled regulatory systems may facilitate 
(i) the development of new methods to maintain ES cells in vitro, a key step toward 
using stem cell therapies to replace diseased or injured tissue, and perhaps (ii) the 
identification of prime targets for new cancer therapeutics in malignant cells 
constitutively expressing the Ronin gene.  
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Figure Legends 
Fig. 1. Ronin binds to a highly conserved promoter element in mouse ES cells that is 
shared with Hcf-1. (A) Ronin-overexpressing clones have a different morphology 
characterized by a rounder cell shape and a more prominent nucleolus. (B) Binding of 
Ronin at the promoter regions of four representative genes, Rpo1-2 (RNA polymerase 
I), Mrlp34 (mitochondrial ribosomal protein L34), Cbx1 (chromobox homolog 1 
[Drosophila HP1 beta]) and Rplp2 (ribosomal protein LP2). Gene structure and 
chromosomal coordinates (mouse build NCBI36) are shown below the graphs; arrows 
indicate transcription start site. ChIP-seq results, shown on the y-axis are reads per 
million reads. (C) Histogram showing the distance of the midpoint of each Ronin 
binding event from the nearest transcription start site (arrow).  There is a highly 
significant preference of Ronin binding for the region immediately upstream of the 
start site. (D) Identification of the consensus Ronin binding motif depicted as a bit 
matrix. The recently discovered M4 sequence in human promoters (14) is included for 
comparison (top). (E) ChIP-seq results obtained in R1 mouse ES cells after 
immunoprecipitation with Ronin and Hcf-1 antibodies. A representative region on 
mouse chromosome 8D3, containing three Ronin-bound genes (Cenpt 
[G630055Po3Rik], Ronin [Thap11] and Nutf2), shows substantial overlap between 
Ronin and Hcf-1 binding peaks in the promoter region of all three genes. (F) ChIP-seq 
results obtained by precipitation with antibodies against Ronin or Oct4. Both factors 
occupy the Max promoter, with the Ronin binding peak positioned closer to the 
transcription start site (arrow). (G) Hierarchical clustering analysis of 22 prominent 
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transcriptional regulators in mouse ES cells, based on target similarity scores 
calculated with a Pearson correlation similarity metric. 
 
Fig. 2. Cellular functions of genes targeted by Ronin in mouse ES cells. (A) Panther 
analysis of Ronin target genes. Categories with enrichment values >1 are significantly 
overrepresented, while those with lower values are significantly underrepresented. (B) 
Examples of Ronin target genes representing six major functional classes.  
 
Fig. 3. Ronin can either activate or repress its transcriptional targets in mouse ES cells. 
(A) GSEA analyses of Ronin target genes, showing enrichment of Ronin target genes 
in wild-type mouse ES cells compared with differentiated cells (top), in Ronin-
overexpressing cell line compared with wild-type ES cells (middle), and in wild-type 
compared with Ronin-knockout ES cells. (B) Overlap between the numbers of Ronin-
bound genes that are up- or downregulated in Ronin-overexpressing ES cells in 
relation to their status in Ronin-knockout ES cells. (C) Luciferase reporter assays with 
pGL3-based promoter constructs, showing effects on the expression of selected target 
genes (Ywhag, Mdh1 and Rplp2) with or without the Ronin binding motif in Ronin-
overexpressing cells. Values are means ±SD of triplicate experiments, asterisks 
indicate a significant difference in relative luciferase activity in Ronin-overexpressing 
versus control cells (* P<0.05, ** P<0.01). ΔRBM, mutant reporter construct with 
deleted Ronin binding motif. (D) Expression of Ronin target genes during the 
differentiation of mouse ES cells. Most target genes (Class I) are highly expressed in 
undifferentiated cells but are rapidly downregulated after induction of differentiation, 
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while a smaller set of genes (Class III) are upregulated. Class II genes appear to be 
regulated in a more complex fashion. Red, upregulated genes; blue, downregulated 
genes. 
 
Fig. 4. Cell growth and metabolism correletate with Ronin expression in mouse ES 
cells. (A, top) Mean diameter of Ronin- versus RoninDHSA-overexpressing and control 
mouse ES cells as determined with an automated cell counter. Values are means ±SD 
of triplicate experiments; asterisk indicates P=5.63x10-4. (A, bottom) Pellet size of 
16x106 control and Ronin- or RoninDHSA-overexpressing mouse ES cells after 
resuspension in PBS and centrifugation. (B, top) Protein amount per cell in lines 
shown in figs S3 and S4. Asterisk indicates P=1.6410x10-2; values are means ±SD of 
triplicate experiments. (B, bottom) Analysis of protein synthesis rate in control cells 
(blue solid line) versus Ronin-overexpressing (red solid line) and RoninDHSA-
overexpressing cells (green solid line) stained with AHA-Alexa Fluor488; additional 
controls were treated with cycloheximide (black dotted line) to block protein synthesis 
osr were not labeled with AHA (green dotted line). (C) ATP content of Ronin- versus 
RoninDHSA-overexpressing and control ES cells, quantified as relative luminescence 
units (RLUx106/5x104 cells). Asterisk indicates P=3.92x10-3, values are means ±SD of 
triplicate experiments. (D) Proliferation rate of Ronin- versus RoninDHSA-
overexpressing and control ES cells over 96 h. 
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This chapter is the result of a collaboration with Aditi Kanhere on work that was 
published in 2010 in Molecular Cell. Aditi requested assistance in determining the role 
for short RNAs during the differentiation of ES cells. I conducted in vitro 
differentiation experiments, and the results are described in this appendix.  
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Summary 
 
Polycomb proteins maintain cell identity by repressing the expression of 
developmental regulators specific for other cell types. Polycomb repressive 
complex-2 (PRC2) catalyses trimethylation of histone H3 lysine-27 (H3K27me3). 
Although repressed, PRC2 targets are generally associated with the 
transcriptional initiation marker H3K4me3 but the significance of this remains 
unclear. Here, we identify a new class of short RNAs, ~50-200 nucleotides in 
length, transcribed from the 5’-end of polycomb target genes in primary T-cells 
and embryonic stem cells. Short RNA transcription is associated with RNA 
polymerase II and H3K4me3, occurs in the absence of mRNA transcription and is 
independent of polycomb activity. The short RNAs form stem-loop structures 
resembling PRC2 binding sites in Xist, interact with PRC2 through the SUZ12 
subunit and, in neuronal cells, are specifically lost from genes no longer subjected 
to polycomb-mediated repression. We propose that short RNAs play a role in 
association of PRC2 with its target genes. 
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Introduction 
 
Polycomb group (PcG) proteins are essential for embryogenesis and for maintaining 
embryonic stem (ES) cell pluripotency and differentiated cell states (Boyer et al., 
2006; Cui et al., 2006; Faust et al., 1995; Kimura et al., 2001; Lee et al., 2006; 
Molofsky et al., 2003; O'Carroll et al., 2001; Pasini et al., 2007; Richie et al., 2002; 
van der Stoop et al., 2008). PcG proteins form at least two polycomb repressive 
complexes (PRCs) that are conserved across Metazoa (Schwartz and Pirrotta, 2007). 
PRC2 catalyses trimethylation of lysine 27 of histone H3 (H3K27me3), forming a 
binding site for PRC1 (Cao et al., 2002; Wang et al., 2004). 
 
Genome-wide measurements of PRC2 localisation and H3K27 methylation have 
revealed that PRC2 represses the expression of hundreds of developmental regulators 
in ES cells that would otherwise induce cell differentiation (Azuara et al., 2006; Boyer 
et al., 2006; Lee et al., 2006). In differentiated cells, activated genes important for the 
identity of those cells lose H3K27me3 whereas genes that regulate alternate cellular 
identities remain methylated and repressed (Bernstein et al., 2006; Lee et al., 2006; 
Mikkelsen et al., 2007; Pan et al., 2007; Roh et al., 2006).  
 
Although repressed, PRC2 target genes are thought to adopt a poised state that allows 
their rapid upregulation upon ES cell differentiation (Boyer et al., 2006; Lee et al., 
2006). This poised state is reflected by the association of PRC2 target genes with 
histone H3K4me3, a marker of transcriptional initiation (Azuara et al., 2006; Bernstein 
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et al., 2006; Roh et al., 2006). The unphosphorylated and Ser-5 phosphorylated forms 
of RNA polymerase II have also been detected at some polycomb target genes but not 
the Ser-2 phosphorylated form that is associated with transcriptional elongation 
(Dellino et al., 2004; Lee et al., 2006; Stock et al., 2007). The block to RNA 
polymerase II elongation at these genes is due, at least in part, to the activity of PRC1, 
which binds to H3K27me3. PRC1 contains Ring1 that ubiquitinates H2A, blocking 
elongation by RNA polymerase II (Stock et al., 2007; Zhou et al., 2008).  
 
PRC1 and PRC2 have no known DNA sequence binding specificity and it is not clear 
how PRC2 associates with its target genes.  Recent results have shown that PRC2 can 
interact with long RNA transcripts. PRC2 interacts with the 1.6 kb ncRNA RepA 
transcribed from Xist and this is necessary for H3K27me3 and X-chromosome 
inactivation (Zhao et al., 2008). Similarly, the ncRNA HOTAIR associates with PRC2 
and induces methylation of the HOXD locus in trans (Rinn et al., 2007) and the 
antisense transcript Kcnq1ot1 associates with PRC2 and induces methylation of Kcnq1 
(Pandey et al., 2008). Possibly related to such mechanisms, exogenous siRNAs 
designed against the promoters of the genes EEF1A1 and CCR5 induce H3K27 
methylation and gene repression that requires the expression of long RNAs transcribed 
from alternative promoters upstream of the major mRNA transcription start site (TSS) 
(Han et al., 2007). These results suggest that ncRNAs may be important for PRC2 
localisation across the genome.  
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Because polycomb target genes show evidence of stalled RNA polymerase II and do 
not transcribe appreciable amounts of mRNA, we hypothesised that short RNAs may 
be transcribed from these genes. We describe here the identification of such a set of 
short RNAs transcribed from the 5’ ends of polycomb target genes in primary human 
CD4+ T cells and in murine ES cells. These RNAs are transcribed from sites enriched 
for markers of transcriptional initiation, but not transcriptional elongation, 
independently of polycomb function and are absent from genes that are derepressed in 
neuronal cells. Short RNAs interact with PRC2 and we propose that this may stabilize 
the association of PRC2 with chromatin. 
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Results 
 
Detection of short RNAs associated with the 5’ end of genes 
We designed a DNA microarray to identify short RNAs at the 5’ end of human genes 
(Figure 1A and Figure S1). RNA from primary human CD4+ T cells was fractionated 
by size into populations of short (<200nt) and large RNAs, labeled with fluorescent 
dyes and hybridized to the microarrays in replicate experiments (Figure S2). The 
arrays contained multiple probes allowing detection of sense-strand RNA at the 
promoter, 5’-most exons, 1st intron and 3’-most exons of known protein-coding genes 
(Supplemental Data and Table S1). These arrays also contained probes for known 
short nuclear RNA (snRNA) and short nucleolar RNA (snoRNA) that acted as positive 
controls and produced strong signals in the short RNA channel of the arrays compared 
to the mRNA and total RNA channels (Figure 1B and Figure S2).  
 
We investigated whether we could detect short RNAs transcribed from protein-coding 
genes. Applying a threshold derived from our snRNA probes, we found thousands of 
short RNAs transcribed from the sense-strands of promoters, exons and introns of 
protein-coding genes in replicate experiments (Figure 1C, Table S2). The RNAs were 
concentrated at the 5’ end of genes, within 700bp upstream and downstream of the 
mRNA TSS (Figure 1D).  A substantial subset of the genes associated with short RNA 
at their 5’ ends in primary human CD4+ T cells also produced short RNAs in cell lines 
and ES cells (Kapranov et al., 2007; Seila et al., 2008) (Figure 1E), although often 
from different locations (Figure S2). These results indicate that short RNAs are 
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generated in primary human T cells, are most abundant in promoter-proximal 
sequences, and are a general feature of the transcriptome of normal somatic cells. 
 
Transcription of short RNAs from genes that are otherwise repressed 
The short RNAs described in previous reports are typically associated with 
transcriptionally active genes but not with repressed polycomb target genes 
(Affymetrix/CSHL ENCODE, 2009; Core et al., 2008; Kapranov et al., 2007; Seila et 
al., 2008; Taft et al., 2009).  We therefore examined the transcriptional status of 
human T cell genes that produce short RNAs. We found that short RNAs could be 
detected both at genes that produced mRNA transcripts and at genes that do not 
produce mRNA transcripts (Figure 2A) (Su et al., 2004) (Figure 2A). Although the 
mRNA signals are quite different between these two sets of genes, the short RNA 
signals are similar in the two classes (Figure 2B). This indicates that the transcription 
of short RNAs can occur in the absence of mRNA transcription. 
 
We next used chromatin immunoprecipitation coupled with microarray analysis 
(ChIP-Chip) to determine whether RNA pol II was present at genes that transcribe 
short RNAs but do not produce mRNA (Figure 2C). The antibody used preferentially 
recognises the non-phosphorylated form of RNA pol II that initiates transcription 
(Thompson et al., 1989). We plotted average enrichment for RNA pol II across the 
TSS of genes that transcribe short RNA but not mRNA and compared this to genes 
that transcribe neither RNA type.  We found that RNA pol II was enriched at genes 
that produce short RNAs but not mRNA. This enrichment of RNA pol II at these 
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genes was also apparent using data from independent ChIP-Seq experiments (Barski et 
al., 2007) (Figure S3).  
 
At genes that produce short RNAs but not mRNA, the location of the short RNA 
correlates with the position of the initiating form of RNA pol II.  At the set of genes 
where short RNA was detected at promoter regions, the RNA pol II peak was shifted 
upstream of the mRNA TSS.  At the set of genes where short RNA was detected at 
exon or introns, RNA pol II occupancy was enriched downstream of the mRNA TSS 
(Figure 2D and Figure S3).  The positioning of RNA pol II at the site of short RNA 
production, as opposed to the annotated mRNA TSS, can also be observed at 
individual genes (Figure 2E). At genes that produce both short RNA and mRNA, RNA 
pol II was concentrated at the mRNA TSS (Figure S3). These results argue that the 
RNA pol II observed at repressed genes is primarily involved in the transcription of 
short RNA rather than mRNA and that these short RNAs can be produced from TSS 
distinct from the mRNA TSS. 
 
We next examined the transcriptional status of RNA pol II at short RNA loci. We used 
ChIP-Chip to map; H3K4me3, a marker of transcriptional initiation, and H3K79me2, a 
marker of transcription through a gene (Guenther et al., 2007; Steger et al., 2008). We 
first examined the average enrichment profile for these histone modifications across all 
human genes and found that H3K79me2 showed comparable enrichment to H3K4me3 
(Figure 2F). In contrast, genes that produced short RNAs but not mRNAs were 
enriched for H3K4me3 but not H3K79me2 (Figure 2G). The presence of RNA pol II 
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and H3K4me3 in the absence of H3K79me2 was also apparent when examining genes 
individually (Figure S3). From these data we conclude that genes associated with short 
RNAs experience transcriptional initiation but the protein-coding portion of the gene is 
not transcribed.  
 
Repressed genes producing short RNAs are associated with H3K27me3 
Genes repressed by polycomb proteins are generally associated with nucleosomes 
containing H3K4me3, a marker of transcriptional initiation, and often RNA pol II 
(Azuara et al., 2006; Bernstein et al., 2006; Chopra et al., 2009; Roh et al., 2006; Stock 
et al., 2007). We considered the possibility that genes that generate short transcripts 
but not mRNA could be associated with polycomb proteins. To test this, we used 
ChIP-Chip to measure H3K27me3 in human CD4+ T cells and compared the results to 
our short RNA data. We found that genes that transcribed short RNA but not mRNA 
were enriched for H3K27me3 (Figure 3A and Figure S4). These results were also 
confirmed using independent measurements of H3K27 from ChIP-Seq experiments 
(Barski et al., 2007) (Figure 3B). H3K27me3 could be detected more frequently at 
genes that transcribe short RNA but not mRNA than at any other category of gene 
(Figure 3C), demonstrating the close association between short RNA transcription and 
H3K27 methylation.  
 
Transcription of short RNAs from polycomb target genes would explain the 
association of these genes with H3K4me3. We therefore sought to verify that the 
transcriptional machinery was present at H3K27-methylated genes that express short 
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RNAs. Plotting enrichment of H3K27me3, H3K4me3 and RNA pol II across these 
genes confirms that transcriptional initiation occurs at polycomb target genes in CD4+ 
T cells (Figure 3D and E). Strikingly, H3K27-methylated nucleosomes flank the sites 
of RNA pol II and H3K4me3 occupancy, consistent with a block to transcriptional 
elongation previously associated with this modification (Stock et al., 2007; Zhou et al., 
2008).   
 
PRC2 targets developmental regulators that must be repressed to maintain cellular 
identity and thus plays a critical role in T cell development (Barski et al., 2007; Boyer 
et al., 2006; Chang and Aune, 2007; Koyanagi et al., 2005; Lee et al., 2006; 
Schoenborn et al., 2007). We therefore asked whether the set of genes that expressed 
short RNAs in the absence of mRNA were enriched for genes that play a role in 
development. Using Gene Ontology (GO) (Dennis et al., 2003) to annotate gene 
function, we found that functional categories such as multicellular development, 
nervous system development and cell-cell signalling were all significantly enriched in 
the set of genes from which short RNA was transcribed in the absence of mRNA 
(Figure 3F). These GO terms were not enriched in the set of repressed genes that are 
not associated with short RNA. Therefore, consistent with polycomb-mediated 
silencing, genes from which short RNA is transcribed in the absence of mRNA tend to 
have functions in development and cell differentiation.  
 
Short RNAs transcribed from polycomb target genes are ~50-200 nt in length 
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We next used Northern blotting to verify the transcription of short RNAs from 
polycomb target genes and to perform a more accurate determination of their size.  We 
selected array probes that detected short RNAs at genes for which no mRNA could be 
detected and were also associated with H3K27me3 (Figure S4). We then purified short 
RNA from peripheral blood mononuclear cells (PBMC), treated it with DNase and 
performed northern blotting for short RNAs (Figure 3G). 14 of the 16 probes we tested 
(88%) detected a short RNA species. Some probes identified a single RNA species of 
between ~50 and 200 nt, while others detected multiple RNA products. Short RNA 
transcripts could be detected from exons, introns and promoter regions, consistent with 
our array data. We did not detect RNA species between 20-30 nt, suggesting that these 
polycomb-associated short RNAs are not substrates for Dicer and are not involved in 
RNAi-mediated transcriptional gene silencing. 
 
Short RNA transcription is not dependent on polycomb activity 
Methylation of H3K27me3 is necessary for transcriptional repression by polycomb 
group proteins. We considered whether the production of short RNAs was dependent 
on H3K27 methylation. To test this, we made use of the murine ES cell line Ezh2-1.3, 
in which deletion of the Ezh2 SET domain can be induced by tamoxifen (derived from 
mice described by Su et al., 2003). We first tested whether short RNAs were 
transcribed from polycomb target genes in ES cells. We identified short RNA loci 
conserved between human and mouse and used histone methylation data (Boyer et al., 
2006) to identify those targeted by polycomb in ES cells. Northern blotting detected a 
short RNA at each of these genes in murine ES cells (Figure 4A), indicating that the 
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transcription of short RNAs from repressed polycomb target genes is common to 
different cell types and conserved between different mammalian species. 
 
We next measured short RNA transcription in Ezh2-1.3 cells at timepoints after the 
addition of tamoxifen. Loss of full-length Ezh2 protein (together with the appearance 
of a truncated form lacking the SET domain) and a reduction in H3K27me3 could be 
observed in these cells over the five-day timecourse (Figure 4B). Blotting for short 
RNAs at the genes Hes5, Msx1 and Ybx2 showed that loss of Ezh2 and H3K27me3 
had no effect on the levels of short RNAs at these genes (Figure 4C). These results 
show that the production of short RNAs at polycomb target genes is not dependent on 
H3K27 methylation.  
The block to mRNA transcription at bivalent genes is dependent on the PRC1 
component Ring1 that catalyzes the ubiquitination of histone H2A (Stock et al., 2007). 
Deletion of Ring1 causes activation of PRC1 target genes, including Msx1. We blotted 
for short RNAs in the murine ES cell line ES-ERT2 with and without addition of 
tamoxifen that induces deletion of Ring1b and loss of H2AK119ub (Stock et al., 
2007). As we found for deletion of Ezh2, loss of Ring1b had no effect on short RNA 
transcription (Figure 4D). These data show that transcription of short RNAs is not 
dependent on H2A ubiquitination and, taken together with the Ezh2 deletion 
experiments, indicate that short RNA transcription is independent of polycomb 
activity. 
 
Short RNAs encode stem-loop structures and interact with PRC2 
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The long ncRNAs HOTAIR and Xist RepA interact with PRC2 and this interaction is 
necessary for H3K27me3 of HOXD and the X-chromosome, respectively. We 
therefore considered that PRC2 may interact with the short ncRNAs identified here.  
 
The PRC2 binding site within mouse Xist RepA appears to be a double stem loop 
structure that is repeated 7 times (Zhao et al., 2008). We therefore first examined 
whether the short RNAs we have identified could form such a structure. We derived a 
general structural motif based on the RepA sequence (Figure 5A) and searched for the 
presence of this motif in the DNA sequences immediately surrounding probes that 
detect short RNAs from H3K27-methylated genes. We found that 71% of these 
sequences encode this PRC2-binding structure, compared to 36% of control sequences 
not associated with short RNAs but with an equal distribution around the mRNA TSS. 
29% of short RNA sequences contained 2 or more consecutive structure motifs, 
compared with 7% for control sequences. Examples of these structures are given in 
Figure 5B. These data indicate that short RNAs transcribed from polycomb target 
genes have the potential to interact with PRC2. However, we found that these 
structures were not limited to short RNAs transcribed from polycomb-associated genes 
and that they were also present within short RNAs transcribed from genes not 
associated with H3K27me3 (Figure 6B). These RNAs may therefore also have the 
potential to bind PRC2. 
 
To test for an interaction between short RNAs encoding the stem-loop structure and 
PRC2, we performed electromobility shift assays (EMSA). Consistent with recent 
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observations (Zhao et al., 2008), we found that incubation of T-cell lysate with 
radiolabeled RNA oligonucleotides encoding the Xist-RepA stem-loop produced a 
mobility shift indicative of binding by cellular proteins and that mutation of the RNA 
stem-loop structure abrogated this interaction (Figure 5C). We then repeated the 
experiment with RNA oligonucleotides corresponding to the stem-loops encoded by 
BSN, C20orf112, HEY1, MARK1 and PAX3 short RNAs. We observed a similar shift 
with RNA oligonucleotides corresponding to these short RNA stem-loop structures as 
we did for Xist-RepA and did not observe an interaction when the BSN short RNA 
structure was disrupted (Figure 5C). The BSN short RNA stem-loop was also able to 
compete with Xist-RepA for binding to the cellular complex, indicating that short 
RNAs bind to PRC2 (Figure 5D).  
 
We next sought to identify which PRC2 component was responsible for the interaction 
with short RNAs. We purified GST-tagged recombinant SUZ12, EZH2, EED and 
RBBP4 from E. coli and incubated each protein with radiolabeled Xist-RepA and BSN 
oligonucleotides (Figure 5E). We found that SUZ12 interacted strongly with Xist-
RepA and BSN short RNA stem-loops. SUZ12 also interacted with other short RNA 
stem-loops (Figure 5F), displayed a weaker interaction with mutated Xist-RepA RNA 
(Figure 5G) and did not bind to the BSN sequence encoded by single-stranded DNA, 
double-stranded DNA or DNA:RNA duplexes (Figure 5H). These data demonstrate 
that SUZ12 specifically interacts with RNA stem-loop structures encoded by Xist-
RepA and short RNAs. 
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PRC2 interacts with short RNAs in cells 
To test for an interaction between short RNAs and PRC2 in living cells, we 
immunoprecipitated the PRC2 subunit SUZ12 from a female T cell line, isolated co-
purifying RNA and subjected this to quantitative reverse-transcription PCR (Figure 
6A). In parallel, we performed RNA IP experiments with a non-specific rabbit control 
antibody. Immunoprecipitation with the Suz12 antibody, but not the control antibody, 
enriched for Xist RNA over Actin mRNA and mRNAs encoding GAPDH and HPRT, 
indicating we could specifically detect PRC2-RNA interactions in these cells. We then 
performed RT-PCR for short RNAs transcribed from polycomb target genes. We 
found that 4 of the 5 short RNAs we tested were enriched by Suz12 IP, although to a 
lesser extent than Xist. These short RNAs also possessed a stem-loop structure (Figure 
S5). Amplification of short RNAs was not observed in control reactions lacking 
reverse transcriptase, demonstrating that these results were not due to contaminating 
DNA (Figure 6B) and enrichment was maintained under stringent wash conditions 
(Figure S5). The snRNAs U1, U2 and U3 and the short structured RNAs 7SK and 5S 
ribosomal RNA, transcribed by RNA pol III, were not enriched by Suz12 IP, 
demonstrating that enrichment of short RNA was specific to the set transcribed from 
the 5’ ends of genes. 
 
We also examined short RNAs transcribed from genes that were not associated with 
H3K27me3. We found that these were also often enriched by Suz12 IP, consistent 
with the presence of double stem-loop structures in these transcripts (Figure 6A). 
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Therefore, PRC2 interacts with short promoter-associated RNA but this interaction 
does not necessarily lead to H3K27 methylation.  
 
We next asked whether the PRC2-binding stem-loop structures could affect 
transcription. To test this, we modified the HIV LTR to encode short RNA sequences. 
The R portion of the LTR located immediately downstream of the TSS encodes the 
structured RNA transactivation response element (TAR) that is present in the 5’ UTR 
of HIV transcripts. We replaced the R and U5 portions of the LTR with the Xist-RepA 
stem loop, the C20orf112 stem loop, which also interacts with PRC2, or the Xist-
RepA mutant that does not interact with PRC2 and used these constructs to drive 
expression of luciferase in Hela cells (Figure 6C). We found that there was a 
significant drop (p<0.05) in luciferase activity in cells transfected with constructs 
containing the wild-type Xist-RepA and C20orf112 stem-loops but not in cells 
transfected with constructs containing the mutated Xist-RepA sequence.  These data 
show that the stem-loop structures present in Xist and short RNAs can repress mRNA 
expression. 
 
Short RNAs are lost from polycomb target genes active in other cell types 
Differential H3K27 methylation allows for cell-type specific expression of 
developmental regulators and this underlies the differing identities of specialized cell 
types. We hypothesised that short RNAs may be specifically lost from polycomb 
target genes that are derepressed in other cell types. To address this, we examined 
short RNA expression in the neuronal cell line SH-SY5Y. We choose neuronal cells 
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because our Gene Ontology analysis (Figure 3F) revealed that many genes that express 
short RNAs in CD4+ T cells play roles in neuronal development. We used gene 
expression and functional data to select polycomb target genes that are repressed in 
CD4+ T cells and active in neuronal tissue (Figure S6). We then purified short RNAs 
from both PBMC and the neuronal cultures and blotted for short RNAs identified at 
these genes in CD4+ T cells (Figure 7A). We found that the increased expression of 
mRNA from the genes FOXN4, HEY1, MARK1, NKX2-2, BSN and HES5 in the 
neuronal cells was accompanied by a reduction in the expression of short RNAs. In 
contrast, short RNAs transcribed from the 1st exon of YBX2, a gene expressed only in 
germ cells, or from the thyroid and lung-specific NKX2-1, were present equally in 
PBMC and neuronal cells. These results show that short RNAs are specific to 
polycomb target genes silent in a given cell type. 
 
We next asked whether activation of polycomb target genes during differentiation of 
ES cells into specialised cell types is accompanied by loss of short RNAs. To test this, 
we differentiated murine ES cells through embryoid bodies and neural precursors to 
precursor motor neurons over 4 days (Wichterle et al., 2002). During this process there 
is an increase in the expression of mRNA encoding the neuronal proteins Hes5 and 
Pcdh8 (Figure 7B). Blotting for short RNAs at these genes reveals that activation of 
Hes5 and Pcdh8 is accompanied by a progressive loss of short RNAs (Figure 7C). As 
the levels of the ~190 nt Hes5 short RNA decrease, there is a concomitant increase in 
the levels of shorter species, implying that the longer RNA is degraded. We conclude 
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that derepression of polycomb target genes during ES cell differentiation is 
accompanied by the loss of short RNA transcripts. 
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Discussion 
 
We report the identification of a novel class of short RNAs transcribed from the 5’ end 
of polycomb target genes in primary CD4+ T cells and in ES cells. These short RNAs 
are approximately 50-200nt in length and are transcribed from promoters, introns and 
exons of protein-coding genes by RNA pol II independent of polycomb activity. The 
short RNAs interact with PRC2 through a stem-loop structure and are lost from 
polycomb target genes derepressed during cell differentiation.  
 
Relationship to other short RNAs 
Short RNAs of less than 200nt have previously been found to be transcribed from the 
5’ end of active genes in ES cells and cell lines (Affymetrix/ CSHL Laboratory 
ENCODE 2009; Kapranov et al., 2007, Core, 2008 #4; Seila et al., 2008; Taft et al., 
2009) and our detection of short RNAs in primary differentiated human cells 
demonstrates that they are a core component of the transcriptome. Previous studies 
have not identified short RNAs at polycomb target genes and there are possible 
reasons for this. Transcription run-on techniques (Core et al., 2008) detect transcripts 
as they are being synthesised and the absence of polycomb-associated RNAs from this 
dataset may be because they are not being continuously transcribed. Analysis of 18-
30nt RNAs (Seila et al., 2008; Taft et al., 2009) will also miss polycomb-associated 
short RNAs that northern blotting demonstrates to be primarily ~50 to 200 nt in size. 
The appearance of smaller RNAs during Hes5 activation hints at how the different 
sizes of RNA may be related. Previously described promoter-associated short RNAs 
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have been suggested to be processed from longer transcripts (Affymetrix/CSHL 
Laboratory ENCODE, 2009) but the lack of H3K79me2 at sites of polycomb-
associated short RNA transcription indicates that these RNAs can be produced 
independently of more extensive transcription.  
 
 
Implications for bivalent chromatin states 
The transcription of short RNAs from polycomb target genes explains why these loci 
are often associated with H3K4me3 (Azuara et al., 2006; Bernstein et al., 2006; Roh et 
al., 2006). The association of genes with both H3K27me3 and H3K4me3 was first 
described in ES cells and was hypothesised to poise genes for activation during 
subsequent stages of embryogenesis (Azuara et al., 2006; Bernstein et al., 2006; Lee et 
al., 2006). The detection of RNA pol II phosphorylated at ser-5, but not ser-2, at 
polycomb target genes in ES cells suggested that the poised state reflected the stalling 
of RNA pol II during mRNA transcription, with this block being released upon ES cell 
differentiation (Stock et al., 2007). We find that short RNAs are often transcribed from 
sites independent of the mRNA TSS. Furthermore, short RNA levels do not change 
upon loss of H3K27 methylation or H2A ubiquitination and therefore short RNAs do 
not appear to be a by-product of polycomb activity. These results argue that the 
bivalent state reflects short RNA production per se and that RNA pol II is not 
necessarily stalled during the initial stages of mRNA production. This would explain 
why genes are associated with H3K27me3 and H3K4me3 in differentiated cells even 
though such genes are unlikely to be poised in preparation for subsequent activation 
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(for example neuronal genes in T-cells). Stalled RNA pol II at developmental genes in 
Drosophila embryos may also be engaged in short RNA transcription independent of 
mRNA production (Muse et al., 2007; Zeitlinger et al., 2007).  
 
Interaction with PRC2 
We have shown that there is no change in short RNA levels upon loss of H3K27 
methylation or H2A ubiquitination. The same short RNAs do however decline upon 
differentiation of ES cells to neurons, indicating that their constancy upon Ezh2 and 
Ring1 loss is not merely a reflection of their stability. These data instead indicated that 
short RNAs could function upstream of polycomb and our binding data indicate that 
this function could be to stabilize the association of PRC2 with chromatin. The 
interaction of PRC2 with ncRNAs was previously described at HOXD, the inactive X-
chromosome and Kcnq1. The polycomb protein Cbx7 has also been shown to interact 
with chromatin in an RNA-dependent manner (Bernstein et al., 2006). A more recent 
study described a large set of long intergenic RNAs that associate with PRC2 (Khalil 
et al., 2009) but how these may effect polycomb association with protein-coding genes 
is unclear.  The interaction of PRC2 with short ncRNAs transcribed from polycomb-
target genes themselves presents a simple model for the association of PRC2 with its 
target genes.  
 
Of all the PRC2 subunits, we found that SUZ12 interacted most strongly with short 
RNA stem-loops. Ezh2 has previously been shown to interact with the Xist-RepA 
stem-loop (Zhao et al., 2008) but we only observed a weak interaction between EZH2 
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purified from bacteria and short RNA stem-loops. It is possible that the use of 
baculovirus as a source of recombinant Ezh2 by Zhao and colleagues could have 
resulted in co-purification of Drosophila Suz12 or that bacteria produce EZH2 protein 
lacking an important post-translational modification. 
 
Loss of short RNAs during gene activation 
Short RNA levels are reduced at polycomb-target genes depressed in neurons and this 
decrease can be observed directly as ES cells differentiate. Given the interaction 
between short RNAs and PRC2, their loss would seem likely to destabilize the 
association of PRC2 with chromatin, thereby allowing demethylation of H3K27 and 
mRNA transcription. Although this provides a mechanism for how polycomb-target 
genes become activated, it does not explain how other genes expressing short RNAs 
capable of interacting with PRC2 remain free of H3K27 methylation. At this set of 
genes, it is possible that PRC2 is inactive or counteracted by H3K27 demethylases. 
 
In summary, we have identified a novel class of short RNAs that are transcribed from 
the 5’ end of repressed polycomb target genes, explaining why these genes are 
associated with markers of transcriptional activation and providing a mechanism for 
the interaction of PRC2 with its target loci across the genome.
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Experimental Procedures 
 
RNA purification and fractionation 
Total RNA was purified with Trizol (Invitrogen) and checked for degradation using an 
Agilent Bioanalyzer. Short RNA (<200bp) was purified using Ambion’s mirVana 
miRNA purification system and size fractionation confirmed using a Bioanalyzer. 
 
Microarray analysis 
Short RNA was poly-adenylated (Ambion), amplified and labeled with Agilent’s Low 
RNA Input Linear Amplification protocol and hybridised with labeled mRNA or 
fractionated long RNA to custom microarrays containing probes for promoters, 5’-
exons, first intron and 3’-exons of human RefSeq genes. The log ratio distribution of 
probes for known short RNAs was used to devise an algorithm for the prediction of 
novel short RNAs (log2 ratio >1.5, p-value <0.01, normalized signal >50 in both 
experiments).   
 
ChIP-Chip 
DNA associated with RNA polymerase II, H3K4me3, H3K79me2, H3K27me3 and 
total H3 was enriched from CD4+ T cells with the following antibodies anti-RNA pol 
II (8WG16, Abcam), anti-H3 (Abcam ab1791), anti-H3K4me3 (Abcam ab8580), anti-
H3K79me2 (Abcam ab3594) and anti-H3K27me3 (Abcam ab6002) and analysed with 
DNA microarrays (Agilent) according to published protocols (Lee et al., 2006). 
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Northern blotting 
Short RNA was resolved on 15% acrylamide-7M Urea TBE gels (Invitrogen) and 
electroblotted to Nytran membranes (Whatman). RNA was crosslinked to the 
membrane and exposed to probes designed from microarray elements and 
radioactively labeled using StarFire 3’-extension (IDT). Estimates of RNA length 
made in comparison to Century and Decade markers (Ambion). 
Conditional deletion of Ezh2 and Ring1 
Ezh2: ES cells were derived from conditional Ezh2 knock-out mice (Su et al., 2003). 
Clone Ezh2-1.3 carries a conditional Ezh2 mutation on both alleles induced by 4-
hydroxy-tamoxifen (800 nM, Sigma) without consequent changes in ES cell self-
renewal. Ezh2-1.3 were maintained on 0.1% gelatin-coated surfaces using KO-DMEM 
medium, 10% FCS, 5% knock-out serum replacement (Invitrogen) and 1000 U/ml of 
leukaemia inhibitory factor (Chemicon).  
Ring1: ES-ERT2 cells were cultured and Ring1b deletion induced with tamoxifen as 
described (Stock et al., 2007). 
 
RNA structure prediction 
RNA structures were identified within 200nt of sequence surrounding probes that 
detected short RNAs using RNAmotif  (Macke et al., 2001) and free-energy structures 
predicted using RNAfold (Hofacker and Stadler, 2006). 
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EMSA 
Full-length SUZ12 was amplified from the IMAGE clone and cloned into pGEX-4T1 
(GE). Plasmids encoding GST-EED, GST-EZH2 and GST-RBBP4 were kindly 
provided by Dr.Y. Zhang. Recombinant proteins were purified by glutathione-agarose 
and 4mg used for EMSA with ssRNA, ssDNA, dsDNA and DNA-RNA duplex 
oligonucleotides end-labeled with [ -32P]ATP, as described (Zhao et al., 2008). 
Nuclear extracts were prepared from the T-cell line CEM using reagents from Active 
Motif. 
 
RNA IP 
RNA associated with PRC2 was enriched from CEM cells with an antibody to Suz12 
(Abcam) or unspecific rabbit antibody (Santa Cruz) following published protocols 
(Keene et al., 2006; Zhao et al., 2008). RNA was treated with DNase-turbo (Ambion), 
and reverse transcribed with SuperScript-III (Invitrogen) using random priming. 
Enrichment of RNA species compared to input RNA was quantified using real-time 
PCR and normalized to housekeeping gene mRNA. 
 
Luciferase assay 
The R and U5 regions of the HIV LTR from SF2 were replaced with DNA encoding 
the murine Xist-RepA stem-loop, mutated Xist-RepA and the stem-loop from 
C20orf112 short RNA, cloned in place of the CMV promoter in pIRESneo3 
(Clontech) and luciferase from pCSFLW inserted downstream. Plasmid DNA was 
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transfected into Hela cells in triplicate together with the Renilla luciferase plasmid 
phRL-null. 48 hours later, firefly luciferase activity was measured in relation to 
Renilla luciferase with the Dual-luciferase reporter system (Promega). The 
significance of differences were estimated with a one-sided paired T-test. 
 
Neuronal cell culture 
SH-SY5Y cells were cultured in DMEM with 10% FCS until 40-50% confluent and 
then differentiated in DMEM with 5% FCS and 10mM retinoic acid (Sigma) for 7 
days. 
 
ES cell differentiation  
ES cell-derived motor neuron precursors were generated as described elsewhere 
(Wichterle et al., 2002). Briefly, v6.5 mouse ES cells were partially dissociated and 
cultured in ADFNK medium optimized for ES cell to HB9+ motor neurons. After two 
days, 1mM retinoic acid and 0.5mg/ml Hedgehog agonist Hh-Ag1.3 were added and 
cells cultured for an additional 24hrs (for NPCs) or 48hrs (for PMNs). 
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Figure Legends 
 
Figure 1. Detection of promoter-associated short RNAs in primary human T cells 
A. Experimental strategy. Short RNA was purified human CD4+ T cells, poly-
adenylated amplified and labeled with Cy5 and hybridized together with Cy3-labeled 
mRNA (experiment 1) or total long RNA (experiment 2) to a custom microarray 
containing probes for the promoters, 5’ exons, first intron and 3’ exons of human 
RefSeq genes, together with control probes for snRNA and snoRNAs. 
B. Background-subtracted array signals for control snRNA and snoRNA probes in the 
mRNA channel (x-axis) and the short RNA channel (y-axis). 
C. Fraction of promoter regions (~1 kb upstream of mRNA transcription start site), 5’ 
exons (up to 1kb downstream of mRNA 5’ end) and first introns that give rise to short 
RNAs. 
D. Distribution of short RNAs relative to the TSS of the average gene, plotted as a 
moving average with a window of 10 bp.  
E. Venn diagram showing the overlap between genes with associated short RNAs 
detected in this study compared with two previous studies (Kapranov et al., 2007; 
Seila et al., 2008). 
 
Figure 2. Transcriptional status of short RNA genes. 
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A. Percentage of genes with promoter-associated short RNAs that produce detectable 
mRNA (black bars) or no detectable RNA (grey bars) according to our mRNA 
expression data (data set 1) or published data (data set 2 (Su et al., 2004)). 
B. Array signals (median and inter-quartile range) for short RNAs (grey) and mRNA 
(white) at genes that produce detectable mRNA or no detectable mRNA. 
C. Composite enrichment profile of RNA pol II at genes for which no mRNA can be 
detected. The plot shows average fold-enrichment (normalized signal from RNA pol II 
ChIP divided by the signal from input DNA) and genes are divided into those that are 
associated with short RNA (green) and those not associated with short RNA (blue). 
The start and direction of transcription of the average gene is indicated by an arrow.  
D. Composite enrichment profile of RNA pol II at genes that express short RNAs in 
the absence of detectable RNA. Genes are divided into those that detect a short RNA 
with probes positioned -100 to +100 (red), -700 to -500 (green) or +500 to +700 (blue) 
relative to the mRNA TSS.  
E. Examples of RNA pol II ChIP signals at short RNA loci. The plots show 
unprocessed enrichment ratios for all probes within a genomic region (RNA Pol II 
ChIP vs. whole genomic DNA). Chromosomal positions are from NCBI build 35 of 
the human genome. Genes are shown to scale below and aligned with the plots by 
chromosomal position (exons are represented by vertical bars, the start and direction of 
transcription by an arrow). The positions of short RNAs are indicated by the vertical 
blue arrow. 
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F. Composite enrichment profile of H3K4me3 (green) and H3K79me2 (red) across all 
human RefSeq genes. The plot shows average fold-enrichment (normalized signal 
from H3 methylation ChIP divided by whole H3 ChIP).  
G. As F., except at genes associated with short RNA but not mRNA.  
 
 
Figure 3. Short RNA loci are associated with H3K27me3. 
A. Composite enrichment profile of H3K27me3 at genes for which no mRNA can be 
detected. These genes are divided into those that are associated with short RNA 
(green) and those not associated with short RNA (blue). The plot shows average fold-
enrichment (normalized signal from H3K37me3 ChIP divided by whole H3 ChIP).  
B. As for A. except for ChIP-Seq sequence tag density from H3K27me3 ChIP material 
(data from (Barski et al., 2007)). 
C. Percentage of genes in different transcriptional categories that are associated with 
H3K27me3. Genes are first divided into those that produce detectable mRNA and 
those that do not and then into those that produce detectable short RNA and those that 
do not. 
D. Heat maps showing enrichment of H3K27me3, H3K4me3 and RNA polymerase II 
at genes associated with short RNAs and H3K27me3.  Each row represents one gene 
and each column represents the data from one oligonucleotide probe, ordered by their 
position relative to the transcription start site. For the first three panels, fold 
enrichment is indicated by color, according to the scale on the right. The last panel 
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overlays the RNA polymerase II (green) and H3K27me3 (red) to show their relative 
locations. 
E. P-values for the enrichment of GO categories in the set of genes that are not 
associated with mRNA and transcribe short RNA (black bars) compared with those 
that do not produce detectable short RNA (grey bars). 
F. Northern blotting for short RNAs transcribed from polycomb target genes in 
PBMC. The position of single-stranded RNA size markers are shown to the left. The 
genes and relative locations from which the short RNAs are transcribed are indicated 
above each blot. 
 
Figure 4. Transcription of short RNAs in murine ES cells deficient for Ezh2 and 
Ring1. 
A. Northern blotting for short RNAs transcribed from polycomb target genes in 
murine ES cells. 
B. Western blotting for Ezh2, histone H3K27me3, and total histone H3 in Ezh2-1.3 ES 
cells over a 5-day treatment with tamoxifen that induces genetic deletion of the Ezh2 
SET domain. 
C. Northern blotting for Hes5, Msx1 and Ybx2 short RNAs and 5S rRNA during 
tamoxifen treatment of Ezh2-1.3 cells.  
D. Northern blotting for Hes5, Msx1 and Ybx2 short RNAs and 5S rRNA in ES-ERT 
cells, 2 and 3 days after the addition of tamoxifen that induces genetic deletion of 
Ring1b, compared with untreated cells at the same timepoints. 
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Figure 5. Short RNAs interact with PRC2 in vitro. 
A. Left: A stem-loop structure motif based on the repeat region of Xist-RepA RNA 
that is known to bind PRC2. Right: Percentage of short RNAs transcribed from genes 
associated with H3K27me3 that contain one or more (black bars) or two or more (grey 
bars) of the RNA structure motifs. The same data for genomic sequences showing 
identical distributions around transcription start sites but that do not produce detectable 
short RNAs are shown as controls.  
B. Example energy structures found in short RNAs transcribed from repressed genes. 
The gene proximal to each short RNA sequence and the free energies are shown 
alongside each structure. 
C. EMSA for the interaction of 32P-labeled RNA probes corresponding Xist-RepA, 
Xist-RepA mut (stem-loop disrupted), BSN short RNA, mutated BSN short RNA, and 
C20orf112, HEY1, MARK1 and PAX2 short RNA probes with T-cell nuclear extract 
(NE).  
D. Competition for Xist-RepA binding with 400 or 800-fold excess of cold Xist-RepA 
or BSN short RNA probes. 
E. EMSA for the interaction of PRC2 subunits expressed as GST-fusion proteins with 
Xist-RepA and BSN short RNA probes. GST alone was used a negative control.  
F. EMSA for the interaction of GST-SUZ12 with short RNA probes. 
G. Affinity of GST-SUZ12 for wild-type and mutant Xist-RepA probes. Increasing 
amounts of SUZ12 were added (0.25, 1.0 and 5µg). 
	   271	  
H. Binding specificity of SUZ12 defined by incubating GST-fusion protein with the 
BSN stem-loop sequence encoded by ssRNA, ssDNA, dsDNA and a RNA-DNA 
duplex.    
 
Figure 6. Short RNAs interact with PRC2 in cells. 
A. Fold enrichment (mean and SD, n=3) of different RNA species in Suz12 
immunoprecipitate (grey) and control immunoprecipitate (white) compared with input 
RNA and normalized to Actin measured by quantitative reverse-transcription PCR. 
The genes and relative locations from which the short RNAs are transcribed are 
indicated above (E=exon, I=intron, P=promoter). 
B. Amplification products from Suz12 IP cDNA and control cDNA reactions lacking 
reverse transcriptase using primers specific for small RNAs (n=3 for each PCR). 
C. Left: Schematic showing the wild-type HIV LTR-luciferase construct and modified 
forms in which R and U5, encoding the transactivation response element (TAR), are 
replaced with the Xist-RepA stem-loop, the Xist-RepA mutant stem-loop or the 
C20orf112 short RNA stem-loop. Right: Luciferase activity in Hela cells transfected 
with plasmids encoding firefly luciferase downstream of wild-type or modified HIV 
LTRs indicated in the schematic to the left. Firefly luciferase activity is plotted relative 
to co-transfected Renilla luciferase and normalized to the wild-type LTR. Error bars 
are standard deviations across 7 independent experiments (performed with 2 
independent clones) with each experiment comprising 3 measurements. * indicates 
comparisons that gave significance at p<0.05. 
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Figure 7. Loss of short RNAs from polycomb target genes activated in neuronal 
cells. 
A. Northern blotting for short RNAs transcribed from genes targeted by polycomb in 
CD4+ T cells in RNA from PBMC (P) and from differentiated SH-SY5Y neuronal 
cells (N). 
B. Gene expression microarray data showing the expression of Hes5 (blue) and Pcdh8 
(red) mRNA during the step-wise 4-day differentiation to precursor motor neurons 
(PMN). EB (day 2 of differentiation process), embryoid bodies; EB+RA, embryoid 
bodies treated with retinoic acid (8 hours later on day 2); NPC, neuronal precursor 
cells (day 3).  
C. Northern blotting for Hes5 and Pcdh8 short RNAs and 5S rRNA in ES cells during 
the step-wise 4-day differentiation to precursor motor neurons described above. 
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